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Abstract
Abstract
The function of proteins is often regulated by the formation of multi-protein complexes or translo-
cation events. Over the last few decades, several methods have been developed to force proteins
to specific locations or induce protein-protein interactions. One of these approaches is based on
small bi-functional molecules, so-called chemical inducers of dimerisation (CIDs), which bind to
two protein tags. Therefore, two proteins of interest fused to the tag protein, are brought into
close proximity in the presence of the CID. Since the pioneering report by Schreiber and Crabtree
in 1996, a variety of novel CIDs were designed and used to regulate protein dimerisation and
translocation. However, most of these systems exhibit relatively low temporal resolution, deter-
mined by the cell permeability of the small molecule. One of the few exceptions is rapamycin,
a naturally occurring CID, which rapidly induces dimerisation between FKBP12 and FRB. Due
to its immunosuppressant properties, several researchers used the ”bump and whole” approach
to design C16 rapamycin derivatives, which do not bind to wild-type FRB, but to a geneti-
cally engineered mutant. Although, various nucleophiles were introduced at the C16 position, no
general method to introduce carbamates was published. Here we describe an efficient Lewis acid-
mediated method to substitute rapamycin at the C16 position with various nucleophiles under
mild conditions. Furthermore, we performed NMR experiments to elucidate the exact mech-
anism of the mentioned method. We observed that treatment of rapamycin with the Lewis
acid BF3-Et2O in CH2Cl2, leads to the heterolytic cleavage of the C16 methoxy group and the
formation of a BF3-carbocation complex, which does not react with carbamates. The addition of
THF further stabilises the carbocation, which results in a fast reaction with the nucleophile. To
demonstrate the utility of this novel method, we introduced a series of representative carbamates
at the C16 position of rapamycin. One of the major challenges, when synthesising rapalogs, is
that small impurities of rapamycin or rapamycin by-products still inhibit mTOR. Therefore,
we extensively purified the diastereomers of C16 phenyl carbamate (pcRap) with preparative
HPLC. In a proof of concept, (R)-pcRap successfully induced dimerisation of FKBP and FRB
fusion proteins without interfering with the mTOR pathway.
The application of light controllable tools is an alternative approach to regulate the localisation
and the activity of proteins with high spatiotemporal precision. Here we report the synthe-
sis of a series of photoactivatable HaXS dimerisers, which contain a photocleavable linker be-
tween the HaloTag-reactive chloroalkane ligand and the SNAP-tag-reactive O6-benzylguanine.
Chemical modification of the photocleavable linker afforded three powerful photocleavable and
cell-permeable CIDs, which could be cleaved independently and orthogonally. Furthermore, in a
proof of concept, one of these photocleavable HaXS molecules was successfully used to translocate
proteins of interest to the plasma membrane, late endosomes, lysosomes, Golgi, mitochondria and
the actin cytoskeleton. Subsequent irradiation of a specific location with either a FRAP-laser or
a mercury lamp with a DAPI filter set, readily liberated the anchored proteins. Furthermore, we
demonstrated the utility of photocleavable CIDs and explicitly MeNV-HaXS in kinetic studies
of protein dynamics and the manipulation of subcellular enzyme activities. Therefore, MeNV-
HaXS was used to anchor a nuclear probe to the Golgi. Subsequent irradiation of cells triggered
the release and the relocalisation of the nuclear probe into the nucleus.
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Introduction
1 Introduction
The function of a particular protein in signaling transduction is strongly dependent on its local-
isation; its concentration at a specific location; and its proximity and orientation towards other
biomolecules[1]. Tools to manipulate these parameters in vivo are essential to understand the role
of specific proteins in signaling pathways[2]. Genetic approaches to regulate protein functions,
such as knockout, overexpression and mutations, allows the targeting of single proteins within a
whole complex, but suffers from aspects such as low temporal resolution, low flexibility after the
genetic change, possible cellular or molecular compensation and lastly, are often restricted to one
specific application[3, 4]. In contrast, cell-permeable small molecules (e.g. inhibitors and activa-
tors) can regulate the function of proteins rapidly, reversibly and in a dose-dependent manner[4,
5]. However, the discovery of a specific chemical effector for the protein of interest (POI) is chal-
lenging. Moreover, most known synthetic small molecules have several targets, which may lead
to side effects[4, 5]. Other chemical methods such as site-specific labeling or chemical ligation
are more selective, but often require incorporation of specific amino acids into the protein[6, 7].
Additionally, protein modification is performed in vitro and microinjection of the protein into
cells is needed for in vivo studies[6, 8].
In the last three decades, numerous chemical genetic techniques were designed to combine the
benefits of these approaches[4, 9]. For example, the orthogonal chemical genetic approach (also
referred to as ”hole and bump” strategy) was developed to increase the selectivity of small
molecules to one specific protein[4, 10]. In this approach, a known ligand for the POI is synthet-
ically modified to the extent that it loses the ability to bind the target protein. In a second step,
a cavity is genetically engineered into the protein to accept the modified ligand. By these means,
Hwang and Miller altered the ligand specificity of the GTPase thermo unstable elongation factor
(Ef-Tu)[11]. Mutation of a single amino acid residue (D138N) in the guanine ring binding motif
(NKXD) led to mutants with low affinity for GTP, but high affinity for xanthine triphosphate
(XTP). Interestingly, this approach was later extended to other members of the GTPase family,
as the NKXD motif is conserved for all known GTPases[4]. Although, the orthogonal chemical
genetic approach yields high protein specificity, it requires modification of a known ligand and
mutation of the targeted protein.
Incorporation of unnatural amino acids is an alternative approach to regulate the function of
proteins. A major breakthrough in this field was the development of an orthogonal aminoacyl-
tRNA synthases/tRNAs pair, to site-specifically introduce unnatural amino acids in vivo[12]. In
this approach, a genetically engineered tRNA synthase specifically aminoacylates the correspond-
ing foreign tRNA with the unnatural amino acids. The aminoacylated tRNA then recognises
a selected codon (nonsense codon or stop codon) and site-specifically incorporates the unnatu-
ral amino acid into the protein. Until today, unnatural amino acids, containing spectroscopic
probes, bio-orthogonal functionalities for chemo-selective reactions, photosensitive groups and
other chemical moieties, were selectively incorporated into proteins in Arabidopsis thaliana, bac-
teria, Caenorhabditis elegans, Drosophila melanogaster, E. coli, mammalian cells and Saccha-
romyces cerevisiae[13]. However, development of new aminoacyl-tRNA synthase/tRNAs pair
generally requires large screenings of approximately 109 synthase variants[14]. Furthermore, the
resulting proteins are restricted to one specific application or depend on slow bio-orthogonal
reactions, such as the condensation of ketons and aldehydes with amines, click chemistry based
reactions, Diels-Alder cyclo-addition, Staudinger-ligation, and several others[6, 13, 15].
A more general approach to regulate the function of specific proteins is based on the genetic
fusion of a gene of interest to a sequence encoding a well-studied ligand-binding domain (chemical
tag)[16–18]. The function of the resulting chimeric protein (fusion protein) can be regulated by
a cell-permeable ligand (figure 1).
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Figure 1: Principle of chemical tags to target specific protein with small molecules in vivo. Cells
expressing POI-Tag fusions are treated with a cell-permeable Tag ligand, which functionalises the tag.
This approach combines the selectivity obtained with genetic encoding and the versatility pro-
vided by synthetic chemistry. Additionally, the use of small cell-permeable molecules allows the
regulation of the POI in a time- and dose-dependent manner. Moreover, the same or slightly
modified fusion proteins can be used for different applications, such as imaging of proteins, reg-
ulation of protein stability, control of protein aggregation, translocation of proteins to specific
cellular compartments, manipulation of protein-protein interactions, regulation of gene expres-
sion, and generation of novel proteins in vivo by simply altering the properties of the small
molecule[3, 19]. However, the synthetic molecule has to; (I) display fast reaction kinetics; (II)
react quantitatively and bio-orthogonal; (III) be cell-permeable and water soluble; and display
no cytotoxicity[16–18, 20]. Currently, several ligand-protein domain pairs have been developed,
which fulfill all or most of these criteria.
In this introduction, we will mainly focus on general approaches to target fusion proteins and
regulate their activity with small molecules. Effector molecules, which target only a specific
protein or a protein family, will be excluded. Methods such as incorporation of unnatural amino
acids and bio-conjugation will be briefly mentioned. For a more detailed summary of these
methods, we refer to several excellent reviews in the field[6, 13, 15, 21].
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1.1 Targeting proteins with chemical tags and their application
1.1.1 Self-labelling chemical tags
The first applied genetically encoded small polypeptide for specific protein labelling was the
tetracysteine (TC) tag, a small polypeptide tag with a CCXXCC core. The cell permeable
biarsenic fluorescein derivative (FlAsH) recognises and binds to the cysteines of the TC tag,
forming a stable complex (Kd = 10 pM) (figure 2, B)[22]. Up to date, several analogues of
FlAsH have been published, including a red fluorescent version called ReAsH, and a bisarsenic
cyanine substrate (AsCy3) with an orthogonal binding sequence (CCKEAACC) (figure 2,
A)[23, 24]. One of the major advantages of FlAsH and ReAsH is that the fluorescence of the
biarsenic compounds dramatically increases after binding to the tetracysteine motif, allowing
to differentiate between bound and unbound substrate[22, 23]. FlAsH and its variants were
used to image HIV-1 proteins in infected cells[25–27], G-protein-coupled receptors[26–29], the
formation of amyloid[30, 31], ATP-gated P2X receptor[32], and β-tubulin[33] among many other
proteins[34–40]. Despite their wide use, biarsenic compounds suffer from several drawbacks,
such as unspecific binding to similar or related sequences and hydrophobic sites in cellular
compartments, as well as from cytotoxicity of the biarsenic ligand and labelling conditions[41].
OO OH
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CO2H
S SS S
O
N
O OH
AsAs
S SS S
FlAsH
ReAsH
O OHO
As As
S S S S
A)
Cys Cys
X X
Cys Cys Cys Cys
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+
Figure 2: TC-tag technology A) Chemcial structure of commonly used biarsenic TC ligands; greenflu-
orescent FlAsH, redfluorescent ReAsH, and orthogonal AsCy3. B) Labelling of TC-tag fused protein
with FlAsH.
Recently, several groups reported conceptually similar metal binding peptide tags. The
group of Schepartz demonstrated the in vivo labelling of a model protein fused to a tetraserine
(TS) tag with a cell permeable bisboronic acid derivative of rhodamine (RhoBO) (scheme
1, A)[42]. Vogel and colleagues designed two Ni2+chelating nitrilotriacetates (NTA), which
recognise a polyhistidine motif (His-tag) (scheme 1, B)[43]. Interestingly, the paramagnetic
nature of Ni2+ quenches nearby fluorophores in a distant dependent manner. The authors used
this property to investigate the structure of the ionotropic 5HT3 serotonin receptor. Similarly,
the research group of Tsien targeted the His-Tag with the Zi2+ chelating molecule HisZiFiT
(scheme 1, C)[44]. In a proof of concept, the authors monitored the translocation of STIM1 from
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the ER lumen to plasma membrane and demonstrated that its N-terminus was externalised.
Ojida et al., reported the high affinity labelling of a tetra aspartic acid (TD) sequences with
multinuclear zinc(II) complexes (Zn(II)-Dpa-Tyrs) (scheme 1, D)[45]. In 2003, Imperiali and
his group reported the in vitro labelling of a polypeptide tag with terbium(III)[46]. The major
advantage of these approaches is the small tag size, which minimises the risk of interfering with
the protein activity. However, this comes at the expense of lower specificity. To overcome this
drawback, several groups designed covalent self-labelling protein tags.
ON NH
CO2H
B BO
O
O
O
RhoBO
R N
H
OMe
O
O-
N
N
N
N
Zn
Zn
O O-O
NHHN
S S
NN
O OO O
ZnZn
Zn(II)-DpaTyrs
HisZiFiT
CO2-
NS
R
OO
HN
O N
CO2-
Ni
CO2-
CO2-
NTA
N
N
A)
B)
C)
D)
Scheme 1: Chemical structure of metal-binding peptide ligands. A) Tetraserine targeting RhoBO
ligand. B) His-tag targeting NTA. C) His-tag targeting ligandHisZiFiT. D) Poly aspartic acid targeting
Zn(II)-DpaTyrs ligand.
In this approach, the POI is fused to an enzyme or a receptor rather than a short peptide, which
can subsequently be targeted with a corresponding cell permeable ligand. By these means, the
group of Kai Johnsson developed the SNAP-tag, a mutant of the human DNA repair protein O6-
alkylguanine-DNA alkyltransferase (hAGT)[47, 48]. In its natural function, hAGT irreversibly
transfers alkyl groups of O6-alkylated guanine to a resident cysteine. Mutations of residues close
to the active-site led to versions with increased selectivity and activity for O6-benzyl guanine
(BG) derivatives (figure 3, A)[48–50]. Later, the same group developed an hAGT mutant with
orthogonal selectivity. The so-called CLIP-tag has a high affinity for O2-benzyl cytosine (BC)
and very low reactivity towards BG (figure 3, B)[47]. Fluorescent SNAP-tag substrates were
successfully used to study the localisation of centromere bound CENP-A, the trafficking of Na,K-
ATPase and Smoothened, as well as the stoichiometry of class A and C GPCRs[51–54]. More
recently, fluorescent BG derivatives were used in combination with super-resolution imaging
techniques, to image cytoskeletal and membrane bound proteins[55], clathrine coated pits[56],
histone proteins[57], and clustering of HIV-1 Gag protein[58].
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Figure 3: Schematic representation of covalent protein labelling based on hAGT. A) SNAP-tag; B)
CLIP-tag technology.
A third covalent self-labelling chemical tag, called HaloTag, was introduced in 2008 by
Promega[59]. The HaloTag is a modified bacterial haloalkane dehalogenase. Haloalkane de-
halogenases naturally catalyse the two-step reaction of an alkylhalide to an alkyl alcohol. In the
initial step, the alkyl group of the alkylhalide is transferred to the site chain of an aspartate
located at the active-site. In the second step, the previously formed ester is hydrolysed by a
water molecule, which is activated by a histidine. Mutation of this histidine in the HaloTag pre-
vents the hydrolysis and the regeneration of aspartate. Thus, the alkyl group remains covalently
attached to the enzyme (figure 4). With 33 kDa, the HaloTag is a rather large tag, which may
limit its application. However, the lack of haloalkane dehalogenase in eukaryotes results in low
background labelling. Recently, HaloTag technology was applied to monitor the distribution of
Cl O O R
O O-
POI
O O
POI
O O R
HaloTag
Figure 4: Schematic representation of covalent protein labelling with the Halo-tag technology.
MMP-2 between the mitrochondria and the mitrochondria-associated membrane in the heart[60],
the localisation of outer mitochondrial membrane proteins and subunits of the respiratory chain
complex II[61], and the Protocadherin-24 mediated translocation of β-catenin in a colon cancer
cell line[62]. Mimicking the partially denatured state of proteins, the Crews group designed a
hydrophobic HaloTag substrate (HyT36) to control proteolysis of proteins (figure 5, A). In vivo
labelling of POI-HaloTag fusion with this hydrophobic small molecule readily induced prote-
olysis of the tagged protein (figure 5, B)[63]. The same group used this approach to regulate
the protein levels of HRas1G12V in mice[64], Smad5 in zebrafish[64] and to study the unfolded
protein response in the endoplasmic reticulum[65]. Recently, Chidely et al., developed a bifunc-
tional chimera tag, based on the HaloTag and the SNAP-tag, termed Covalin[66]. In a series of
proof-of-principle experiments, the authors conjugated antibodies to fluorophores, enzymes and
to magnetic beads.
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Figure 5: HyT36 induced protein degradation A) Chemical structure of HyT36. B) Schematic
representation of HyT36 induced protein degradation.
New self-labelling chemical tags continue to be introduced, but most of these are yet to be
sufficiently tested. The Kikuchi lab genetically engineered a suicide protein based on the bacterial
β-lactamase TEM-1 (BL-tag) (figure 6, A)[67]. The process whereby β-lactamases hydrolyse
antibiotics containing β-lactam is conducted in two steps. In the first step, Ser70 reacts with
the amide bond of the lactam, forming an ester, whilst in the second step, Glu166 catalyses the
hydrolysis of this ester bond. Mutation of residue E166 to aspartic acid drastically reduced the
deacylation reaction, leading to accumulation of protein-small molecule conjugate. Later, the
same group developed an orthogonal tag-system based on the yellow protein (PYP-tag)[68–70].
PYP is a 125 amino acid small protein, which binds thioester derivatives of 4-hydrocycinnamic
acid or 7-hydroxycoumarin through transthioesterification (figure 6, B). Importantly, PYP does
not exist in mammalian cells and no endogenous target for its substrates is known. Bonasio
et al. applied cutinase (a fungal serin esterase) variant that reacts with its suicide substrate
p-nitrophenyl phosphonate (pNPP) as the tag (Cutinase tag) (figure 6, C). However, so far this
system is limited to extracellular studies, due to the low cell permeability of the tag substrates.
N
H
N
O
R
O
S
CO2
S
RO
-
N
NH
O
R
O
S-O2C
HS
R
NO2
PHO
O
O
POI
O
POI
+
O-
POI
O
POI
P
O
O
NO2
RR
O
S
OH
RR
OO
POI
S-
POI
S
O R
OHOO
BL-tag
PYP-tag
Cutinase tag
A)
B)
C)
Figure 6: Schematic representation of novel self-labelling tags based on proteins. A) BL-tag. B)
PYP-tag. C) Cutinase-tag.
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1.1.2 Affinity-based chemical protein tags
As the name suggests affinity-based chemical protein tags take advantage of high affinity inter-
actions between a tag and their effectors. In contrast to most of the self-labelling tags discussed
above, labelling of affinity-based tags can be reversed by addition of a competing tag substrate.
One of the most established affinity tags is based on the immunosuppressant FK506 (scheme
2), which binds tightly to the cytosolic Human FKBP12 protein and subsequently inhibits cal-
cineurin. However, the ubiquitous and high expression of Human FKBP12 in mammalian cells
limits this approach. To overcome this drawback, synthetic ligands for FKBP12 (SLF) lacking
the immunosuppressant effect of FK506, were created (scheme 2)[71]. Appling the ”bump and
hole” approach, the research group of Clackson introduced a steric group into the synthetic lig-
and for FKBP12 (SLF*) to disrupt its binding to endogenous FKBP12 (scheme 2). Subsequent
mutation of FKBP12(F36V), containing a corresponding ”hole” re-established the binding of
SLF*[72].
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Scheme 2: Structure of the FKBP12 binding FK506 and its none immunosuppressant analogs SLF,
SLF* and Shield-1
.
During the course of the FKBP remodeling study, Clackson and colleagues observed that the
F36MFKBP mutant spontaneously formed dimers, which could be dissociated by addition of the
SLF*[73]. Capitalising on this behavior, the group developed a ”reverse dimerization” system
to regulate protein secretion. In this system, POI fused to F36MFKBP form large aggregates,
which are unable to exit the endoplasmic reticulum (figure 7, A). Incubation of cells with SLF*
dissolves the aggregates and ultimately restores the activity of POI. In this way, the authors
regulated the secretion of insulin and growth hormones in vivo[74]. Extending the scope of ap-
plications of FK506 based tags, the Wandless group genetically engineered an unstable FKBP
mutant (DDFKBP) (figure 7, B)[5]. Proteins fused to this destabilising domain (DD), are readily
and constitutively degraded when expressed in cells. In the presence of cell-permeable Shield-1
(an SLF derivative with improved pharmacokinetic properties) (scheme 2), the protein fusion is
rescued from proteolysis restoring their original function. To validate this approach, the authors
regulated the levels of two kinases, two cell cycle regulatory proteins, and three small GTPases.
Complementary to this, the same group developed a ligand-induced degradation system, fusing
a 19 amino acid degradation sequence (degron) to the C-terminus of FKBP (LID)[75]. In the
absence of Shield-1, the degron intra-molecularly binds to FKBP, thus preventing the degra-
dation of the protein. Addition of a synthetic FKBP ligand displaces the degron and induces
degradation of the POI-tag fusion protein (figure 7, C). In the proof of concept, the authors
investigated the small molecule-dependent regulation of transcription factors involved in repro-
gramming differentiated cells. Additionally, the authors used Shield-1 to simultaneously deplete
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YFP-LID domain fusions and simultaneously rescue mCherry-DDFKBP from degradation.
B)
POI POI
POI POI
POI
SLF*
POI
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Tra
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POI aggregates in the ER
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Figure 7: FK506-based approaches to regulate protein function. A) Self-assembling F36VFKBPPOI
fusion proteins accumulate in the ER. The membrane-permeable SLF* binds to the FKBP mutant and
disrupts the aggregate. The liberated chimeric proteins translocate to their active site, in this case the
plasma membrane, where they regain their function. B) Proteins genetically fused to the destabilising
FKBP mutant readily undergo proteolysis. Binding of Shield-1, stabilises the tag protein and rescues
the fused protein from degradation. C) The protein of interest is fused to a FKBP mutant with C-
terminal degron buried in the binding pocket. Addition of Shield-1 displaces the degron, which induces
proteolysis.
The group of Cornish capitalised on the high affinity of trimethoprim (TMP) to the protein
dihydrofolate reductase from E. coli (eDHFR) to design an alternative high affinity tag (figure 8,
A). TMP is easily modified at the para methoxy position and has low binding affinity for
mammalian DHFR (Kd > 1 µM)[76]. The same group published a covalent version of the TMP-
tag, using proximity-induced reactivity. Therefore, a lysine at the eDHFR surface was mutated
to a cysteine. TMP binds to the mutated eDHFR and an acrylamide linked to the TMP reacts
with the cysteine, forming a covalent bond (figure 8, B)[77].
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Figure 8: Schematic representation of protein labelling with the TMP-tag technology. A) Reaction of
TMP derivatives with eDHFR fusions B) TMP-directed covalent labelling of protein with a function-
alised small molecule.
Analogues to their destabilising FKBP mutant, the Wandless group engineered a destabilising
eDHFR domain (DDeDHFR), which can be prevented from inducing tag-POI fusion protein
degradation by addition of TMP[78]. In the first applications, the authors regulated the protein
levels of the transmembrane protein CD8α and POIs in rat brain. Additionally, the group
simultaneously and independently regulated the concentration of two different proteins in one
cell, co-expressing DDeDHFR-POI and DDFKBPPOI fusion proteins. Conceptually similar,
the Hedstrom group designed a TMP-Boc3Arg derivative to post-translational control protein
levels (scheme 3)[79]. This hydrophobic small molecule binds to its target protein and triggers
proteasome-mediated protein degradation. Notably, the proteolysis of the fusion protein could
be stopped with the addition of an excess of TMP.
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Scheme 3: Chemical structure of TMP-Boc3Arg.
Recently Tsukiji and colleagues designed a family of self-localising ligands (SLLs) based on
TMP and SLF* to control the spatial distribution of POIs, in vivo[80]. In this approach the
ligand for an endogenous protein or chemical tag is covalently linked to a specific small-molecule
localisation motif. After cell incubation with this bi-functional small molecule, the POI is rapidly
translocated to a targeted intracellular region. In the proof of concept, the authors translocated
POIs to the inner leaflet of the plasma membrane, the nucleus and to the cytoskeleton.
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1.1.3 Enzyme-mediated chemical tags
Enzyme-mediated chemical tags were exploited to combine the advantages of metal-binding pep-
tides and self-labelling chemical tags. In this approach, the POI is fused to a small peptide,
which is modified by a small-molecule cofactor in the presence of the corresponding enzyme.
biotin ligase from E. coli (BirA) catalyses the reaction of biotin with specific polypeptide,
which is not recognised by biotin ligases from other species (figure 9, A). To reduce the size
of the tag, the laboratory of Schatz identified a 14-residue peptide as a minimal requirement
for BirA-catalysed biotinylation. Initially, the biotinylated proteins were further modified with
streptavidin-conjugates[81, 82]. In 2005, the Ting lab discovered that BirA tolerates a ketone
derivative of biotin as a substrate, which enabled the possibility to specifically functionalise the
ketobiotin with hydrazide or aminooxy compounds in bioorthogonal reactions[83]. More recently,
the same group applied biotin ligases from yeast (yBL) and Pyrococcus horikoshii (PhBL), to
covalently bind biotin analogues with azide or alkyne groups to an acceptor protein[84]. However,
more dramatic modifications of the biotin are not tolerated. Furthermore, the requirement of a
second bioorthogonal reaction to introduce a specific function, limits this approach. Extending
their studies, the same group investigated the covalent ligation of lipoic acid to a 22-amino acid
long E. coli lipoic acid ligase (LplA) substrate (LplA-tag) (figure 9, B). Initially, LplA exhib-
ited similar small molecule substrate tolarence as BirA and only small functional groups, such
as azides or alkynes, were tolerated[85]. Mutation of the crucial residue W37 within LplA ex-
panded the substrate specificity, allowing introduction of coumarins[86–88], aryl aldehydes[89],
aryl hydrazines[89], aryl iodid[90], and trans-cyclooctene[91]. Despite these advances, most toler-
ated substrates depend on a second reaction to introduce functionalities for specific applications.
Moreover, incorporation of different and more complex substrates requires an individual mutant
for each substrate.
The formylglycine-generating enzyme (FGE), another enzyme applied to site-selectively modify
proteins, suffers from similar limitations. FGE oxidizes a cysteine within a six-amino acid motif
(aldehyde tag) found in typ I sulfatases to formylglcine (FGly) (figure 9, C). The modification
occurs prior to the protein folding and is required for the catalytic activity of sulfatases[92].
Bertozzi and colleagues genetically encoded the aldehyde tag to cytosolic, as well as membrane-
associated proteins in E. coli and mammalian cells[92–94]. Co-expression of tagged POIs and
FGE rapidly produced aldehyde-containing proteins, which could be further functionalised by
condensation reactions with aminooxy or hydrazide probes[92–94]. Interestingly, endogenous
proteins possessing the FGly residue (e.g. lysosomal and secreted sulfatases) did not undergo
condensation reactions, outlining the high selectivity of the aldehyde tag[92]. Lin and Ting
exploited the transglutaminase (TGase) catalysed amide formation between the central glutamine
within a small polypeptide tag (Q-tag) and aliphatic amine derivatives (figure 9, D)[95]. In a
proof of concept, the authors selectively labelled cell surface proteins fused to a Q-tag with
functionalised cadaverine derivatives in the presence of TGase. Although, TGase tolerates a
broad scope of amine substrates, its low selectivity for Q-tag and competing endogenous TGase
substrates, limits this method to extracellular studies[95].
Sortase is another well-studied enzyme used to incorporate novel functionalities into proteins.
One of the most commonly applied sortases is Sortase A from Staphylococcus aureus, which
cleaves a 5 amino acid motif (LPXTG) between threonine and glycine and subsequently links
the carboxyl group of threonine to the amino group of a N-terminal glycine in the presence of
Ca2+ (figure 9, E)[96]. Popp et al., successfully demonstrated labelling of POI-LPETG fusion
proteins ex vivo[97]. Similarly, the group of Nagamune site-specifically labelled POIs expressed
at the cell surface with a fluorophore- or biotin-containing peptide derivative[98]. More recently,
the Ploegh group used the Ca2+-independent sortase A from Streptococcus pyogenes to target
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proteins in the cytosol and in the lumen of the endoplasmic reticulum[99].
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Figure 9: Protein labelling with different enzyme-mediated chemical tags. A) BirA catalysed labelling of
specific polypeptide with biotin (X = NH) or its ketone bearing analogue (X = CH2). B) LplA catalysed
ligase of a lipoic acid deriative to the primary amine in the substrate sequence. C) FGE catalysed
oxidation of the thiol to the corresponding aldehyde in the unfolded protein and subsequent protein
folding. D) TGase catalysed amide formation between the primary amine and the central glutamine in
the Q-tag. E) Sortase catalysed labelling of POI F) PPtase catalysed phosporylation of a serine in the
substrate G) FTase catalysed isoprenilation.
Phosphopantetheinyl transferases (PPtases) from E. coli (AcpS) and B. subtilis (Sfp) are ar-
guably the most promising enzymes to modify proteins, as they tolerate a variety of function-
alities and are orthogonal to mammalian PPtases[100]. Sfp and AcpS catalyse the transfer of
a phosphopantetheinyl unit from coenzyme A (CoA) to a serine residue within peptide carrier
protein (PCP) and acyl carrier protein (ACP), respectively (figure 9, F)[100, 101]. In a proof
of concept, Walsh and co-workers genetically fused PCP to the N-terminus of β-galactosidase
or luciferase. Sfp post-transcriptionally modified tagged proteins with biotinylated CoA, in
cell lysates[101]. Simultaneously, the Johnsson group reported the AcpS-catalysed labelling of
ACP-cell surface protein fusions[100]. However, the low cell permeability of CoA limited these
approaches to extracellular studies. To overcome this drawback, Clarke et al. capitalised on
the biosynthesis of CoA[102]. The authors incubated E. coli cells with a nonhydrolyzable and
cell permeable coumarinyl derivative, which was biosynthetically converted to the corresponding
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coumarinyl CoA analogue. Subsequently, Sfp recognised this analogue and linked it to a PCP
fusion protein. To reduce the size of ACP and PCP tags, Walsh and colleagues screened a phage-
displayed library[103]. The resulting 11-residue peptide YbbR13 was selectively recognised by
Sfp. Extending their studies, the same group identified two new peptides (S6 and A1) with
orthogonal reactivities for Sfp and AcpS[104].
Farnesyltransferase (FTase) and geranylgeranyl transferase-1 (GGTase-1) are enzymes, which at-
tach 15 or 20-carbon long isoprenoids to a four amino acid sequence (CAAX) (Figure 9, G)[105].
Although, FTases and GGTases-1 tolerate a variety of isoprenoid derivatives, site-reactions with
endogenous proteins containing the CAAX sequence, limit this approach to extracellular stud-
ies[105, 106]. However, the results in recent studies suggest that mutation of the acceptor peptide
and enzymes from different species may lead to completely orthogonal enzyme/substrate pairs,
which could be applied in vivo[107–109].
1.2 Labelling two proteins with a bifunctional molecule
In the last decades, in vivo studies revealed that the function of proteins is strongly regulated
by the formation of multi-protein complexes. Each protein typically has several alternative in-
teraction partners, and the selectivity of this protein-protein interaction (PPI) determines the
specific function of the proteins. Techniques to identify interaction partners, such as Fo¨rster
resonance energy transfer (FRET), yeast two hybrid systems, protein complementation or im-
munoprecipitation from cell lysates, are restricted to rather strong interactions[3]. In contrast,
small bi-functional molecules can induce protein-protein interactions or increase their stability.
Protein cross-linkers covalently link previously dimerised interacting proteins together (figure 10,
A and B), whereas chemical inducers of dimerisation (CIDs) force the dimerisation of two pro-
teins (figure 10, C and D). Two types of bi-functional molecules can be distinguished regarding
their functional groups. Homobi-functional molecules contain identical functional groups at both
reactive sites and heterobi-functional reagents contain two orthogonal functions[3, 110, 111].
POI POIPOI POI
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Figure 10: Concepts of chemical inducers of dimerisation and selective bi-functional cross-linkers. A)
Cross-linking of two identical self-dimerising proteins. B) Cross-linking of heterodimerising proteins. C)
Dimerisation of two identical proteins with a homodimeriser. D) Dimerisation of two different proteins
with a heterodimeriser.
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1.2.1 Protein cross-linkers
A wide variety of direct homobi-functional and heterobi-functional cross-linkers are commercially
available[3]. Most of these bi-functional molecules contain NHS ester derivatives, maleimide
and/or disulfides to label amines or thiolates on the protein surface. However, these cross-
linkers are mainly limited to in vitro experiments, due to their poor selectivity. This drawback
was partially solved for heterobi-functional cross-linkers by using a two-step reaction to link
the two proteins of interest[3]. Therefore, a photoreactive moiety was introduced on one side
of the cross-linker. Firstly, the photoinsensitive functional group reacts with the protein and
after irradiation, the photoreactive group reacts non-specifically with the nearest C-H or N-H
bond[112]. Photoreactive groups used for this approach include aryl azides and diazirine rings,
which form highly reactive nitrene, respectively carbene, intermediates. To further improve
this approach, various groups introduced photoreactive amino acids at defined positions of the
protein[113, 114]. However, their small size requires close proximity of the interacting proteins
and incorporation of several unnatural amino acids into the protein. Alternatively, a chemical
tag-based approach can be used to selectively cross-link interacting proteins. Interestingly, the
group of Scherpartz split the TC tag into two bicysteine (BCys) motifs[115, 116]. The bipartied
TC tag were fused apart from each other, either in two different proteins or in the same. Upon
interaction or folding of the BCys containing proteins, the two dicysteine pairs were brought
in close proximity and were recognised by FlAsH or ReAsH. However, the short distance
between the two arsenic groups (= 4.65 A˚) limits this approach. To overcome this limitation,
Schultz and co-workers synthesised a dimeric derivative of FlAsH (xCrAsH). Two bisarsenic
derivatives of carboxyfluorescein were connected with a flexible spacer. xCrAsH successfully
cross-linked FKBP fused to TC tag with FRB fused to TC Tag in the presence of the CID
rapamycin (section 1.2.2.3), in vivo (scheme 4, A)[117]. Alternatively, the group of Johnsson
designed a novel technique (S-CROSS) to detect and characterise hetero- and homo-dimeric
protein-protein interactions in cell lysate[118]. S-CROSS is based on the specific cross-linking
of SNAP-tag and/or CLIP-tag fusion proteins with a bi-functional small molecule consisting of
fluorescent BG and/or BC derivatives (scheme 4, B). To demonstrate the utility of S-CROSS,
the authors quantitatively and simultaneously studied a number of homotypic and heterotypic
protein-protein interactions. Moreover, S-CROSS permitted to investigate the stability of protein
complexes and to differentiate between strong and weak interactions. In collaboration with the
Johnsson group, Go¨nczy and colleagues used fluorescent microscopy techniques in combination
with S-CROSS to investigate interactions between centrosomal proteins[119]. Therefore, a set
of 31 centrosomal proteins fused to SNAP-tag and CLIP-tag were pairwise incubated with a
fluorescent BG-BC. Samples were subjected to SDS gel electrophoresis and analysed by in-gel
fluorescence scanning, resulting in identification of three novel interacting partners. Recently,
Sun et al., reported the first in vivo application of S-CROSS[120]. In this study, S-CROSS was
used to investigate the ligand-mediated homodimerisation of the epidermal growth factor receptor
(EGFR) and subsequent activation of downstream transduction pathway. Thus, cells expressing
recombinant EGFR-SNAP-tag fusion proteins were treated with a bi-functional BG cross-linker
in the presence or absence of ligand stimulus. Although only small amounts of dimers were
observed in unstimulated cells, these results support the hypothesis that EGFR monomers and
dimers are in equilibrium. However, PPI interactions identified with bi-functional tag substrates
require careful analysis as these cross-linkers may also induce dimerisation on their own[117,
121]. Alternatively, the Ting lab engineered an LplA mutant, which specifically labelled its
acceptor peptide with a photoreactive aryl azide. To validate their method, cell lysate containing
predimerised FRB and FKBPLAP fusion proteins and the LplA mutant were treated with the
aryl azide derivative and subsequently irradiated[122, 123]. Mayer and co-workers designed a
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targeted and releasable affinity probe (TRAP), consisting of a FlAsH derivative covalently
tethered to a photoreactive benzophenone (scheme 4, C)[124]. TRAP targets specific POIs
fused to TC-tag and captures binding partners upon light activation. The authors successfully
used TRAP to identify fibronectin as a binding partner of the abundant muscle membrane
protein, phospholamban.
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1.2.2 Chemical inducers of dimerisation
While cross-linkers are useful tools to detect and characterise naturally occurring PPIs, chemical
inducers of dimerisation (CIDs) allow specific and independent regulation of protein activity.
In principle, CIDs are small organic molecules, which trigger the assembly of two POI-Tag fu-
sion proteins resulting in a trimeric complex. Homodimerisers promote the dimerisation of two
identical proteins, whereas heterodimerisers force the dimerisation of two distinct proteins. The
nature of the CID can vary from a simple natural bi-functional product that binds to pro-
teins (e.g. coumermycin, rapamycin), molecules that induce a conformational change of the
protein, thereby creating a binding site for a second protein (e.g. S-(+)-abscisic acid, gib-
berellin), to synthetic molecules, which are composed of two protein ligands connected with a
flexible linker[125]. In general, natural CIDs display better biophysical properties, such as cell
permeability and water solubility, but are harder to modify. In contrast, the linker of synthetic
CIDs allows the relatively simple introduction of new functionalities or modification of the bio-
physical properties. Two general strategies are frequently used to artificially regulate protein
activity (figure 11). In the first strategy, the CID interferes with the activity of the protein. In
this way, the CIDs are used to dimerise two proteins to force a specific response[126, 127], translo-
cate proteins to or away from their site of action to trigger or prevent signal transduction[128–
132], induce protein secretion[133] and destabilise PPI by inducing unfavorable steric interac-
tions[134, 135]. In the second strategy, the protein levels are controlled. In the most common
approach, the CID triggers the dimerisation of a DNA-binding domain (DBD) fusion and a tran-
scriptional activation domain (TAD) fusion, resulting in the transcription of a targeted gene[136,
137]. Other approaches regulate protein levels post-translational through translocation POIs to
the proteasom[138], dimerisation of the POI to the E3 ubiquitin ligase[139], reconstitution of
split ubiquitin sequences[140], or rely on unstable protein domains[141, 142]. Finally, CIDs can
be used to dimerise fusions of split-inteins, thereby generating new proteins with custom-made
properties[143, 144].
Protein translocation
Heterodimeric signal transducion
Homodimeric signal transducion
Regulated gene expression
Protein secretion
CID induced protein splicing
Destabilized PPIs
CID induced degradation
Figure 11: General approaches to regulate protein function with chemical inducers of dimerisation.
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1.2.2.1 Homodimerisers
The groups of Schreiber and Crabtree pioneered in the field of CIDs in the early 90’s[145]. Ani-
mated by the naturally occurring heterodimeriser FK506, which binds to the cytoplasmic protein
FKBP12 and calcineurin, they synthesised a symmetrical FK506 dimer (FK1012) (scheme 5,
A) able to bind to two FKBP12 proteins. To demonstrate the utility of this tool, the au-
thors treated cells expressing FKBP12 domains fused to the ξ-subunit of the T-cell receptor
with FK1012. Dimerisation of ξ-subunits led to rapid and dose-dependent activation of down-
stream targets. Although, FK1012 was used in several biological studies, binding to endogenous
FKBP12, its relatively big size and intolerance for modifications limited its application. Since
this first report, numerous synthetic FK1012 variants were designed with reduced affinity to
endogenous FKBP12, higher specificity, reduced complexity and improved conformational ori-
entation (scheme 5, B)[71, 72, 146, 147]. FK1012 and its improved analogues were frequently
used to regulate numerous biological processes, including the activation of MEKK2 [148], the
Fas-receptor and caspase mediated apoptosis[149–154], the activation of c-Abl Kinase[155], and
protein synthesis in neurons[156], among many other biological processes.
A complementary homodimeriser system is based on the N-terminal domain (220 amino
acids) of the B subunit of bacterial DNA gyrase (GyrB) and its natural bi-functional ligand,
coumermycin (scheme 5, C)[157]. Importantly, the coumermycin-mediated dimerisation of
GyrB can be readily reversed by addition of the monofunctional substrate, novobiocin. Moreover,
neither coumermycin nor novobiocin has any high-affinity targets in eukaryotic cells. In a first
application, Farrar et al. successfully activated MEK by homodimerising Raf-1-GyrB fusions in
the cytosol127. Interestingly, downstream targets such as Erk1 and Erk2 were not affected by
cytosolic Raf activation. In contrast, recruitment of Raf-GyrB fusion to the membrane, prior to
activation with coumermycin, led to complete activation of downstream targets, underlining
the importance of correct localisation to activate signaling pathwys[158]. Apart from this study,
the coumermycin/GyrB system was extensively used to investigate the Jak/Stat pathway[159–
165], dimerise membrane-bound receptors[166–169], study intracellular signal transducers[170–
172] and control gene expression[173].
Several different systems were developed to expand the palette of homodimerisers. In an early
example, the groups of Crabtree and Schreiber used the orthogonal chemical genetic approach to
create an artificial receptor-ligand pair based on cyclosporin A (CsA) and its target cyclophilin
(CyP)[174]. Connecting two modified CsA molecules via a short linker, resulted in a cell-
permeable non-toxic homodimeriser (CsA-CsA) (scheme 5, D)[175]. In a first application, this
CsA-CsA dimeriser was used to induce Fas-mediated cell apoptosis. The group of Hu connected
two MTX derivatives with a flexible linker (scheme 5, E). The resulting bisMTX molecule
was able to homodimerise DHFR domains in vitro[176]. Interestingly, excessive addition of
dimeriser did not lead to saturation and formation of dimeric bisMTX-DHFR complex, suggesting
a cooperative binding model. Likewise, the group of Johnsson synthesised a series of small
molecules containing two BG groups connected with different flexible linkers (CoDis) (scheme
5, F)[121]. In a proof of concept, the authors treated cells expressing fusions of POI-SNAP-tag,
with CoDis, which resulted in rapid and proximity-dependent dimerisation.
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1.2.2.2 Heterodimeriser
The most widely used heterodimeriser system is based on the natural immunosuppressant ra-
pamycin (Rap) or its analogues (Rapalogs) (scheme 6). rapamycin sequentially and rapidly
binds to FKBP12 and the FRB (FKBP12-rapamycin-binding) domain of mTOR (mechanistic
or mammalian target of rapamycin), thereby forming a tertiary FKBP-Rap-FRB complex[177].
The formation of this complex leads to efficient inhibition of mTOR complex 1 (mTORC1), a
kinase strongly involved in cell growth and cell proliferation[178]. In its first application, Rivera
et al., regulated the gene expression of the secreted alkaline transferase in human fibrosacroma
cells[179]. Since this initial study, the rapamycin dimeriser system has frequently been used to
study numerous biological processes[180]. However, the intrinsic activity of rapamycin dramat-
ically limits its applications. To overcome this drawback, research groups subjected this system
to the ”bump and hole” approach, to generate a bioorthogonal ligand-protein pair. X-ray crys-
tal structures of the FKBP12-rapamycin-FRB tertiary complex revealed that the C16-methoxy
group of rapamycin directly points toward the FRB domain[178]. The group of Luengo demon-
strated that substitution of this methoxy group can alter the FRB-binding affinity[181]. Inspired
by this study, the Schreiber group synthesised a series of rapalogs, containing a bulky substituent
at FRB-binding site and evaluated their toxicity (e.g. iRap, AP21967, scheme 6) [182]. Triple
mutation in the α-helix of FRB led to FRB mutants with a compensatory ”hole” able to bind
the identified non-toxic rapalogs. Up until now, numerous C16 rapalogs/FRB mutant pairs have
been designed to improve the pharmacokinetics of the rapalogs[131, 141, 181].
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Scheme 6: Chemical structure of rapamycin and two mTORC1 safe rapaloges iRAP and AP21967.
Aside from the nucleophilic substitution at the C16 position, to disrupt endogenous FRB bind-
ing, modification of the C40-hydroxyl allows for introduction of specific functionalities without
interfering with FKBP binding. Among many examples of C40 rapalogs, some of the most ex-
citing ones are labelled with fluorescein for cell imaging[183, 184], attached to biotin derivatives
to immobilise the rapalog on surfaces[183], or contain photocleavable groups to spatiotemporally
control the dimerisation (section 1.3.1)[185, 186]. Since the initial report from Schreiber et al.,
rapamycin and rapalogs, were commonly used to manipulate GTPase signaling pathways[131],
intracellularly activate GPCRs[187, 188], and regulate phosphoinositide levels at specific cellular
compartments[189–191]. Apart from inducing transduction pathways, the rapamycin system
has been used to develop several techniques to translocate the POI to the proteasome, which
induced complete degradation of the POI[138]. In contrast, Crabtree and co-workers designed
a destabilised FRB mutant[142]. Analogues to DDFKBP and DDDHFR proteins, fused to
this destabilised FRB mutant, are readily degraded, which is prevented by the addition of ra-
pamycin. The group of Muir used the rapamycin system to post-translationally change the
primary structure of a protein[143, 144]. Therefore, they combined the concepts of trans-splicing
and CIDs. Splicing refers to a naturally occurring process, in which an internal domain of the
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protein (intein) is excluded from the protein followed by ligation of the two adjacent sequences
(exteins). In the presence of rapamycin, split-inteins fused to FKBP and FRB, were comple-
mented and the exteins fused to the inteins, were ligated. Pratt et al. reported a conceptually
similar approach to control protein levels[140]. They inserted a split-ubiquitin and FRB between
a POI and a small sequence, that induces protein degradation (degron). Addition of rapamycin
results in dimerisation with FKBP and the complementary split-ubiquitin. The reconstituted
ubiquitin is subsequently recognised and cleaved by a protease, thus releasing and rescuing the
POI[140]. Alternatively, the rapamycin method can be used to anchor POIs away from their
site of action and thereby inhibiting the function of the protein. This approach was applied to
arrest adaptor proteins to the mitrochondrial membrane, and to trap nuclear proteins in the
cytoplasma by dimerising these proteins to large ribosomal subunits[129, 130]. Rapamycin was
also used to shuttle several proteins across the nuclear membrane[141, 192–195].
Recently, three other natural products were reported to chemically induce protein heterodimeri-
sation. Binding of S-(+)-abscisic acid (ABA) (scheme 7, A) to a PYL1 protein domain, induces
a conformational change in this domain, thereby creating an extensive binding surface for an
ABI1 domain. ABA and its target domains fused to corresponding proteins were used to in-
duce gene transcription, localise proteins to subcellular compartments, and regulate signaling
transduction in mammalian cells. Moreover, the ABA system and the rapamycin system were
used in parallel to translocate different proteins independently[126]. However, this novel het-
erodimeriser system displayed significant slower reaction kinetics compared to the rapamycin
system. Analogues, the plant hormone gibberellin (GA3) (scheme 7, B) regulates the dimerisa-
tion of truncated GAI and GID1 fusion proteins. However, the negative charge of the carboxyl
group reduces the cell permeability of this dimeriser dramatically. To overcome this drawback,
Myamoto et al., protected this side of the molecule with an acetoxymethyl group (GA3-AM)
(scheme 7, B), which is readily hydrolysed by endogenous esterases[196]. The orthogonallity
of the GA3 and rapamycin was demonstrated by recruiting CFP-FKBP to membrane bound
FRB, and YFP-CID1 to mitochondria localised GAI. In contrast to ABA, GA3 induced dimeri-
sation of its target proteins with similar speed compared to rapamycin. Ottmann and his group
used the natural product Fusicoccin (scheme 7, C), a diterpenoid glycoside to dimerize T14-
3-3-cΔC and CT52 fusion proteins. to translocate[197]. In proof of concept, the authors suc-
cessfully translocated POIs to the plasma membrane, into and out off the nucleus. Notably, the
fusicoccin-induced dimerization of fusion proteins could be reversed by exchanging the medium.
However both the dimerization and dissociation of T14-3-3-cΔC-CT52 fusion proteins proceeded
at relatively slow rates[137].
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Scheme 7: Chemical structure of protein dimerising plant hormones. A) ABA. B) GA3 and the cell
permeable analogue GA3-AM C) Fusicoccin.
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To increase the scope of application, several groups generated synthetic heterodimerisers con-
necting two tag ligands with a variety of linkers. An important technique developed on the basis
of synthetic heterodimerisers, is the yeast three-hybrid system[198]. In contrast to standard gene
expression assays, the synthetic CID consists of a known ligand for the DNA-binding domain
fusion and a ligand for the unknown protein. Screening of activation domain fusion libraries
allows the identification of protein targets for the ligand under investigation. In the course of
developing this system, Licitra and Liu designed the first synthetic heterodimeriser, based on
FK506 and the glucocorticoid ligand (GR) dexamethasone (DEX-FK506) (scheme 8, A)[198].
Simultaneously, Belshaw et al., reported a synthetic heterodimeriser, tethering FK506 and CsA
with an aliphatic linker (FK506-CsA) (scheme 8, B)[199]. First applications of this CID have
included recruitment of a POI to a specific subcellular location and regulation of gene expression.
In recent years, several conceptual similar CIDs were reported. The Cornish group for example
covalently linked the tag substrates TMP and SLF (TMP-SLF) to promote the dimerisation of
FKBP and eDHFR fusion proteins (scheme 8, C)[200]. In 2003, the group of Wandless designed a
variation of this CID system. The authors introduced a very small linker between MTX and SLF
(MTX-SLF) to destabilise protein-protein interactions (scheme 8, D)[134, 135]. The resulting
steric collisions and electrostatic repulsions between the dimerised proteins were severe enough to
favor reaction of the bi-functional molecule with only one tag, thus preventing dimerisation. In
a model experiment, DHFR was selectively inhibited in cells lacking FKBP. In contrast, DHFR
was resistant to treatment with the MTX-SLF dimeriser in cells expressing FKBP[135]. Gest-
wick et al., used a conceptually similar approach to prevent aggregation of Aβ-amyloid, a key
process in the pathogenesis of Alzheimer[133]. Therefore the amyloid ligand, Congo Red, was
chemically linked to SLF (congoRed-SLF) (scheme 8, E). The molecule-induced dimerisation
of FKBP and Aβ, which sterically prevented aggregation of the latter. In 2014, the Wu group
regulated targeted gene expression with an SLF*-TMP dimeriser (scheme 8, F)[137]. Notably,
addition of monomeric TMP rapidly disrupted the heterodimeric complex. Similarly, Schultz
and co-workers developed a reversible CID system based on the SNAP-tag and F36VFKBP[201].
Therefore, the authors synthesized BG-SLF* (scheme 8, G). The addition of SLF* readily led
to the dissociation of BG-SLF* -induced SNAP-tag and F36VFKBP tag fusions proteins. Feng
et al. used this system to reversibly control PI3K activity in HeLa cells.
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Given the broad utility of these heterofunctional CIDs, the Cornish lab prepared an alternative
dimeriser system, containing ligand-receptor pairs, which avoid FKBP12-binding. Through this
approach, DHFR targeting MTX and DEX were covalently connected with different linkers
(scheme 9, A)[202, 203]. Based on these MTX-DEX dimerisers, the same group designed two
three-hybrid systems to monitor the activity of enzymes[8]. In the first approach, the enzyme
target is introduced as a linker between DEX and MTX as a linker. In the presence of active
enzyme, the linker between the protein ligands is cleaved, leading to disruption of the reporter
gene expression (figure 12, A)[8]. As a model reaction, the β-lactam hydrolase-mediated hydrol-
ysis MTX-cephalosporin-DEX was investigated. This system was successfully applied to study
the evolution of antibiotic resistant class C β-lactamase[204]. Complementary to this, the same
group used split-CIDs to investigate enzyme-mediated complementation (figure 12, B). The au-
thors used glycosynthases to bind DEX linked to cellobioside and MTX to lactosyl fluoride205.
In more recent studies, the MTX moiety was replaced with the eDHFR selective inhibitor TMP
to reduce potential reactions with endogenous DHFR (TMP-DEX) (scheme 9, B)[205]. Like-
wise, Athavankar et al., controlled gene expression of POIs in vivo with unmodified biotin as a
CID[206]. This system relies on the co-expression of BirA, streptavidin-POI fusion protein and a
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biotin acceptor peptide, fused to a second POI. BirA catalyses the acylation of a lysine in the bi-
otin acceptor peptide, and biotin yields a biotinylated fusion protein, which then binds with high
affinity to streptavidin and completes the dimerisation. Later, the group of Fussenegger used this
system to design a gene repression system[207]. Therefore, the authors co-expressed tetracycline-
dependent transactivator (tTA)-AviTag, BirA and streptavidin-KRAB (krueppel-associated box
protein of human kox -1 gene) in mammalian cells. In the absence of biotin, tTA-AviTag binds
and activates tetracycline-responsive promoters, whereas biotin-mediated dimerisation of tTA-
AviTag fusion and streptavidin-KRAB fusion, represses gene expression.
Enzyme
Enzyme
A)
B)
Figure 12: Principle of enzyme-mediated three-hybrid system. A) The heterodimeriser containing a
substrate for the enzyme induces the reporter gene expression. In the presence of enzyme, the CID is
cleaved and the expression stopped. B) The split CID is unable to induce reporter gene expression on
its own. In the presence of enzyme, the CID is complemented and the reporter gene is expressed.
The group of Kikuchi, synthesised a heterodimeriser, biotin-6-aminohexanoylampicillin
(ampicillin-biotin) (scheme 9, C) to dimerise E166NTEM-1 and streptavidin fusions[208]. In
a first application, this group labelled POI-E166NTEM-1 with streptavidin containing super-
paramagnetic iron oxide nanoparticles, which allowed detection of POI expression with 1H-MRI.
The lab of Peterson synthesised a series of different heterodimerisers, fusing biotin to DEX, and
the β-esteriol inhibitors estrogen or estrone oxime (scheme 9, E, F, G)[209, 210]. In a proof of
concept, the authors successfully regulated the gene expression of a reported protein. Similarly,
the group of Johnsson tethered biotin to 4-(Aminomethyl)-O6-benzyl guanine (scheme 9,
H)[211]. However, this CID was mainly used in phage displays to immobilise SNAP-tag fusion
proteins. The same group also designed heterodimeriser systems based on the SNAP-tag and
DHFR, connecting 4-(Aminomethyl)-O6-benzyl guanine and MTX (scheme 9, I)[212]. This
system rapidly induced dimerisation of DNA-bound LexA-SNAP-tag fusions and B42-DHFR fu-
sions to trigger gene expression of a reporter protein. Etoc et al. developed a magnetogenetic
approach to spatially induce signaling transduction of self-assembling proteins. In this approach,
POI functionalised magnetic particles act as a hot spot for endogenous interacting partners[213].
To functionalise the magnetic particles, the authors used a heterodimeriser based on biotin and
the HaloTag substrate (scheme 9, D). In proof-of-concept, the authors microinjected strepta-
vidin containing magnetic particles into cells expressing TIAM1-HaloTag. Incubation of these
cells with a biotinylated chlorohexane derivative recruited TIAM1-HaloTag to the magnetic par-
ticle. Subsequential translocation of the POI functionalised particles to the cell membrane with
a magnetic force triggered TIAM1-Rac1 interaction, thus locally inducing a signaling response.
22 ∣ p a g e
Introduction
Halo-biotin
Cl
OO O
H
N
N N
N
NH
N
HN
S
O
HH
O
N
H
O
H
N
O
O
4
HN NH
S
O
H H
O
H
NN
O
HN NH
S
O
H H
O
H
NN
H
O
N
H
8HO
OH
9
O
O
HOHO
F
HN NH
S
O
H H
O
H
NNNON
O
O
HO
8
N
NN
N
N
N
H
O
HO2C
H
N O
NH2
NH2
H
N
O
O
N
NN
N
H NH2
DEX-biotin
OH
H F
O
O
H
N
HO
SSN
H
CO2HO
N
N
N
N
N
NH2
H2N MTX-DEX
n
OH
H F
O
O
H
N
HO
SS
H
N
TMP-DEX
8O
O
OMe
OMe
N
N
NH2
H2N
estroge-biotin
estrogen oxime-biotin
BG-MTX
A)
B)
C)
D) O
N
NN
N
H NH2
H
N
O
N
H
O
HH
O
S
NHHN
BG-biotin
E)
F)
G)
H)
HN NH
S
O
H H
O
H
NN
H
OH
N
O
S
OO
OH Ampicillin-biotin
I)
Scheme 9: Chemical structure of alternative heterodimerisers; A) MTX-DEX. B) TMP-DEX. C)
DEX-biotin. D) Halo-biotin. E) estrogen oxime-biotin, F) estrogen-biotin. G) BG-biotin. H)
BG-MTX.
Our group recently reported the first example of a completely covalent heterodimeriser, based
on the SNAP-tag and HaloTag technologies[128]. Therefore, we covalently linked the SNAP-tag-
and the HaloTag-substrate with various linkers, giving rise to a series of CIDs named HaXS. To
biologically validate these HaXS molecules, dimerisation of SNAP-GFP fusions and Halo-GFP
fusions was performed in HeLa cells. The covalent nature of the dimerisation allowed simple
SDS-page analysis. HaXS8 (scheme 10), the best performing dimeriser in this study, bears a
short tetrafluophenyl moiety for improved cell permeability, as well as a small polyethylene glycol
chain for better water solubility. In a proof of concept, we successfully translocated a protein of
interest to different subcellular compartments. Further, HaXS8-mediated translocation of Halo-
iSH2-GFP fusion protein to the plasma membrane, rapidly activated the PI3K/mTOR pathway.
Although the described CIDs are powerful tools to regulate protein activity in living cells, they
suffer from relative low temporal and spatial resolution based on their cell permeability and their
diffusion inside the cells. To overcome such limitations, numerous light-activatable systems were
developed to control protein functions in vivo.
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1.3 Photo-activatable tools to regulate the function of proteins
The concept of regulating biological processes with light was introduced into the field of chemical
biology in the late 70’s by the groups of Schlger and Hoffman. In these early studies, biologically
active compounds were deactivated or ”caged” with photolabile protecting groups (PPGs). Since
then, several approaches have been developed to manipulate protein function with light using
protein tags and as a result, will be discussed in this section.
1.3.1 Chemical tag based tools to modify proteins with light
Photosensitive protecting groups are most often applied to cage a bioactive molecule. Upon
irradiation with light at an adequate wavelength, the cage is cleaved and the active compound
is liberated. Until now, numerous examples of caged bioactive molecules have been reported,
including important signaling molecules, several other small protein effector molecules and en-
zyme substrates[214]. Alternatively, protein activity can be regulated by directly caging the
protein. Here, a caged unnatural amino acid is introduced at the active site of the protein,
through unnatural amino acid site-directed mutagenesis and can then be expressed in cells using
orthogonal synthase/tRNA pairs[21]. Cropp and co-workers for example, genetically encoded a
caged cystein into the TC-tag sequence, thereby dramatically decreasing the affinity of FlAsH.
In fact, labelling of TC-tag fusion protein was not observed in yeast cells prior to irradiation[215].
The laboratory team of Hahn, introduced the photocleavable methyl-6-nitropiperonyloxycrbonyl
group at the C40 position of rapamycin (pRap) (scheme 11, A)[186]. However, this photocaged
rapalog was still able to induce dimerisation between FKBP and FRB. To overcome this limita-
tion, the authors genetically engineered a mutant FKBP (iFKBP) to avoid interaction of tag with
pRap prior to its uncaging. In contrast, Sadovski et al. caged the C16 position of rapamycin
with a dimethyl nitrobenzyl group (C16-DMNB Rap) (scheme 11, B)[216]. However, cells were
only incubated with C16-DMNB Rap after irradiation, hinting that C16-DMNB rapamycin
might not be cell permeable or that photolysis in cells might be problematic. Similarly, Johns-
son and his group observed that the introduction of a photocleavable nitrophenyl group at the
N7-position (C7-NPE-BG), but not at N9 of BG, disrupted SNAP-tag reactivity (scheme 11,
C)[217]. Based on this observation, the authors successfully photoregulated fluorescent labelling,
as well as homodimerisation of proteins,in cell lysate. Most recently, Ballister et al. developed
a cell-permeable and photo-activatable CID system, based on a NVOC-caged TMP and the
HaloTag substrate (cTMP-Htag) (scheme 11, D)[218]. In a proof of concept, the authors suc-
cessfully recruited a POI protein to the centromer, kinetochores, centrosomes and mitrochondria
in HeLa cells, after the photocleavage of the protecting group.
In a complementary approach, the PPGs are incorporated into the core of molecules as pho-
tocleavable linkers. This approach was effectively used in several studies to selectively release
bioactive molecules from nanoparticles, reversibly alter the cell permeability of molecules, de-
grade bioactive molecules, reversibly cross-link proteins, release proteins from specific locations,
and deactivate proteins[214, 219]. Inoue and co-workers for example, introduced a photocleavable
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methyl-6-nitroveratryl group between a biotin and He-rapamycin, a C40 rapalog with similar
properties as rapamycin (Rap-MeNV-biotin) (scheme 11, E)[185]. The high affinity of bi-
otin towards avidin was used to arrest the designed rapalog extracellularly. Upon irradiation,
He-rapamycin was released, penetrated the cell membrane and induced dimerisation inside the
cell. Although, active He-rapamycin can be released with high spatial and temporal control,
free diffusion of active He-rapamycin inside cells limits this approach. The lab of Williams syn-
thesised a photocleavable homodimeriser based on the FKBP-FK506 system[220]. The authors
tethered two SLF* with a photocleavable o-nitrobenzyl derivative (PhAP) (scheme 11, F) In
proof of concept, they used PhAP in combination with a previously developed LC8TRAP protein
to inhibit the interaction of LC8 with its endogenous ligands, ultimately leading to the dispersion
of the endosome. Irradiation of cells with light at 365 nm for 10 minutes resulted in cleavage
of the PhAP-LC8-LC8TRAP complex and gradual recovery of the endosomes to the perinuclear
region. Although, these result demonstrate the high potential of cell-cleavabel dimerisers, the
relative long irradiation times required to induce photolysis may be critical.
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Incorporation of a photosensitive group into the backbone of a protein presents an attractive pos-
sibility to trigger proteolysis and thereby control the activity, lifetime and localisation of proteins.
Therefore, several groups genetically or semi-synthetically introduced 2-nitrophenylglycine or 2-
nitrophenylalanine into a protein[221–225]. This approach was successfully applied to regulate
the activity of Shaker B K+ channel, nicotinic acetylcholine receptor, caspase-3, and Smad[221–
223]. Chromophore-assisted light inactivation (CALI) is an alternative strategy to instanta-
neously down-regulate the activity of proteins with subcellular precision. In CALI, the reaction
of an excited chromophore with oxygen is used to produce reactive oxygen species (ROS), which
leads to the elimination of POIs (figure 13). To avoid cell damage and cell death caused by unspe-
cific oxidation, ROS requires to be generated in close proximity to the POI. Originally, CALI used
target-specific antibodies conjugated to the chromophore, Malachite Green, to selectively inacti-
vate POIs[226]. Unfortunately, this system requires microinjection of the antibody-chromophore
conjugate and the design of a unique antibody for each target. Additionally, Malachite Green is
hydrophobic and tends to aggregate. Several years later, Surrey et al. used a fluorescein isothio-
cyanate (FlTC) and GFP to address these limitations[227]. In a model experiment, a fluorescein
labeled antibody inactivated β-galactosidase 50 times more effectively than the corresponding
Malachite Green conjugate, whereas GFP only partially degraded the enzyme. In subsequent
years, the most common chemical tags and corresponding fluorescent ligands were applied to
target and inactivate POIs. FlAsH and ReAsH for example were used to regulate the polarity
of cells, in vivo[228]. Similarly, Marks et al. inactivated β-galactosidase-FKBP12(F36V) fusion
with light, in the presence of fluorescein labeled SLF*[229]. Although fluorescein SLF* has
no known endogenous targets, cells incubated with this ligand showed a considerable amount
of off-target effects. To improve the labelling selectivity, the group of Ellenberg adopted the
SNAP-tag system for CALI[230]. In a proof of concept, α-tubulin and γ-tubulin, genetically
fused to SNAP-tag, were expressed and labelled with BG diacetyl fluorescein in mitotic cells.
Light-induced inactivation of α-tubulin led to an arrest in metaphase, accompanied by a change
in spindle morphology. In contrast, inactivation of centrosomal γ-tubulin disrupted nucleation
of microtubules and impaired their growth. Takemoto et al., demonstrated that eosin, another
xanthene-based chromophore, exhibited a five-fold greater CALI efficiency and requires less in-
tense irradiation compared to fluorescein[231]. Subsequently, an eosin haloalkane was adminis-
tered to cells expressing HaloTag-POI fusion proteins. Regiospecific irradiation of cells containing
the labelled fusion protein, rapidly led to POI inactivation. In this way, the authors regulated
the translocation of PKCγ to the cell membrane, cell survival and cell division. Although GFP
does not generate ROS as effective as fluorescein, mutant variants with enhanced fluorescence
(eGFP, eYFP etc.) are frequently used to image and inactivate proteins. Two additional protein
tags, namely KillerRed and miniSOG, were applied in CALI experiments. In fact, KillerRed
generates 1000-fold more ROS compared to eGFP and is the protein of choice for self-labelling
CALI. The applications of CALI in combination with tags are versatile and are summarised in
recent reviews[232–234].
POIPOI
hυ
Figure 13: Principle of chemical tag-based CALI. Tag-POI fusion proteins are labelled with a fluo-
rophore containing tag substrate. Irradiation of the labelled tag rapidly leads to ROS induced fusion
protein degradation.
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In contrast to photoprotecting groups, photoswitchable groups allow reversible regulation of pro-
tein activity with small molecules. Most commonly used organic photoswitches, such as azoben-
zene, stilben, hemithioindigo, and spiropyran, undergo cis-trans isomerisation after irradiation.
This geometrical alteration is accompanied with a more or less strong change in polarity, depend-
ing on the photoisomeriser. Ideally, these changes are severe enough to switch between an active
and inactive state of the probe. However, none of the available organic photoswitches displays
complete conversion from one isomer to the other. Nonetheless, photoswitchable compounds are
becoming more and more popular in biology. Similar to photocleavable protecting groups, pho-
toisomerisable groups can be used to reversibly alter the activity of a small effector molecule. In
this manner, the activities of several protein classes were regulated, including enzymes, ligand-
gated ion channels and G-protein-coupled receptors[235, 236]. Recently, Fischer and colleagues
used a photoswitchable CsA derivative to reversibly regulate peptidyl prolyl cis-trans isomerase
(PPIase)[237]. Interestingly, the authors introduced a second protein-binding moiety on the
photochromic group to increase the activity difference of the two isoforms. Specifically, biotin
or CsA were linked through an azobenzene to CsA (scheme 12). Light-mediated isomerisation
from trans to cis of CsA-azo-CsA led to a seven-fold increase in inhibition of PPIase. Moreover,
in cells transfected with streptavidin, the cis isomer of CsA-azo-biotin exhibited a twelve-fold
higher suppressive activity than its trans isoform.
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Scheme 12: Chemical structure of photoswitchable bi-functional small molecules CsA-azo-CsA and
CsA-azo-biotin.
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1.3.2 Optogenetic approaches to regulate protein-protein interactions
Optogenetics is a rapidly immerging method to control the activity of whole cells or specific
proteins with light. In contrast to the techniques described above, optogenetics relies solely
on genetically encoded photosensitive proteins. First applied in neuroscience, the concept was
quickly adopted to regulate intracellular signaling[3, 214]. Therefore, several naturally occurring
plant photoreceptors were re-designed to control PPIs in living cells. Upon irradiation, these
optogenetic tags undergo chromophore-mediated conformational changes, which results in the
binding of their effector domain. Some of the first studies in the field of optogenetic protein
dimerisation used the phytochrom B (PhyB), the exogenous cofactor phycocyanobilin (PCB)
and members of the phytochrome interacting factor (PIF) family. The light insensitive apo-PhyB
autocatalytically ligates to the PCB chromophore, which is readily activated and rapidly binds to
the PIF protein, after irradiation with light at 650 nm. This dimerisation can be reversed within
seconds upon exposure to light at 750 nm. Quail and his group were the first to demonstrate the
feasibility of this approach[238]. In a model experiment, light-mediated dimerisation of PhyB-
DBD and PIF-TAD fusions reversibly induced the gene expression of a reporter protein. The
research groups of Muir and Voigt adopted this approach to regulate protein splicing of POI[239]
and to translocate the POI to membranes[240] with high spatial resolution. Light oxygen voltage
(LOV) protein domain is another class of plant photoreceptor subdomain, frequently used to
control PPIs. In response to blue light (440 - 473 nm), LOV domains bind to the endogenous
chromophore, flavin, which either induces or disrupts the assembly of LOV, with its interacting
partner. Kennedy et al. applied the LOV domain protein FKF1 and GIGANTEA, to control
the activity of the small GTPase Rac1 and the transcription factor Gal4[241]. However, this
system displays slow kinetics and the reaction is virtually irreversible. Similarly, the research
groups of Yang and Gardner, used the homodimerising LOV domain, VVD, respectively EL222,
to reversibly activate gene expression[242, 243]. In contrast, Wu et al., fused the LOV2 domain
to the carboxy-terminal of its binding partner, the helical extension (Jα) and Rac1[244]. In
the dark, LOV2 interacted with Jα adopting a sterically demanding closed conformation, which
prevented the dimerisation of the Rac1 with its effectors. Irradiation of the fusion protein
with blue light induced the formation of a covalent bond between LOV2 and flavin, thereby
dissociating and unfolding the sterically inhibiting LOV2-Jα complex and re-installing a Rac1-
effector interaction. A third class of optogenetic system is based on Cryptochrome 2 (CRY2) and
the N-terminal domain (CIBN) of its natural binding partner, CIB1 (Cryptochrome-interacting
basic helix-loop-helix 1). Upon stimulation with blue light (405 - 488 nm), CRY2 binds to flavin;
this in turn triggers the formation of a dimeric complex with CIBN, within a sub-second time
scale. In the absence of light, previously excited CRY2 relaxes and the formed complex dissociates
within a few minutes. In the proof of concept, Kennedy et al., regulated the translocation of POI
to the cell membrane, targeted gene expression and recombination of split-proteins[245]. Finally,
the Lin group used a combination of two photoactivatable fluorescent Dronpa mutants (145K
and 145N), to reversibly induce dimerisation. Notably, light-induced conformational change of
the chromophore not only triggers dimerisation, but also alters the fluorescence of the proteins
giving a direct read-out for successful dimerisation. In the monomeric state (dark state), Dronpa
displays no green fluorescence. Illumination of this monomeric species with violet light (390 -
400 nm) results in the rapid formation of a green-fluorescent dimer, which can be reversed by
irradiation with light at 490 nm. In an elegant application, the authors reversibly regulated the
activity of intersectins and proteases with light. Therefore, Dronpa145K and Dronpa145N were
fused to the N-terminus and C-terminus of POIs. Intramolecular dimerisation of Dronpa in cells
resulted in reduced POI activity, which was completely restored after irradiation with light at
490 nm. Although all four approaches display excellent spatial and temporal control of protein
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dimerisation, they suffer from several disadvantages, such as large protein tags, formation of
unwanted homodimers and sensitivity to visible light[246].
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2 Scope of the thesis
Chemical inducers of dimerisation are a powerful tool to specifically and independently regulate
the activity of virtually any protein within a cellular context. However, the majority of the
published CID systems, interfer with endogenous proteins or suffer from relatively low temporal
resolution, requiring 10 or more minutes until significant amounts of dimerisers are formed. We
therefore envisage to design novel CIDs, which enable the regulation of proteins with high spatial
and temporal control, without interfering with endogenous proteins. Since its first application in
1996, CID rapamycin has become the most widely used heterodimeriser, due to its fast in vivo
dimerisation kinetics, inducing dimerisation of FKBP and FRB fusion protein, on a timescale of
seconds to minutes (manipulating signaling at will). However, the immunossupressive activity
of rapamycin may counteract the advantage of this system. Despite the efforts to synthesise
rapamycin analogues with substituents at the FRB-binding site, small impurities of rapamycin
or rapamycin byproducts in these C16 rapalogs, still interfere with mTORC1. Therefore, we plan
to develop a simple and fast procedure to synthesise C16 rapalogs, which allows the reduction
of the rapamycin content to a minimum, prior to the purification step. This procedure would
enable the possibility to introduce a variety of substituents and proceed under mild conditions.
Ultimately, to demonstrate the feasibility of this procedure, the synthesis of a C16 rapalog, which
does not interfere with mTORC1 but induces dimerisation of FKBP, and an FRB mutant, was
targeted.
In an alternative approach to regulate protein dimers or the location of proteins with high spatio-
temporal control, the objective was the design and synthesis of cell permeable HaXS molecules,
which rapidly trigger the formation of stable protein dimers and undergo photolysis upon irra-
diation. Such molecules would allow to regulate the dimerization and sequentially reverse the
protein-protein interaction with two independent events. For cellular applications, these CIDs
should possess rapid photolytic rates at wavelengths of > 300 nm, without producing cytotoxic
by-products. Therefore, the aim was to introduce different o-nitrobenzyl and C7 substituted
coumarinyl-4-methyl derivatives into the core structure of the HaXS molecules, and to deter-
mine their photophysical properties. Ideally, the photophysical properties of two or more photo-
cleavable HaXS CIDs are different enough, that they could be used simultaneously and cleaved
independently. Additionally, we tried to synthesize a general photocleavable linker, which could
be incorporated into different synthetic CIDs. Ultimately, the goal was to demonstrate the
dimerization and subsequent cleavage of protein fusion proteins in a cellular context.
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3 Results and Discussion
3.1 Efficient Synthesis of C16-carbamyl Rapalogs via Lewis Acid De-
complexation
Rapamycin is a natural occurring CID, which binds sequentially to FKBP12 and only then to
FRB, a subunit of mTORC1[125]. Thus, rapamycin can conditionally induce dimerisation of
FKBP12-POI1 and FRB-POI2 fusion proteins[180]. Although rapamycin exhibits a very fast
dimerisation rate, its interference with endogenous mTORC1 signaling, limits its application.
Rapamycin analogues (so called rapalogs), which bear a substituent at the FRB-binding site,
were reported to prevent cross-reaction with endogenous TORC1[181, 182], and allow these
rapalogs only to interact with FRB domains with a compensatory small side chain mutation
(”the hole”), to accommodate binding of the ”bump” in rapamycin. The majority of these
TORC1 safe rapalogs possess a bulky substituent at the C16 position of rapamycin. AP23102
is one of these non-immunosuppressive rapamycin derivatives, which bears a phenyl carbamate
substituent at the C16 position. Although AP23102 was used in several biological studies to
regulate the function of proteins[247, 248], no general method to introduce carbamates into
rapamycin has been published to date. To develop a procedure to substitute the C16 methoxy
group of rapamycin with carbamates, we decided to synthesise C16-phenyl carbamate rapamycin
(pcRap), a C28 diastereomer of AP23102, as a model compound. Under acidic conditions,
the C16-methoxy group of rapamycin undergoes a heterolytic cleavage, forming a relatively
stable carbocation, which can be trapped with various nucleophiles[141, 181, 182]. Therefore,
we treated solutions of rapamycin and phenyl carbamate (pc) with different acids. After basic
work-up, we analysed the resulting crude mixtures with MALDI-TOF. Attempts to carry out the
nucleophilic addition of pc to C16-rapamycin carbocation by using TFA[181] (table 1, entry 1)
and p-toluenesulfonic acid[149] (table1, entry 2) in CH2Cl2 at -40
○C, gave a mixture of products
containing only traces of pcRap. It is likely that pcRap, as well as pc itself, were not stable in
the presence of protic acids, such as TFA and p-TsOH. We next applied the Lewis acid BF3-Et2O
to generate the carbocation at the C 16 position[181]. Addition of the Lewis acid to a solution of
Rap and pc in CH2Cl2 at -40
○C led to a new mixture of inseparable products containing starting
material, the product of methoxy-elimination[181] and traces of pcRap (table 1, entry 3). These
results and the observation of a dark-red colour change after addition of BF3-Et2O, suggest that
the reactive carbocation intermediate is formed under these conditions, but the nucleophilic
substitution is impaired. To increase the stability of the transient carbocation and increase the
yield of the reaction, we used THF as the solvent instead of CH2Cl2. Surprisingly, no colour
change was observed after the addition of BF3-Et2O and only rapamacin and pc were recovered,
indicating that the transient carbocation complex is not formed in THF (table 1, entry 4). To
generate the carbocation and subsequently stabilise it, we treated a solution of pc and rapamycin
in CH2Cl2 at -40
○C with BF3-Et2O, followed five minutes later, by the addition of an excess of
THF. MS- analysis of the crude mixture revealed formation of large amounts of pcRap, and
starting materials (pcRap/rapamycin approximately 70:30). This mixture of compounds was
re-dissolved in CH2Cl2 and the resulting solution re-treated with BF3-Et2O and THF, to increase
the formation of product and minimise the rapamycin content. After repeating this procedure
an average of 3 to 4 times, the crude mixture contained mainly pcRap with small traces of
rapamycin and elimination products. Column chromatography of the crude product afforded
a diastereomeric mixture of pcRap with an 83% yield (table 1, entry 5). Similar results were
obtained, when less or more polar ethers, such as Et2O or 1,4-dioxane were used as an additive
(table 1, entries 6 and 7).
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Table 1: Optimization of Lewis Acid-Mediated Synthesis of pcRap.
Rapamycin
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O
OH
O
OH
16 16
1. Solvent, Acid
    Phenylcarbamate
    -40°C
2. Additive
    -40°C
HN
O
O Ph
pcRap
Entry Solvent Additive Acid Yield[%]
1 CH2Cl2 - TFA
[a] Traces
2 CH2Cl2 - p-TsOH
[b] Traces
3 CH2Cl2 - BF3-Et2O
[c] Traces
4 THF - BF3-Et2O
[c] -
5 CH2Cl2
[d] THF BF3-Et2O
[c] 83
6 CH2Cl2
[d] Dioxane BF3-Et2O
[c] 76
7 CH2Cl2
[d] Et2O BF3-Et2O
[c] 79
Table 1: [a] pc (6 equiv.), TFA (10 equiv.); [b] pc (6 equiv.), p-TsOH (10 equiv.); [c] pc (6 equiv.),
BF3-Et2O (4 equiv.); [d] 5 min.; [e] 20 min.
To validate the generality of this procedure, we extended the scope of the study by intro-
ducing a series of representative carbamates into rapamycin. Using benzyl carbamate, C16-
benzylcarbamate-Rap (bnRap) was synthesised to provide an excellent yield (88%, table 2,
entry 1). Reactions with the lower electron-donating and unhindered aliphatic n-butyl carba-
mate, gave C16-n-butylcarbamate-Rap (buRap) a yield of 73% (table 2, entry 2). Interestingly,
comparable results were still achieved with the acid-sensitive, table 2, entry 3). We assumed that
the compound tbuRap could be applied as an extended selective modification of the rapamycin
core, via the C16-Boc-protected amine. Other nucleophiles, such as phenyl urea, phenyl thiourea,
phenol or 3-methylindole, were also readily introduced into the C16-position under the described
reaction conditions (table 2, entries 5-8). These products were only analysed by MALDI-TOF,
since we were not able to separate the two diastereomers. Interestingly, 3-methylindole also re-
acted with rapamycin in the absence of THF additive, however to a much lesser extend. This
result suggests that the nature of the nucleophile has an influence on the reaction outcome, which
is in contrast to common unimolecular nucleophilic substitution reactions.
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Table 2: BF3-Et2O/THF-mediated synthesis of C16 rapalogs.
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OH
O
OH
16 16
1. Nucleophile
    BF3-Et2O, CH2Cl2
    -40°C
2. THF
    -40°C
R
Entry Nucleophile Product Yield[%][a] C16 (R)/(S ) ratio
1 phenyl carbamate pcRap 83 49:51
2 benzyl carbamate bnRap 88 49:51
3 butyl carbamate buRap 73 51:49
4 ter -butyl carbamate tbuRap 78 50:50
5 phenylurea[b] puRap 74 -
6 phenylthiourea[b] ptRap 68 -
7 phenol[b] pRap 81 -
8 3-methylindole[b] iRap 83 -
Table 2: Indicated nucleophile (6 equiv.), CH2Cl2, -40
○C, BF3-Et2O (4 equiv.), 5 min, THF, 20 min,
-40○C. [a] Isolated yield of the diastereomeric mixture [b] products were only analyzed by MALDI-TOF
To elucidate the exact role of the additive and to determine the mechanism of the reaction of ra-
pamycin with carbamates, we performed low temperature NMR studies. Therefore, we recorded
and compared the 1H-, 11B- and 19F-NMR spectrum of mixtures of BF3-Et2O, rapamycin, and
phenyl carbamate, respectively, in CD2Cl2 or CD2Cl2/THF with the corresponding homomolec-
ular solutions (Figure 13, A and B). In the absence of phenyl carbamate, addition of BF3-Et2O
to a solution of rapamycin in CD2Cl2 resulted in the characteristic colour change of the solution.
Comparing the 19F-NMR spectra of this solution with the spectra of BF3-Et2O in the same
solvent, exhibited a new broad signal, suggesting formation of a BF3-coordinated rapamycin
intermediate (Scheme 13). This complex readily disassociated after the addition of an excess
of THF, indicated by the disappearance of the broad signal and formation of BF3-THF. Since
CH2Cl2 and THF have similar dielectric constants, we assumed that the observed stabilisation
of the carbocation is an effect of the coordinating ability of the additive rather than its po-
larity. This hypothesis is supported by the fact that the product pcRap is also formed when
using less polar additives, such as diethyl ether. To determine the coordination site of BF3 we
next recorded the HMQC spectrum of rapamycin in the presence and absence of the Lewis acid
(figure 14, C). As expected, the correlation peak of the C16 methoxy group disappeared after
addition of BF3-Et2O, demonstrating that this position is the most favoured reaction site.
Although BF3-Et2O selectively reacts with the C16 methoxy group, irreversible formation of a
free or solvent-separated carbocation is unlikely, as no nucleophilic substitution is observed under
these conditions. More likely, a BF3-methanolate complex forms a tight and stable ion pair with
the rapamycin ion. Addition of THF leads to the sufficient stabilisation of the carbocation,
the subsequent formation of a solvent-separated ion pair and finally to a fast reaction with the
nucleophile. In contrast, using THF as the solvent in the first step prevents the BF3 from
interacting with the methoxy group at C16, avoiding the formation of rapamycin carbocation
(scheme 13). We next investigated the effect of the Lewis acid on phenyl carbamate. Analysis of
the proton and fluorine NMR spectra of BF3-Et2O with phenyl carbamate in CD2Cl2 revealed
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A)
B)
C)
Figure 14: NMR study to elucidate the mechanism of the BF3-mediated synthesis of pcRap. A)
19F-
NMR spectra of the indicated mixtures were recorded at -30○C; 1.3 mg rapamycin, 0.74 µL BF3-Et2O
in 0.4 µL CD2Cl2 respectively 0.4 µL CD2Cl2/THF (2:1) B) 1H-NMR spectra of indicated mixture at
-30○C; 1.2 mg phenyl carbamate, 1.3 mg rapamycin, 0.74 µL BF3-Et2O in 0.4 µL CD2Cl2 respectively
0.4 µL CD2Cl2/THF (2:1). C) HMQC of 12 mg rapamycin in 0.4 µL CD2Cl2 in the presence (down) or
absence (up) of 0.74 µL BF3-Et2O at -30○C.
signals for two different carbamate species, as well as two different BF3 containing complexes.
These results implicate that BF3 also coordinates to phenyl carbamate, presumably forming
a boro-iminium complex. Moreover, NOESY experiments of phenyl carbamate and BF3-Et2O
revealed that the two phenyl carbamate species exist in a slow exchanging equilibrium. Similar
to rapamycin-BF3 complex, the addition of THF readily disrupted the boron-phenyl carbamate
complex (scheme 13).
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Scheme 13: Proposed mechanism for the Lewis acid-mediated formation of pcRap. After addition of
BF3-Et2O to a mixture of rapamycin and phenyl carbamate, a BF3-carbocation and a BF3-iminiumion
complex are formed, which are not able to further react. Addition of THF stabilizes the carbocation
and the reaction with the liberated phenyl carbamate yield pcRap.
Previous studies on rapamycin derivatives demonstrated that the stereochemistry of the substi-
tution at C16 can influence the binding affinity for wild-type and mutated FRB[141, 181]. There-
fore, we expected that each pcRap diastereomer might possess a stereospecific profile towards
the possible binding partners. To verify this hypothesis, we first separated the two diastereomers
by column chromatography, assigned the stereochemistry of (R)-pcRap and (S)-pcRap via
ROESY experiments and then validated their potential to interfere with endogenous TORC1.
Correlations between the protons at the cyclic hemiacetal, at C15 and C16, as well as at the
NH proton of the carbamate function, were used to determine the absolute configuration of the
diastereoisomers. The most important ROE correlations, that were used to determine the abso-
lute configuration, are shown in figure 15. Only the (S )-configuration at C16 could explain the
observed correlation between H16 and H13a, and without violating any of the other correlations.
In contrast, only the (R)-conformation could explain the observed correlation between the H15a
and H18, and the correlation between the NH proton and H15a.
Figure 15: Key ROESY correlations to elucidate the absolute conformation of pcRap diastereomers.
(R)-pcRap (d.r. 51%), left, and (S)-pcRap (d.r. 49%), right.
One of the major challenges of synthesising non-cytotoxic rapalogs is the purification phase, since
minimal contamination of rapamycin or other FRB wild-type-binding rapamycin derivatives
cause extensive TORC1 inhibition. To minimise the risk of such contamination, we further
purified the two diastereomers using preparative HPLC (for an example of the UV-Vis spectra
of HPLC separated reaction mixture see figure S1). Finally, we assayed the two pcRap isomers
for their ability to inhibit TORC1 in cells (figure 16, A). Therefore, we treated HEK cells with
either (S)-pcRap , (R)-pcRap or rapamycin for 15 minutes, lysed the cells and monitored the
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phosphorylation of Thr389 on the ribosomal protein S6 kinase (S6K1), a downstream target of
TORC1. Incubation of HEK cells with rapamycin or (S)-pcRap resulted in a rapid inhibition
of the TORC1, indicated by non-phosphorylated S6K1. However, it is presently not entirely
clear if co-eluting contaminations of rapamycin and rapamycin by-products or (S)-pcRap
impaired mTOR activity. In contrast, the phosphorylation of S6K1 was intact in cells treated
with (R)-pcRap. Even after increasing the concentration of (R)-pcRap by a factor of ten,
or increasing the incubation time to 30 minutes (figure 16, B), no inhibition of TORC1 was
observed. Similarly, (R)-pcRap did not inhibit the phosphorylation of S6K1 in A2058 cells,
after the cells were treated for 1 hour with the CID (figure 16, C). The elongated incubation time
was necessary, as rapamycin did not down-regulate TORC1 after 15 minutes. However, under
these conditions the IC50 value of (R)-pcRap was measured to be above 1 µM. In comparison,
we measured an IC50 value of 0.47 nM for rapamycin, which is comparable to values reported in
the literature[249]. Although, we were able to synthesis pure and mTOR-safe (R)-pcRap, only
small amounts (yield < 5%) were obtained after several rounds of purification by preparative
HPLC (for an example of of the UV-Vis spectra of purified (R)-pcRap see figure S2). . The
majority of (R)-pcRap still contained small amounts of impurities, which inhibited mTOR and
require further purification. To demonstrate the utility of the TORC1-safe (R)-pcRap isoform
as a heterodimeriser, we investigated the CID-induced translocation of a cytosolic red fluorescent
protein (monomeric RFP; TagRFP) to the cell plasma membrane (figure 16, D). Therefore, we
co-transfected Hela cells with an FRB-RFP fusion protein and enabled the plasma membrane
anchoring of an FKBP12-GFP-CAAX fusion. The addition of 0.5 µM (R)-pcRap resulted in
rapid translocation of the chimeric TagRFP-T2098LFRB protein to the cytosolic surface of the
plasma membrane. In contrast, no translocation was observed in untreated transfected cells.
These results demonstrate that (R)-pcRap is a powerful, non-toxic tool to chemically regulate
the assembly and location of proteins of interest.
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Figure 16: Biological evaluation of (R)-pcRap and (S)-pcRap. A) HEK cells grown in fetal calf
serum supplemented media were exposed to DMSO, rapamycin, (R)-pcRap and (S)-pcRap for 15
min at 37○C, before cells were lysed and proteins were subjected to SDS PAGE, and immune-blotting
using antibodies against total p70S6K (total S6K), and phosphorylated p70S6K (pS6K, Thr389). Data
represent means SEM, n=3; difference from DMSO control; B) HEK cells grown in fetal calf serum
supplemented media were exposed to DMSO, rapamycin, and (R)-pcRap for indicated time at 37○C.
Samples were analysed as described in A); C) A2058 cells were treated with indicated amount of ra-
pamycin or (R)-pcRap for 1 hour. Samples were analyzed as described in A); D) Hela cells expressing
the FKBP12-GFP-CAAX membrane anchor [green (-CAAX is the polybasic isoprenylation sequence
from KRas-4B)] and FRBT2098L-RFP (red) fusion proteins were exposed to DMSO or 0.5 mM (R)-
pcRap for 15 min. at 37○C. Translocation of FRBT2098L-RFP to the plasma membrane was imaged by
confocal microscopy in fixed cells.
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3.2 Synthesis and evaluation of cell permeable and photocleavable
HaXS derivatives
Although common CIDs have been extensively used in numerous studies, many biological pro-
cesses occur with spatiotemporal precision beyond the resolution of most common CIDs[3]. The
concept of using light to alter the biological activity of CIDs, provides a non-invasive method
to regulate biological processes in vivo with the required resolution to study fast occurring bio-
logical processes[219]. As described in in the introduction, different caged CIDs were developed
and used in proof of concept experiments. These caged CIDs do not induce dimerisation of the
targeted proteins immediately, instead they require light-induced cleavage of the cage prior to
triggering protein dimerisation[219]. In a complementary approach, we envisaged to design CIDs,
which contain the photosensitive group in the core of the molecule, covalently linking the two
tag substrates together. Photocleavable CIDs would allow to firstly trigger the dimerisation of
POIs and then secondly, to irreversibly split the formed protein complex in a highly controlled
way (figure 17). The possibility to regulate protein dimerisation by two independent events
can be used for different applications. For example, POIs can be anchored away from their
active site, followed by subsequent irradiation leading to liberation and relocation of the POI,
thereby restoring its function. Other scenarios include the activation and controlled deactivation
of metabolic pathways or vice versa, kinetic studies of protein trafficking, investigation of cell-
compartment-associated signaling, and the simulation of cell-wide physiological and pathological
signaling dynamics.
POI
POI
POI
POI
POI POI
hυ 360 nm
Extracellular
Intracellular
photocleavable CID
Free
Linked
Free
Figure 17: Principle of photocleavable CID. Treatment of cells with a photocleavable, and cell-
permeable CID leads to dimerization of tag-POI fusion proteins. Illumination of CID cleaves the link
between the POIs, and releases them from the covalent complex.
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Based on the results of our previous study, the development of cell permeable HaloTag and SNAP-
tag homodimerisers (HaXS)[128], we decided to introduce the photocleavable moiety into the core
module, tethering the HaloTag-reactive chloroalkane ligand and the SNAP-tag-reactive BG. Syn-
thetically, the modular synthesis enables a straight forward approach to build HaXS derivatives
with different properties using a minimal number of steps. Biologically, HaXS molecules show
excellent selectivity, good cell permeability and fast dimerisation. Additionally, the covalent
and irreversible nature of these CIDs ensure that the formed protein complex is stable, prior to
irradiation and thus allows simple analysis of the formed protein dimers to be carried out by
Western blot.
3.2.1 Selection of the photolabile groups
Photolabile protecting groups (PPGs) are widely used in chemistry as protecting groups or pho-
tolabile linkers in solid-phase syntheses. Due to their big impact in synthetic chemistry, numerous
classes of photolabile groups have been developed to date. However only a handful display the
properties required for biological applications. The PPG should (I) be stable towards hydrolysis,
(II) absorb light at wavelengths higher than 300 nm to prevent cell damage, and (III) display
high quantum yields for efficient photolysis. Additionally, the intermediates and products that
are formed should not be cytotoxic or absorb the emitted light[214, 219, 250]. o-Nitrobenzyl,
and coumarinyl-4-methyl derivatives are two of the classes of PPGs, which exhibit all or most of
the necessary properties and were applied in several biological studies[219, 250]. Therefore, we
decided to introduce these two PPGs into our HaXS molecules. The o-nitrobenzyl group and
its many derivatives (scheme 14, A) are the most frequently used PPGs in biology[219]. Mech-
anistically, the absorption of a single electron leads to the formation of an excited nitro group
(n to pi* electron transition), which abstracts a hydrogen from the o-alkyl substituent. Sub-
sequently, the aci-nitro intermediate is formed, which is followed by intramolecular cyclisation
and release of a nitrosoaldehyde and the leaving group (scheme 14, B)[250]. The photophysi-
cal properties of o-nitrobenzyl groups can easily be fine-tuned, introducing substituents at the
benzylic position or at the aromatic ring, as well as changing the leaving group (Figure 14, A).
For example, the o-nitrophenylethyl group, which bears a simple methyl group in α-position
displays increased quantum yields[251]. Introduction of a strong electron-withdrawing group,
such as CF3, CBr3, or CN at this position further improves the photolysis rate[250]. However,
synthesis of these electron-withdrawing compounds remains challenging[250]. Modification of the
aromatic region influences the absorption and consequently the quantum yield. Introduction of
electron donating groups in meta and/or para position(s) to the nitro group shift the absorption
maximum to longer wavelengths[250, 252, 253]. Despite having a bathochromic effect, these
modifications also decrease the quantum yield of the photolytic reaction[250]. Beside benzylic
or aromatic substituents, the leaving group also has an influence on the quantum yield. Bochet
and co-workers demonstrated that the quantum yield of the photolysis correlates with the radi-
cal stabilisation properties of the leaving group (quantum yields decrease in the series alcohol >
amine > N-carbamate > amide > O-carbamate > ester > carbonate [254]). Although alcohols and
amines exhibit the highest quantum yields for the photolysis after irradiation with light at higher
wavelength, they are generally protected as carbonates or carbamates, due to more convenient
synthetic procedures.
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matic and benzylic substitution on the photophysical properties of o-nitrobenzyl group. B) Mechanism
of the photolytic decomposition of o-nitrobenzyl based PPGs.
Based on these considerations, we decided to incorporate the methyl-6-nitroveratryl (MeNV)
moiety into the HaXS molecule via carbamate formation (MeNV-HaXS) (scheme 15). The
methyl group of MeNV-HaXS should increase the photolytic rate, whereas the methoxy group
should red-shift the absorption without decreasing the quantum yield too much. However, to
evaluate the protein dimerisation properties of nitrobenzyl containing HaXS, we decided to first
synthesise model compounds, which contain the commercially available 5-hydroxynitrobenzyl
alcohol. Additionally, we envisaged to vary the number of PEG units, linking the HaloTag
reactive chloroalkane and the PPG. Increasing the number of PEG units should improve the
water solubility of the CID, reduce the chance of steric clashes between dimerised proteins, but
may decrease the cell permeability. To find the optimal number of PEG units, we planned to
synthesise three Nb-HaXS (scheme 15) molecules with either four, five or six PEG available in
three steps, starting from the 5-hydroxynitrobenzyl alcohol, BG −NH2 and Halo −PEGn-Br
building block.
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Scheme 15: Chemical structure of photocleavable HaXS molecules based on o-nitrobenzyl derivatives:
MeNV-HaXS, Nb-HaXS1, Nb-HaXS2, and Nb-HaXS3.
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The second class of PPGs which we planned to incorporate into our HaXS, are based on
coumarinyl-4-methyl group (scheme 16, A). These PPGs possess higher extinction coefficients,
fast photolysis rates, fluorescent properties and are well suited for two-photon excitation[250].
After excitation with light, the electron from the pi transitions to the pi* orbital and the 7-
methoxycoumarinyl-4-methyl derivative relaxes via fluorescent emission, nonradiative processes
or heterolytic C-X bond cleavage. The latter results in the formation of a tight ion pair. The
coumarinylmethyl cation rapidly reacts with close-by nucleophiles or solvent molecules to gen-
erate a new stable product (scheme 16, B)[250]. Similar to o-nitrobenzyl group based PPGs,
the photophysical properties of coumarinyl-4-methyl PPGs can be fine-tuned by substitution
and selection of the leaving group (scheme 16, A). Introduction of electron-donating groups at
the C7 and C6 position significantly improves the quantum yield of the photolysis, as well as
shifts the absorption maximum to higher wavelengths[255]. The 7-methoxycoumarinyl-4-methyl
derivatives for example (328 nm) displayed a ≈20 nm red-shifted compared to the parent molecule
(310 nm)[250]. Amino substitution of C7 further shifts the absorption maxima to 350 - 400 nm.
Additionally, these coumarinyl derivatives exhibited excellent quantum yields, ranging from 0.21
to 0.28[250]. The nature of the leaving group has a dramatic influence on the photolysis rate.
For example, good leaving groups readily undergo photolysis and additionally minimise the pos-
sibility of ion pair recombination. In contrast, weak leaving groups such as alcohols, amines,
phenols and thiols do not undergo photo-induced heterolysis. These groups are best protected
as the corresponding carbonate, carbamate or thiocarbonate[250].
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Scheme 16: Theoretical evaluation of coumarinyl-4-methyl based PPGs. A) Influence of the leaving
group and substitutions on the photophysical properties of coumarinyl-4-methyl B) Mechanism of the
photolytic decomposition of coumarinyl-4-methyl based PPGs.
Therefore, we planned to synthesise ACM-HaXS and MACM-HaXS, which contain a sec-
ondary or a tertiary amino substitution at C7 and a carbamate as the leaving group (scheme
17). However, to validate if coumarin containing HaXS still induce dimerisation of SNAP-tag
and HaloTag fused proteins in vivo, we decided to synthesise the more readily accessible 7-
alkoxycoumarinyl-4-methylhydroxyl derivative (HCM-HaXS) (scheme 17).
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3.2.2 Synthesis of SNAP-tag and HaloTag substrate building blocks
BG −NH2 was prepared according to the procedure published by the group of Johnsson[48,
121] (scheme 18, A). The synthesis of BG −NH2 was initiated with the reduction of methyl-
4-cyanobenzoate (1) using an excess of LiAlH4 giving 4-(aminomethyl)-benzyl alcohol (2) in
acceptable yield. Subsequently, the amino group of the benzyl alcohol was protected with ethyl
trifluoroacetate under mild basic conditions to yield 3. The activated guanine derivative 5 was
obtained after the reaction of 6-chloro-guanine with 1-methyl-pyrrolidine in DMF, which was
further used with 3 under basic conditions to form the protected benzylguanine derivative 6
as a white solid. Finally, the deprotection of the trifluoroacetamide with methylamine gave
BG −NH2 in an overall yield of 55% over 5 steps. The Halo −PEGn-Br building blocks were
synthesised as described by Erhart et al. (scheme 18, B)[128]. Thereafter, the polyethyleneglycols
7a, 7b and 7c were each treated with 6-chloro-1-iodohexane, in the presence of sodium hydride
for 16 h, to give a mixture of the HaloTag substrates 8a, 8b, and 8c and their corresponding
bis alkylated analogues in a ratio of approximately 2:1. The Apple reaction of 8a, 8b, and 8c
with triphenylphosphine and carbon tetrabromide readily produced the desired Halo −PEGn-
Br building blocks in overall yields within the range of 30 to 42%, with slightly higher yields for
the longer analogues. Halo −NH2 was produced in a similar reaction sequence (scheme 18, C).
However, an additional protection and deprotection step was required to prevent alkylation of the
amine. Following the synthesis reported by So et al.[256] we protected the primary amine of 2-
(2-aminoethoxy)ethanol (9) with a Boc protecting group using Boc2O. Reaction of the protected
amine with 6-chloro-1-iodohexane in the presence of sodium hydride afforded 11 as a colorless
oil. Cleavage of the Boc protecting group of 11 in a 4 M HCl solution (dioxane) and subsequent
evaporation of the solvent, produced the HCl salt of Halo −NH2 as a white solid.
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Scheme 18: Synthesis of BG −NH2, Halo −PEGn-Br and Halo −NH2 building blocks. A) Reaction
conditions: a) LiAlH4, THF, 70
○C, 3 h; b) Ethyl trifluoroacetate, DIPEA, MeOH, r.t., 2 h; c) 1-Methyl-
pyrorlidine, DMF r.t., 16 h; d) 3, NaH, DMF, r.t., 5 h; e) Methylamine, MeOH, r.t., 16 h. B) Reaction
conditions: a) NaH, THF, 6-chloro-1-iodohexane, r.t., 16 h; b) PPh3, CBr4, THF, r.t., 16 h. C) Reaction
conditions: Boc2O, EtOH, r.t., 2 h; b) NaH, THF, 6-chloro-1-iodohexane, r.t., 16 h; c) 4 M HCl in
dioxane, r.t., 3 h.
3.2.3 Synthesis and evaluation of nitrobenzyl derivative containing HaXS molecules
We initiated the synthesis of Nb-HaXS1, Nb-HaXS2, and Nb-HaXS3 (scheme 19) with the
alkylation of 5-hydroxynitrobenzyl alcohol (12) with the different Halo −PEGn-Br building
blocks . The reaction proceeded under mild basic conditions and gave the desired products
13a, 13b, and 13c in moderate yields as colorless oils. No major difference of reactivity was
observed for the three electrophiles as the yields ranged from 41% to 46%. The carbamate
formation between BG −NH2 and 13a, 13b, respectively 13c was achieved using various cou-
pling procedures. However, the highest yields were obtained by activating the primary alcohol
with bis(p-nitrophenyl) carbonate for 16 hours at room temperature, followed by the addition of
BG −NH2 and NEt3.
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Scheme 19: Synthesis of Nb-HaXS1, Nb-HaXS2, and Nb-HaXS3. Reaction conditions: a) Corre-
sponding Halo −PEGn-Br, K2CO3, DMF, 60○C, 16 h; b) bis(p-nitrophenyl) carbonate, triethylamine,
DMF, r.t., 16 h; c) BG −NH2, 60○C, 6 h.
To validate the dimerisation efficacy of Nb-HaXS molecules in a cellular system, we treated
HeLa cells, co-expressing Halo-GFP and SNAP-GFP fusions, with 0.5 µM of Nb-HaXS1, Nb-
HaXS2, Nb-HaXS3 or HaXS8 for 60 minutes (figure 18). After washing and lysing the
cells, the tagged proteins were analysed by Western blot. Despite the difference in polarity, due
to the increasing number of PEG units, no significant difference in the dimerisation activity be-
tween Nb-HaXS1, Nb-HaXS2 and Nb-HaXS3 was observed. All three compounds exhibited
slightly lower dimerisation activity compared to HaXS8, as they induced approximately 65% of
protein dimerisation compared to 78% dimerisation triggered by HaXS8.
Figure 18: Nb-HaXS induced in vivo dimerisation of Halo-GFP and SNAP-GFP fusion proteins. a)
HeLa cells transfected with expression constructs for SNAP-tag-GFP (SNAP-GFP) and HaloTag-GFP
(Halo-GFP) fusion proteins were exposed to 5 µM Nb-HaXS1, Nb-HaXS2, Nb-HaXS3 or HaXS8 for
60 minutes in cell culture medium at 37○C. Subsequently, cells were lysed and proteins were subjected
to SDS PAGE and immunoblotting. Tagged proteins were detected using anti- GFP (primary) and
horseradish peroxidase labeled (secondary) antibodies, and chemiluminescence.
We next investigated the photophysical and photochemical properties of the Nb-HaXS molecules.
As expected, the number of PEG units introduced had no influence on the photophysical prop-
erties of Nb-HaXS molecules. They all exhibited the highest absorption at 328 nm and displayed
molar extinction coefficient of approximately 1700 M-1cm-1 at 360 nm (figure 19, A). To evaluate
the ability of the Nb-HaXS compounds to undergo photolysis, we irradiated 5 µM solutions of
corresponding CID in DMSO/water (10:90) in an LED based reactor with light at 360 nm for
a given time (figure 19, B). The time courses for the photolysis reaction were analysed with a
UPLC, monitoring the disappearance of the single ion signal of the starting material. Although,
all compounds were successfully cleaved under the described conditions, 20 minutes of irradiation
were required to achieve 95% of photolysis.
44 ∣ p a g e
Results and Discussion
Figure 19: Photophysical properties of Nb-HaXS1, Nb-HaXS2, and Nb-HaXS3. A) The UV/Vis
spectra of 0.5 mM Nb-HaXS molecules in DMSO were recorded at room temperature. B) 5 mM of
solutions of Nb-HaXS1, Nb-HaXS2, and Nb-HaXS3 in a DMSO/water (10:90) mixture were irra-
diated with four RPR-3500 A˚ lamps with light at 360 nm for the indicated time period. Subsequently,
samples were subjected to a UPLC. Decrease of starting material was detected using a ESI-SQD mass
spectrometer.
The results of the following part were published in 2014 at Angewandte Chemie International
Edition Volume 53, Issue 18[257].
To improve the photophysical properties of nitrobenzyl based HaXS molecules, we car-
ried out the synthesis of MeNV-HaXS. Incorporation of the methoxy group in the aromatic
region should shift the absorption maximum to longer wavelengths[252] and thereby minimise
possible cell damage, whereas the methyl group in an α-position should increase the decom-
position rate of the CID[251]. Due to the higher water solubility of Nb-HaXS3 compared
to its shorter analogues, we decided to use six PEG units to tether the chloroalkane with
the MeNV moiety. Inspired by the synthesis of nitroveratril caged compounds reported by
Tsai and Klinman[258], we initiated the synthesis of MeNV-HaXS with the protection of
acetovanillone (14) with the benzyl protecting group (scheme 20). Under basic conditions, the
phenol group was readily protected with benzylbromide to form 15 in an excellent yield as a
white precipitate, which was used without further purification. Subsequent nitration of 15 in
a mixture of nitric acid, acetic acid and acetic anhydride produced 16 as a 53% yield. After
the cleavage of the benzyl protecting group in the presence of hydrogen bromide to give 17,
alkylation of the phenol group with Halo −PEG6-Br gave the intermediate 18 in a 60% yield
over two steps. Reduction of the carbonyl group was successfully performed using NaBH4 in a
1:1 mixture of MeOH/Dioxane to yield 19. Finally, the coupling between 19 and BG −NH2
with bis(4-nitrophenyl) carbonate produced MeNV-HaXS in an overall yield of 15% over 6
steps.
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Scheme 20: Synthesis of MeNV-HaXS. Reaction conditions: a) K2CO3, benzyl bromide, DMF,
80○C, 16 h; b) Acetic acid, acetic anhydride, HNO3, r.t., 16 h; c) Acetic acid, HBr, 85○C, 1.5 h; d)
K2CO3, Halo −PEG6-Br, DMF, 60○C, 16 h; e) NaBH4, MeOH/Dioxane, r.t., 2 h; f) bis(p-nitrophenyl)
carbonate, triethylamine, DMF, r.t., 16 h; g) BG −NH2, 60○C, 6 h.
To investigate the photophysical properties of MeNV-HaXS, we recorded the UV-Vis spectra
of different concentrated solutions of the photocleavable CID in DMSO (figure 20, A). As en-
visaged, the introduction of the methoxy group in a para position to the nitro group improved
the absorption properties of the CID, red-shifting its absorption maximum by 35 nm to 355
nm and increasing the molar extinction coefficient at 360 nm (ε = 4058 M-1cm-1) and 405 (ε
= 1238 M-1cm-1), compared to the parent Nb-HaXS series. To validate the influence of the
methyl group in the α-benzylic position on the reaction rate of the photolysis, we measured the
decay rate of a 0.5 µM solution of MeNV-HaXS in a DMSO/water (1:10) mixture, under the
same conditions as described for the Nb-HaXS series. After 5 minutes of irradiation, over 95%
of the substrate was successfully cleaved, increasing the photolytic activity by a factor of four
compared to the first generation of photocleavable HaXS molecules (data not shown). However,
this measurement strongly depends on several factors, such as the concentration, the power of
the lamp, the distance of the lamp, and so on. In contrast, the quantum yield of a molecule
only depends on the specific chemical reaction, the irradiation wavelength and the solvent. The
quantum yield (φ) of a given molecule can be determined by dividing the photolytic rate by the
number of photons entering the photoreactor per unit of time (quantum flow). Therefore, we
used ferrioxalate actinometry to measure the quantum flow of the photoreactor. Based on these
results, we calculated that MeNV-HaXS has an excellent quantum yield of 0.075 in a 10%
solution of DMSO in water at 360 nm and 0.07 at 405 nm (figure 20, B and C).
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Figure 20: Photophysical properties of MeNV-HaXS. A) The UV/Vis spectra of different MeNV-
HaXS solutions in DMSO were recorded at room temperature. B) A 0.5 mM solution of MeNV-
HaXS in DMSO/water mixture (10:90) was irradiated for the indicated time period with an LED lamp,
emitting 1.33⋅10-8 E/s at 360 nm. Subsequently, samples were subjected to a UPLC. Decrease of starting
material was detected using an ESI-SQD mass spectrometer. C) A 0.5 mM solution of MeNV-HaXS in
DMSO/water mixture (10:90) was irradiated for the indicated time period with an LED lamp, emitting
1.33⋅10-8 E/s at 405 nm. Subsequently, samples were subjected to a UPLC. Decrease of starting material
was detected using an ESI-SQD mass spectrometer.
We next investigated the time-dependent dimerisation of Halo-GFP and SNAP-GFP fusion
proteins expressed in HeLa cells, in response to the addition of MeNV-HaXS and HaXS8
(figure 21, A). The two CIDs exhibited similar reaction rates and only slight differences were
measured at earlier time points (t > 10 min). The slightly inferior in vivo dimerisation rate of
MeNV-HaXS can most probably be attributed to a reduced cell permeability, resulting from its
increased molecular weight and higher polarity in respect to HaXS8. However, after 15 minutes
of incubation the difference became insignificant and both, MeNV-HaXS and HaXS8 induced
over 90% fusion protein dimers, which were stable for more than 5 hours at ambient light. Thus,
the noncleavable HaXS8 can be used as control compound to analyze the efficiency of photo-
cleavage, and to detect possible side effects arising from UV irradiation. In a proof of concept,
we tested the intracellular photocleavage of a MeNV-HaXS-dimerised HaloTag-SNAP-tag com-
plex. We incubated HeLa cells expressing Halo-GFP and SNAP-GFP fusion proteins with either
MeNV-HaXS or HaXS8 for 15 minutes. Irradiation of the cells with a 360 nm lamp (Blak-Ray,
B-100A, UVP) for 10 minutes led to quantitative cleavage of MeNV-HaXS-induced dimers. In
contrast, HaXS8-containing dimers remained intact (figure 21, B) during and after irradiation.
MeNV-HaXS thus induces covalent dimerisation of Halo-POI and SNAP-POI fusion proteins,
which can be readily reversed in bulk with high temporal resolution.
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Figure 21: MeNV-HaXS-induced intracellular dimerisation of HaloTag and SNAP-tag fusion proteins
and subsequent cleavage upon UV illumination. A) HeLa cells co-expressing SNAP-tag-GFP (SNAP-
GFP) and HaloTag-GFP (Halo-GFP) fusion proteins were exposed to 5 µM MeNV-HaXS or 5 µM
HaXS8 for the indicated time periods in cell culture medium at 37○C. Subsequently, cells were lysed
and proteins were subjected to SDS PAGE and immunoblotting. Tagged proteins were detected using
anti- GFP (primary) and horseradish peroxidase labeled (secondary) antibodies, and chemiluminescence
(means SEM, n = 3). B) HeLa cells co-expressing SNAP-GFP and Halo-GFP as in (A) were incubated
with 5 µM MeNV-HaXS or HaXS8 for 15 minutes. Cells were then washed and submerged in
phosphate-buffered saline (PBS) to remove unreacted compounds. Subsequently cells were illuminated
with a high-intensity UV lamp (100 W, 5 cm distance) for 10 minutes. Analysis of dimerisation products
was performed as in (A); values represent means SEM, n=3; * indicates p < 0.05.
Many biological events occur at specific intracellular locations and to investigate these events
manipulation techniques with high precision are required. To demonstrate the high spatial reso-
lution of MeNV-HaXS, we anchored tagged proteins to Golgi (figure 22, A), and subsequently
released the dimerised proteins. Therefore, we co-transfected HeLa cells with cytosolic teal
fluorescent (cyan) SNAP-tag fusion protein (SNAP-mTFP1) and the Golgi-targeting, red fluo-
rescent Halo-RFP-Giantin[259]. Incubation of these cells with 5 µM of MeNV-HaXS or 5 µM
of HaXS8 led to efficient translocation of SNAP-mTFP1 to the cytosolic surface of the Golgi
membrane (figure 22, A). The irradiation of a specific region of the Golgi with 8x5 ms pulses at
355 nm from an XY scanning excitation FRAP laser, efficiently and selectively released SNAP-
mTFP1 from the illuminated Golgi-derived vesicles, indicated by a reduced fluorescence intensity
in the illuminated region. In contrast, no significant loss of fluorescence intensity was observed
after the irradiation of HaXS8-induced SNAP-mTFP1-Halo-RFP-Giantin dimers (figure 22, B
and C), confirming that the observed decrease in fluorescence at the Golgi, in MeNV-HaXS
treated cells, results from the release of SNAP-mTFP1, and not from photobleaching. These
results show that MeNV-HaXS can be used to regulate the localisation of a protein with ex-
cellent subcellular precision on a timescale of seconds. To underline the high potential of this
approach, we tagged proteins to other intracellular compartments such as the plasma membrane,
lysosomes, mitochondria, and the actin skeleton (see figure S3). Since a scanning FRAP laser is
not part of the standard fluorescence microscopic equipment, we next explored the photocleav-
age of MeNV-HaXS-induced protein complexes using global field of view illumination with
standard DAPI excitation filters (377 +/- 25 nm; standard mercury halide lamp). Irradiation
of the cells for <20 s was sufficient to completely liberate SNAP-mTFP1 from Golgi membranes
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(figure 22, D and E), indicated by a decrease in the mTFP1 fluorescence at the Golgi. The cor-
responding increase of cyanic fluorescence in the cytoplasm demonstrates that the light-induced
fluorescence decrease at vesicles, results from the release of SNAP-mTFP1 and not from global
photobleaching. As expected the photoclevage of MeNV-HaXS-induced dimers under these
conditions is slower, due to the limited excitation energy. However, the use of DAPI excitation
filters on a conventional fluorescence microscope greatly expands the range of applications.
Figure 22: Translocation of cytosolic SNAP-mTFP1 proteins to the Golgi and their subsequent release
after irradiation. A,B) HeLa cells expressing SNAP-mTFP1 and Halo-RFP-Giantin were treated with
A) 5 µM MeNV-HaXS or B) 5 µM HaXS8 in cell culture medium for 15 minutes at 37○C. The
fluorescens of SNAP-mTFP1 was monitored in the indicated circular regions of interest by live cell
microscopy, before and after illumination of a subcellular region within the cell (white, dotted square)
with a scanning FRAP laser (8 areas 5 ms at 355 nm). C) Quantification of mTFP1 fluorescence intensity
in selected regions of interest (labeled circles) for SNAP-mTFP1 after addition of MeNV-HaXS (circles)
or HaXS8 (squares). Quantifications of mTFP1intensity in illuminated areas (green curves) and non-
illuminated Golgi vesicles (black curve). D) HeLa cells as in (a) were exposed to 5 µM MeNV-HaXS and
illuminated for 20 s using a standard DAPI filter set on a conventional fluorescence microscope (t=20 s,
377 ± 25 nm). E) Quantification of mTFP1 fluorescence intensity in selected regions of interest (circles)
at Golgi-derived vesicles, and in the cytoplasm before and after illumination as described in (d).
49 ∣ p a g e
Results and Discussion
To further demonstrate the utility of MeNV-HaXS, we anchored a nuclear probe to the perin-
uclear sites of the Golgi. Therefore, we studied cells co-transfected with a fusion protein nucleus
localising fusion protein consisting of the nuclear localisation sequence (NLS), cyan fluorescent
protein and the SNAP-tag (NLS-CFP-SNAP) and a Golgi targeting Giantin-RFP-Halo fusion
in the presence or absence of CID. In untreated cells, the NLS-CFP-SNAP fusion protein accu-
mulated in the nucleus. However in the presence of MeNV-HaXS, NLS-CFP-SNAP is quickly
trapped at perinuclear sites on the Golgi (figure 23, A). Upon irradiation, the multi protein com-
plex was cleaved and NLC-CFP-SNAP relocated to the cytosol within seconds. The observed
delay of the nuclear import of released NLS-CFP-SNAP (figure 23, B), is due to nuclear im-
port processes[260] These results clearly demonstrate that MeNV-HaXS can be used to study
translocation kinetics in real time in a simple experiment.
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Figure 23: MeNV-HaXS-controlled translocation of NLS-CFP-SNAP probe from the nucleus to the
Golgi and light-induced nuclear import of NLS-CFP-SNAP. A) HeLa cells expressing Halo-RFP-Giantin
and NLS-CFP-SNAP were exposed to 5 µM MeNV-HaXS in cell-culture medium for 15 minutes at
37○C and subsequently irradiated with a scanning FRAP laser (150 areas 5 ms at 355 nm). CFP
fluorescence intensity was monitored in the indicated circular regions of interest by live-cell microscopy,
before and after illumination of the cell (white, dashed rectangle). B) Quantification of CFP fluorescence
intensity in selected regions of interest (labeled circles) monitoring vesicle-associated (green curve) and
nuclear NLS-CFP-SNAP concentrations (blue curve) before and after illumination of the cells are shown;
values are means SEM, n=7 cells, error bars not shown where smaller than symbols used.
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3.2.4 Synthesis and evaluation of coumarin derivative containing HaXS
Coumarinyl-4-methyl derivatives and especially 7-aminocoumarinyl-4-methyl (ACM) derivatives
possess larger extinction coefficients, higher absorption maxima and faster photolysis rates com-
pared to most common nitrobenzyl derivatives[250]. Additionally, coumarins are well suited for
two-photon excitation, allowing cleavage at a very high wavelength, in respect to the single-
photon photolysis. Therefore, incorporation of a coumarin-based PPG into the core of HaXS
molecules would enable the possibility to cleave the formed protein complex more efficiently
and under less toxic conditions. Moreover, the combination with MeNV-HaXS would en-
able the independent control of the formation and release of two different protein complexes,
simultaneously. To validate the dimerisation activity of coumarin containing HaXS, we syn-
thesised 7-alkoxycoumarinyl-4-methylhydroxyl HaXS derivatives (HCM-HaXS) in four steps,
starting from the commercially available resorcinol (20) (scheme 21). In the presence of ethyl
4-chloroacetoacetate, resorcinol underwent an acid catalysed Pechmann condensation, giving a
good yield of the desired 7-hydroxy coumarinyl-4-methyl chloride (21). Subsequent substitu-
tion of the chloro group with a hydroxyl group in a water/dioxane (1:1) mixture resulted in
the formation of the coumarinyl-4-methyl alcohol 22. Alkylation of the 7-hydroxy group with
the Halo −PEG4-Br under mild basic conditions provided the HaloTag substrate 23, as a
yellow-tinted oil. Treatment of 23 with carbodiimidazole (CDI) furnished the corresponding
activated carbamate, which was subsequently coupled to BG −NH2 to provide HCM-HaXS
in a moderate overall yield of 10 % over 4 steps.
O
H
N
O
O
N
NN
N
H NH2
O
O
O O O O O Cl
HO
O
O
O O
HO
O
O
OH
Cl
O
O
OH
OH
OH
Cl4
a) b) c) d)
HCM-HaXS
48%
22
53%
23
61%
21
67%
20
Scheme 21: Synthesis of HCM-HaXS. Reaction conditions: a) Ethyl 4-chloroacetoacetate, MeHSO4,
60○C, 16 h; b) H2O/Dioxane, 100○C, 16 h; c) K2CO3, Halo −PEG4-Br, DMF, rt, 16 h; d) CDI, DMF,
rt. 16 h; e) BG −NH2, DIPEA, DMF, 50○C, 5 h.
To validate the dimerisation activity of HCM-HaXS in vivo, we incubated HeLa cells, co-
expressing Halo-GFP and SNAP-GFP fusions, with 5 µM of HCM-HaXS or HaXS8 for varying
60 minutes. Western blot analysis revealed that HCM-HaXS and HaXS8 both induced over
70% of SNAP-tag and HaloTag fusion protein dimerisation (figure 24, A). We next measured
the UV-Vis absorption spectra and the photolytic rate of HCM-HaXS (figure 24, B and C).
As expected from reported values[201], the HCM-HaXS exhibited a relatively low absorption
maxima (322 nm) and molar extinction coefficients at 360 nm (990 M-1cm-1) and 405 nm (678
M-1cm-1).
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Figure 24: Evaluation of the photophysical and biological properties of HCM-HaXS. A) Absorption
spectra of a 0.50 mM solution of HCM-HaXS in a DMSO/water (10:90) mixture. B) The UV/Vis spectra
of 0.5 µM HCM-HaXS molecules in DMSO were recorded at room temperature. C) A 5 µM solution
of HCM-HaXS in DMSO/water (10:90) was irradiated for the indicated amount of time with four
RPR-3500 A˚ lamps emitting light at 360 nm. CID in a DMSO/water (10:90) mixture was irradiated
with four RPR-3500 A˚ lamps with light at 360 nm for the indicated amount of time. Decrease of starting
material was detected using a UPLC equipped with an ESI-SQD mass spectrometer.)
The photolytic rate of HCM-HaXS was far inferior to the photolytic rate measured for MeNV-
HaXS at 360 nm, reflectin the low extinction coefficient. As previously mentioned, the introduc-
tion of electron-donating groups at either the C7 or C6 position improves the spectroscopic and
photochemical properties of coumarin derivatives[255]. Among these coumarinylmethyl deriva-
tives, 7-amino substituted exhibit the highest quantum yields (0.21-0.28) and absorption maxima
between 350-400 nm[250]. Therefore, we further targeted the synthesis of 7-aminocoumarin-
4-methylhydroxyl and 7-aminomethylcoumarin-4-methylhydroxyl containing HaXS molecules
(ACM-HaXS and MACM-HaXS) (scheme 22). Similar to HCM-HaXS, we built the core
coumarin structure (25a and 25b) by Pechmann condensation of either aminophenol (26a) or
methylaminophenol (26b) with ethyl 4-chloroacetoacetate. Alkylation of the amino group of
either the methylchlorocoumarin or the methylhydroxylcoumarin with the Halo −PEG4-Br
building block under basic conditions should result in the corresponding HaloTag substrate 24a
and 24b. Finally, we envisaged forming the carbamate between 24a, or 24b and BG −NH2
using common coupling reagents, such as DCC, CID or PyBOP.
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Scheme 22: Retrosynthetic analysis of the synthesis of ACM-HaXS and MACM-HaXS.
The reaction sequence to synthesise MACM-HaXS started with the alkylation of the commer-
cially available 3-aminophenol (30a) with iodomethane under basic conditions. In our initial
attempts, a one to one mixture of mono- and bismethylated product was observed and the yield
of the desired 3-methylaminophenol (30b) was increased to 73% by using a slight excess of
the starting material, as well as a dropwise addition of iodomethane in a diluted solution of
3-aminophenol in DMF. In contrast to the synthesis of HCM-HaXS, the electron donating
character of the amino group prevents the direct cylisation of aminophenol derivatives. There-
fore, we protected 30a and 30b with ethyl chloroformate,enabling the deactivated aminophenols
29a and 29b to occur with good yields. Treatment of these protected aminophenols with ethyl 4-
chloroacetoacetate in methane sulfonic acid at 60○C and subsequently quenching with an excess of
ice cold water, created 7-aminocoumarin-4-methyl chloride (27a) and 7- methylaminocoumarin-
4-methyl chloride (27b) as an orange precipitate. The hydrolysis of the carbamate to de-protect
the amino group was carried out in a mixture of H2SO4 and acetic acid at 100
○C and gave 24a
and 24b as a dark red precipitate. Subsequent substitution of the chlorides with a hydroxyl group
in water proceeded with moderate yields. Unfortunately, all attempts to alkylate the coumarin
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compounds 25a or 25b with Halo −PEG4-Br failed. In an alternative approach to synthesise
24a and 24b, we attempted to introduce a Halo −PEG4 moiety prior to the cylisation reaction.
The first two steps, the alkylation of aminophenol with the Halo −PEG4-Br and the subse-
quent protection with ethyl chloroformate proceeded with no difficulties under basic conditions.
However, the Pechmann condensation under acidic conditions led to coumarinyl-4-methyl chlo-
ride products missing the chloroalkane. Therefore, we modified the synthesis of ACM-HaXS
and MACM-HaXS, incorporating an acetamide moiety between the HaloTag substrate and the
coumarinyl group, which could be formed by coupling the corresponding amine and carboxylic
acid (scheme 23).
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Scheme 23: Key steps of the synthesis of novel designed coumarin-4-methyl containing HaXS molecules.
Analogues to the coumarinylmethyl ester synthesis previously described by Hagen et al.[261],
we attempted to introduce a tert-butyl protected carboxylic acid after the coumarin formation.
In order to prevent possible side reactions with the chlorine or the hydroxyl group, we investi-
gated the alkylation of the 7-aminocoumarine-4-methyl and 7-methylaminocoumarine-4-methyl
derivatives. Compounds 33a and 33b were obtained as described above (scheme 24). Pech-
mann condensation of 33a and 33b with ethyl acetoacetate in MeHSO3 provided coumarinyl
derivatives 34a and 34b as a red precipitate, which was used without further purification. Sub-
sequently, de-protection of the amino group under acidic conditions yielded the amines 35a and
35b. Alkylation of 35a and 35b with an excess of tert-butyl bromoacetate at 100○C led to the
formation of 36a and 36b in acceptable yields. The allylic oxidation of 36b with freshly sub-
limated SeO2 gave the corresponding aldehyde, which was subsequently reduced to the alcohol
37b in moderate yields, using NaBH4. In contrast, the same oxidation and reduction sequence
of the non-methylated analogue 36a provided 10 % of the desired product 37a and increased
amounts of degradated product. Cleavage of the tert-butyl group with TFA yielded two general
photocleavable building blocks 37a and 37b, which could be used to attach a variety of func-
tionalities in two synthetic steps. The carboxylic acids of 37a and 37b were activated using
DCC and NHS, followed by amide formation with Halo −NH2 to give compounds 32a and
32b. Carbamate formation between 32a and 32b and BG −NH2 under the same conditions
described for HCM-HaXS yielded CACM-HaXS and CMACM-HaXS1 in 32, respectively
39%, yields.
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Scheme 24: Synthesis of CACM-HaXS, CMACM-HaXS1 Reaction conditions: a) K2CO3, methyl
iodide DMF, r.t., 16 h; b) K2CO3, Ethyl chloroformate, DMF, r.t., 16 h; c) Ethyl acetoacetate, MeHSO3,
60○C, 16 h; d) Conc. sulfuric acid, acetic acid 100○C, 16 h; e) K2CO3, tert-butyl bromoacetate DMF,
100○C, 16 h; f) SeO2, p-xylene, 140○C, 16 h; g) Sodium borohydride, THF/MeOH rt, 4 h; h) TFA,
CH2Cl2, r.t., 3 h; i) DCC, NHS, DMF, rt, 2 h; j) Halo −NH2, TEA, r.t., 16 h; k) bis(p-nitrophenyl)
carbonate CH2Cl2 r.t. 3 h; l) BG −NH2, DMF, TEA, 60○C, 3 h.
Starting from the general building block 37b, we additionally synthesised CMACM-HaXS2,
an analogue of CMACM-HaXS1, with reversed orientation of the tag substrates (Scheme 25).
Treatment of 37b with DCC and NHS followed by the addition of BG −NH2 under basic con-
ditions gave compound 38 in moderate yields. Activation of the alcohol 38 with p-nitrophenyl
carbonate for 16 hours at room temperature and a subsequent reaction with Halo −NH2, pro-
duced CMACM-HaXS2 in comparable yields to CMACM-HaXS1.
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Scheme 25: Synthesis of CMACM-HaXS2. Reaction conditions: a) DCC, NHS, DMF, r.t., 2 h; b)
BG −NH2, TEA, r.t., 16 h; c) bis(p-nitrophenyl) carbonate, CH2Cl2 rt 3 h; d) Halo −NH2, DMF,
TEA, 60, 3 h
To validate the in vivo dimerisation activity of these new 7-aminocoumarin-4-methyl HaXS
molecules, we treated Hela cells co-expressing SNAP-GFP and Halo-GFP fusion proteins with 5
µM CACM-HaXS, CMACM-HaXS1, CMACM-HaXS2 and HaXS8 (figure 25, A). The
results of these in vivo assays clearly demonstrate that CACM-HaXS and HaXS8 induced
dimerisation of Halo-GFP and SNAP-GFP fusion proteins at similar rates. Both compounds
triggered the formation of 80% fusion protein dimers after 15 minutes. In contrast to the previ-
ously discussed MeNV-HaXS, no difference was observed at early time points (t = 5 minutes).
Thus, CACM-HaXS may be preferred in biological experiments where rapid dimerisation is
required. Surprisingly, the methylated compounds CMACM-HaXS1 and CMACM-HaXS2
induced dimerisation approximately two times less effectively with respect to CACM-HaXS.
The orientation of the tag substrate has only minor influence on the dimerisation activity of the
CID, as both CMACM-HaXS1 and CMACM-HaXS2 trigger dimerisation of fusion protein
at similar rates. To investigate reasons for different in vivo reactivities of methylated and non-
methylated coumarine containing HaXS molecules, we next treated recombinant SNAP-GFP
with HaXS8, CACM-HaXS or CMACM-HaXS1, followed by the addition of recombinant
Halo-GFP. Interestingly, all three compounds induced similar amounts of fusion protein dimers
in vitro (figure 25, B). These results suggest that the lower in vivo dimerisation activity of the
CMACM-HaXS derivatives may be due to a reduced bioavailability.
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Figure 25: In vivo and in vitro dimerisation efficacy of CACM-HaXS, CMACM-HAXS1 and
CMACM-HaXS2. A) HeLa cells co-expressing SNAP-GFP and Halo-GFP fusion proteins were in-
cubated with 5 µM HaXS8, CACM-HaXS, CMACM-HaXS1 and CMACM-HaXS2 for 5 or 15
minutes in cell culture medium at 37○C before cells were lysed and proteins were subjected to SDS
PAGE, immunoblotting and chemiluminescence. B) 5 µM of recombinant SNAP-GFP fusion protein
was incubated with 5 µM of HaXS8, CACM-HaXS or CMACM-HaXS1 for 30 minutes, prior to
the addition of 5 µM Halo-GFP. Thereafter, proteins were denatured, separated by SDS PAGE and
detected by Coomassie-Blue staining.
To determine the molar extinction coefficient of CACM-HaXS at 360 nm and 405 nm, we
measured the UV-Vis absorption spectra of different concentrated solutions in DMSO. The ab-
sorption maxima of CACM-HaXS (365 nm) is only slightly higher than the absorption max-
ima of MeNV-HaXS (355 nm) and significantly lower compared to other amino-subtituted 7-
aminocoumarinyl-4-methyl derivatives, which exhibit absorption maxima typically in the range
of 380 - 400 nm (measured in different aqueous solutions, methanol or ethanol)[250]. Most likely
the relatively low absorption maxima CACM-HaXS can be attributed to a solvent effect. In
fact, more polar solvents cause a red shift of the absorption bands of pi to pi* (coumarinyl deriva-
tives) electron transitions[262, 263]. In contrast, the absorption bands of n to pi* (o-nitobenzyl
derivatives) electron transitions experience a blue shift[262, 263]. Thus, we assume that the
absorption maxima of CACM-HaXS in water or in a DMSO/water mixture should be red
shifted with respect to the measured values, whereas the absorption maxima of MeNV-HaXS
should be prominently blue shifted. However, CACM-HaXS still exhibits four-times higher
molar extinction coefficients at 360 nm (23120 M-1cm-1) and two-times higher molar extinction
coefficient at 405 nm (2622 M-1cm-1) compared to MeNV-HaXS (ε360 = 4058 M-1cm-1 respec-
tively ε405 = 1238 M-1cm-1). To determine the quantum yield of CACM-HaXS at 360 nm
and 405 nm we irradiated 3 mL of 0.5 mM solutions of the CID in a Lumos 43A photoreactor
for indicated time. Aliquots of the samples were transferred to a HPLC and the disappearance
of the starting material was monitored. CACM-HaXS exhibited significant lower quantum
yields (0.006 at 360 nm and 0.016 nm at 405 nm), compared to the quantum yields reported
for other 7-aminocoumarinyl-4-methyl carbamates (0.04 - 0.11)[264, 265]. Interestingly, samples
irradiated at 360 nm displayed a higher photolytic rate at early time points (5 times higher at
t < 5 minutes). This may indicate that the formed by-products absorb at 360 nm and therefore
interfere with the photolysis reaction[266]. Based on these results it is difficult to compare the
photophysical properties of CACM-HaXS and MeNV-HaXS and draw conclusions on their
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behaviour in cells. To obtain results, which better reflect the in vivo measurements, the UV-Vis
spectra of CACM-HaXS and MeNV-HaXS should be recorded in the same medium used in
the biological experiments. Additionally, the quantum yield experiments should be repeated us-
ing the same time scales for both compounds and lower concentrations. However, the product of
the quantum yield and the molar extinction coefficient, which is proportional to the efficiency to
release the leaving group at a given excitation wavelength[250], of CACM-HaXS (139 M-1cm-1
at 360 nm and 42 M-1cm-1 at 405 nm) is only slightly lower in respect to the values measured
for MeNV-HaXS(304 M-1cm-1 at 360 nm and 87 M-1cm-1 at 405 nm). Thus, we assume that
irradiation of CACM-HaXS-induced protein dimers at 360 nm or 405 nm should lead to effi-
cient cleavage. Experiments to determine the two-photon cross section of CACM-HaXS and
MeNV-HaXS at wavelength >700 nm are ongoing.
Figure 26: Photophysical properties of CACM-HaXS. A) The UV/Vis spectra of different CACM-
HaXS solutions in DMSO were recorded at room temperature. B) A 0.5 mM CACM-HaXS solution
of in DMSO/water mixture (10:90) was irradiated for the indicated amount of time with an LED lamp,
emitting 5.44⋅10-7 E/min at 360 nm. Subsequently, samples were subjected to a UPLC. Decrease of
starting material was detected using a ESI-SQD mass spectrometer and plotted against time. C) A
0.5 mM CACM-HaXS solution of in DMSO/water mixture (10:90) was irradiated for the indicated
amount of time with an LED lamp, emitting 5.44⋅10-7 E/min at 405 nm. Samples were analysed as
analogues to B).
We next compared the in vivo photolysis reaction of CACM-HaXS and MeNV-HaXS
dimerised SNAP-GFP and Halo-GFP fusion proteins at 360 nm (figure 27). Therefore, we incu-
bated HeLa cells co-expressing Halo-GFP and SNAP-GFP with 5 µM of either CACM-HaXS,
MeNV-HaXS or the non-cleavable HaXS8 for 15 minutes, prior to irradiation of the cells with
a black ray B-100A 360 nm long wave lamp. After 10 minutes of irradiation, approximately 90%
of CACM-HaXS- and MeNV-HaXS-induced protein dimers were cleaved (figure 27, A). In
contrast, dimers were not cleaved in cells treated with the photostable HaXS8. Interestingly,
CACM-HaXS-induced dimers were approximately two times more efficiently cleaved, compared
to MeNV-HaXS-induced dimers, when the irradiation time was reduced to 2 minutes (figure 27,
B). This may be due to the increased absorption of coumarinyl compounds and reduced absorp-
tion of o-nitrobenzyl compounds in polar solvents[267, 268], and the higher quantum yield of
CACM-HaXS displayed at early time points. Thus, CACM-HaXS can be used to covalently
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dimerise Halo-POI and SNAP-POI fusion proteins, which can be cleaved with high temporal
precision under mild conditions. Experiments comparing the photolysis of CACM-HaXS- and
MeNV-HaXS-induced dimers are currently under investigation.
Figure 27: Comparison of the photocleavage of MeNV-HaXS and CACM-HaXS at 360 nm. A)
HeLa cells expressing SNAP-GFP and Halo-GFP fusion proteins were treated with 5 µM of HaXS8,
MeNV-HaXS or CACM-HaXS for 15 minutes. Subsequently, cells were washed with PBS to remove
unreacted compounds and illuminated with a high-intensity UV lamp (100 W, 5 cm distance) emitting
light at 360 nm for 10 minutes A) or 2 minutes B) in 600 µL PBS. Analysis of dimerisation products
was performed as describedpreviously. Values in B) represent means +/- SEM, n=3.
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Given the high potential of CACM-HaXS, we attempted to increase the overall yield of the
general building block 32a. To avoid the allylic oxidation with SeO2, we designed a similar route
as for the planned synthesis of ACM-HaXS. However, this time we decided to substitute the
amino group prior to the Pechman condensation (scheme 26). Therefore, we started the synthesis
of 32a with the alkylation 3-aminophenol (30a) with ethyl-2-iodoacetate under basic conditions,
which gave 39 in good yields. We then deactivated the amino group with ethyl chloroformate
under the same conditions as those previously described for 33a. The acid catalysed cyclisation
of 39 with ethyl 4-chloroacetoacetate generated the coumarine 40 with a good yield. In contrast
to the Pechmann condensation procedure discussed above, chromatographic purification of 40
was necessary, as the product did not precipitate. Hydrolysis of the ethyl carbamate and the ethyl
ester in a mixture of H2SO4 and acetic acid at 100
○C yielded 41 as a red solid. Unfortunately,
the substitution of the chloride with a hydroxy group was not achieved using the same procedure
as that described for the synthesis of 22. Attempts to use basic conditions to substitute the
chloride with the hydroxyl group, were not made, but rather we substituted the chloride of 40
with the hydroxyl group to give 42. The saponification and cleavage of the protecting group
with H2SO4 and acetic acid, followed by basification to pH 5.3, led to the precipitation of 32a,
which was purified by recrystallisation in isopropanol. With this synthetic strategy, we were able
to increase the overall yield of 32a from 3.5% to 21%.
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Scheme 26: Alternative synthetic route to the synthesis of 32a. Reaction conditions: a) Ethyl-
2-iodoacetate, K2CO3, DMF, r.t., 16 h; b) Ethyl chloroformate, K2CO3, DMF, r.t., 16 h; c) Ethyl
4-chloroacetoacetate, MeHSO4, 60
○C, 16 h; d) Conc. sulfuric acid, acetic acid 100○C, 16 h; e)
H2O/Dioxane, 100
○C, 16 h; f) Conc. sulfuric acid, acetic acid, 100○C, 16 h.
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This route opened the path to the synthesis of an alternative coumarin containing an HaXS
molecule (scheme 27). Therefore, we refluxed compound 41 for 3 days in water, rather than 16
h (see above), which resulted in the formation of compound 44. Coupling of the Halo −NH2
building block to compound 44 proceeded under various coupling conditions to create compound
45. However, the best yields were obtained using DCC and NHS to activate the carboxylic acid,
followed by coupling under mild basic conditions with Halo −NH2 . Treatment of 45 under
harsh basic conditions resulted in the formation of the glycolylurea derivative 46 with high yields.
Attempts to carry out the reaction under milder reactive conditions failed. Finally, carbamate
formation between 46 and BG −NH2 using p-nitrophenyl carbonate generated GUCM-HaXS
with good yields.
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Scheme 27: Synthesis of GUCM-HaXS. Reaction conditions: a) H2O/Dioxane, 100
○C, 3 days; b)
DCC, NHS, DMF, r.t., 2 h; c) Halo −NH2, TEA, DMF, r.t., 16 h; d) NaOH, H2O, 16 h, 60○C; e)
bis(p-nitrophenyl) carbonate, triethylamine, DMF, r.t., 16 h; f) BG −NH2, 60○C, 6 h.
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To investigate the absorption properties of GUCM-HaXS, we measured the UV-Vis spectra of
different concentrated solutions in DMSO (figure 28, A). Not suprisingly, the electron withdraw-
ing glycourea substituent at the C7 position of the coumarin core, blue shifted the absorption
band to 330 nm and reduced the molar extinction coefficient at 360 (2346 M-1 cm-1) and 405
nm (1313 M-1 cm-1), compared to CACM-HaXS. The quantum yields at 360 nm (figure 28,
B) and 405 nm (figure 28, C) were determined as described above. GUCM-HaXS exhibited
quantum yields of 0.007 at 360 nm and 0.009 at 405 nm. However, the relative low absorption of
GUCM-HaXS at these wavelength suggest that efficient cleavage of dimers may be difficult.
Figure 28: Photophysical properties of GUCM-HaXS. A) The UV/Vis spectra of different GUCM-
HaXS solutions in DMSO were recorded at room temperature. B) A 0.5 mM GUCM-HaXS solution
of in DMSO/water mixture (10:90) was irradiated for the indicated amount of time with an LED lamp,
emitting 5.44⋅10-7 E/min at 360 nm. Subsequently, samples were subjected to a UPLC. Decrease of
starting material was detected using a ESI-SQD mass spectrometer and plotted against time. C) A
0.5 mM GUCM-HaXS solution of in DMSO/water mixture (10:90) was irradiated for the indicated
amount of time with an LED lamp, emitting 5.44⋅10-7 E/min at 405 nm. Samples were analysed as
analogues to B).
We then investigated the time-dependent GUCM-HaXS-mediated dimerisation of SNAP-GFP
and Halo-GFP. We treated HeLa cells, co-expressing SNAP-GFP and Halo-GFP, with 0.5 µM
of the GUCM-HaXS, and HaXS8, for the indicated time period (figure 29). Like most of the
photocleavable HaXS molecules described above, the dimerisation activity of GUCM-HaXS
was comparable to HaXS8 (figure 29, A). Both CIDs induced over 85% of fusion protein dimers
after only 5 minutes of treatment, which were stable at ambient light, for a minimum of 60
minutes. To validate the in vivo photocleavage of GUCM-HaXS-induced fusion protein dimers,
we irradiated cells containing the dimerised fusion proteins, with a black ray B-100A 360 nm long
wave lamp and compared the results to the photolysis rate of HaXS8-, MeNV-HaXS-, and
HCM-HaXS-induced dimers (figure 29, B). Surprisingly, fusion protein complexes which formed
with GUCM-HaXS did not undergo photolysis after irradiation for 10 minutes. In contrast,
dimers formed by HCM-HaXS were slightly cleaved, despite having an approximately 2-times
lower molar extinction coefficient at 365 nm compared to GUCM-HaXS. No irregularities were
observed in the control experiments, as HaXS8-induced protein complexes were photo insensitive
and MeNV-HaXS-induced dimers were quantitatively cleaved. Based on the results of the in
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vivo and in vitro photolysis experiments, we concluded that GUCM-HaXS can be used to
induce the formation of a Halo-POI-SNAP-POI complex, which can be cleaved orthogonally to
dimers formed by MeNV-HaXS.
Figure 29: In vivo dimerisation and cleavage efficacy of GUCM-HaXS. A) HeLa cells co-expressing
SNAP-GFP and Halo-GFP fusion proteins were incubated with 5 µM HaXS8, and GUCM-HaXS in
cell culture medium at 37○C for indicated time, before cells were lysed and proteins were subjected to
SDS PAGE, immunoblotting and chemiluminescence. B) HeLa cells expressing SNAP-GFP and Halo-
GFP fusion proteins were treated with 5 µM of HaXS8, GUCM-HaXS, MeNV-HaXS or HCM-
HaXS1 for 15 minutes. Subsequently, cells were washed with PBS to remove unreacted compounds
and illuminated with a high-intensity UV lamp (100 W, 5 cm distance) emitting light at 360 nm for 10
minutes. Samples were analysed as described in A)
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4 Conclusion and outlook
In the first part of this project, we successfully developed a novel Lewis acid-mediated method to
synthesis C-16 modified rapalogs. The relatively mild reaction conditions allow the introduction
of acid sensitive groups, such as different carbamates, ureas and thioureas. Notably, we were
able to introduce a tert-butyl carbamate at the C16 position. We assumed that this rapalog
could be applied in an extended selective modification of the rapamycin core after de-protection
of the amine. The mechanism of the addition of carbamates onto the C16-carbocation appears
to involve the prior establishment of a tight rapamycin-BF3 ion pair, which exhibits reduced
reactivity towards nucleophiles. Additionally, BF3 also forms transient complexes with carba-
mate, reducing the nucleophilicity of the carbamate. The addition of THF subsequently leads
to the irreversible formation of the desired rapalogs in high yields. The resulting C16 carbamyl
diastereomers were readily separated by column chromatography and the absolute configura-
tion of the C16 stereocenter was determined through NMR spectroscopic analysis. Moreover, we
demonstrated that phenyl carbamate substitution can abolish potential interference with endoge-
nous mTOR. However, extensive purification was required to remove traces of mTOR inhibiting
byproducts and a method to quantitatively purify the product will be the focus of future studies.
Nonetheless, (R)-pcRap is a powerful, non-toxic tool to rapidly induce protein-protein inter-
actions. Future work will focus on the scale up of (R)-pcRap purification, as well as on its
biological applications. The combination of (R)-pcRap with other orthogonal CID systems (e.g.
HaXS molecules) would be an attractive method to simultaneously regulate multiple proteins,
without off-target effects.
In the second part of this project, we synthesised a series of cell-permeable HaXS, which rapidly
induced the formation of covalently linked and photocleavable protein dimers. Most of the synthe-
sised photocleavable HaXS molecules induced significant amounts of dimers after a short period of
time, highlighting the feasibility to modify the properties of HaXS molecules without decreasing
the dimerisation activity. The covalent link formed between the photocleavable HaXS molecules
and its target proteins, simplifies the analysis of protein complexes and prevents degradation of
the complex prior to irradiation. The fast photolytic rates of the photocleavable HaXS molecules
provides a choice between irradiation with a high-intensity UV lamp, a standard fluorescence
microscope equipped with a mercury halide lamp or with a FRAP laser. Photocleavable HaXS
molecules are therefore a novel asset to the CID toolbox, which combines intracellular protein
dimerisation with photocleavage. Photocleavable HaXS molecules enable the possibility to se-
quester any protein of interest away from its functional compartment. Sequential photo-induced
cleavage of the CID can release the anchored proteins and restore their function. Alternatively,
photocleavable HaXS molecules can be used to reversibly switch the activity of proteins on or
off. The choice between global and local illumination triggering dissociation of the CID-mediated
complex permits the investigation of cell-compartment-associated signaling, and the simulation
of cell-wide physiological and pathological signaling dynamics. Given the influence of the solvent
on the photophysical properties of photocleavable groups, it might be interesting to investigate
whether MeNV-HaXS and CACM-HaXS behave differently at various subcellular localisa-
tions. Combinations of cleavable HaXS molecules simultaneously with other orthogonal CIDs
systems, would be an interesting approach to controlling multiple proteins. The combination
of MeNV-HaXS or CACM-HaXS with other photo-activatable CIDs, such as cTMP-Htag
would certainly be of specific interest. This would allow, either sequentially (in the case of
CACM-HaXS) or simultaneously (in the case of MeNV-HaXS) to photo-induce the cleav-
age of a protein complex and independently trigger the formation of another protein-protein
interaction. A combination of orthogonal photocleavable HaXS molecules could also be used
to regulate multiple protein networks; however such experiments would require an elaborative
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design. One possibility would be to control the expression of the fusion proteins and to treat the
cells sequentially with MeNV-HaXS and CACM-HaXS. Alternatively, the intermediate 32a
presents a valuable precursor to tether different tag substrates, thus enabling the possibility to
develop a series of photocleavable CIDs with orthogonal reactivities in two synthetic steps. Fi-
nally, the protection of the guaninyl nitrogen in MeNV-HaXS with a re-shifted coumarin-based
photocage would give access to a highly powerful tool, which would allow the formation and the
dissociation of a protein complex with light, to be controlled. Similar CIDs could be designed,
using the aminocoumarinyl-4-methyl protected TMP or BG −NH2, linked via a nitrobenzyl
linker to a second tag substrate.
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5 Experimental Section
5.1 General Information
5.1.1 Reagents and Solvents
Materials and reagents were of the highest commercially available grade and used as received
from ABCR GmbH Co. KG (Karlsruhe, Germany), Acros OrganicsTM (Basel, Switzerland),
Betapharma Co., Ltd (Shanghai, China), Fluka AG (Buchs, Switzerland), Fluorochem Ltd.
(Hadfield, United Kingdom), or Sigma-Aldrich® (Buchs, Switzerland) unless stated otherwise.
Dry solvents were purchased as anhydrous grade from Acros Organics or Fluka. Technical-grade
solvents used for extractions and chromatographies were obtained from Brenntag AG (Basel,
Switzerland) and were used without purification. Deuterated solvents for NMR spectroscopy
were purchased from Cambridge Isotope Labratories, Inc. (Andover, MA, USA).
5.1.2 Sensitive reactions
All reactions were performed at ambient light as none of the photocleavable molecules showed any
sensitivity towards ambient light. Air- and water-sensitive reactions were performed under an
inert atmosphere using nitrogen from PanGas AG (Damarsellen, Switzerland). Low temperature
reaction were performed with an external cooling bath, containing isopropanol and dry ice.
5.2 Instrumentation
5.2.1 Nuclear Magnetic Resonance (NMR) spectroscopy
All NMR spectra were recorded on a Bruker Avance III NMR spectrometer operating at 600 MHz
(for 1H-NMR), 151 MHz (13C-NMR), 565 MHz (19F-NMR) or 193 Mhz (11B-NMR) equipped
with a z-axis pulsed field gradient broadband direct detection probe-head, on a Bruker Ultra
Shield Avance III with a BBO probe-head spectrometer operating at 500 MHz (for 1H-NMR),
126 MHz (13C-NMR) or a Bruker Avance III 400 with a BFFO+ probe-head operating at 400
MHz (1H-NMR), 101 MHz (13C-NMR), 376 MHz (19F-NMR). Chemical shifts (δ) are reported
in parts per million (ppm) relative to residual solvent peaks or trimethylsilane (TMS). Coupling
constants (J) are reported in Hertz (Hz). NMR experiments to determine the structure of
compounds were performed at 298 K. Experiments to determine the mechanism of the Lewis
acid-mediated C16 substitution of rapamycin were performed at 243 K. For low temperature
measurements the spectrometer was calibrated using a methanol sample. The multiplicities of
the signals are described as: s = singlet, d = doublet, t =triblet, q = quartet, p = pentet, h =
hextet, hept = heptet and m = multiplet. For multiplets, the range of the chemical shift (ppm)
of the signal is reported, for the other signals the centre of the signal is reported.
5.2.2 Two-dimensional nuclear magnetic resonance (2D NMR) spectroscopy
1H-1H COSY, 1H-1H NOESY, 1H-1H ROESY, 1H-1H TOSCY, 1H-13C HMQC, and 1H-13C
HMBC experiments, required to assign 1H- and 13C-signal, determine the absolute configuration
of rapalogs or for the mechanistic study, were performed on Bruker Avance III NMR spectrometer
equipped with a z-axis pulsed field gradient broadband direct detection probe-head at 600 and 151
MHz, respectively, or on a Bruker Ultra Shield Avance III with a BBO probe head spectrometer
at 500 and 126 MHz, respectively. Phase-sensitive ROESY experiments as well as TOCSY
experiments were performed with 2048 time points in F2 and 1024 time increments in the indirect
dimension F1,which corresponds to acquisition times of 155 ms in F2 and 77 ms in F1.The
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Spinlock pulse for the ROESY experiment was set to 350 ms and the experiment times were
between 3 and 18 hours. The mixing time for the TOCSY experiment was set to 200 ms and the
experiment times were between 3 and 10 hours.
5.2.3 Mass Spectroscopy (MS)
Mass spectra were recorded with a fast atom bombardment (FAB) VG70-250 spectrometer, a
electron ionization (EI) Finnigan MAT MS 312 spectrometer, a electrospray ionization (ESI)
Finnigan MAT LSQ spectrometer, or a matrix assisted laser desorption ionization time of flight
(MALDI-TOF) Bruker microflexTM spectrometer. High resolution mass spectra (HRMS) were
recorded with a Thermo Fisher Scientific LTQ Orbitrap XL, nanoelectrospray ion source.
5.2.4 Thin-Layer Chromatography (TLC) and Preparative Thin-Layer Chromatog-
raphy (PTLC)
TLC was performed using Merck silica gel 60 F254 plates with a thickness of 0.25 mm. Compounds
were visualised by UV lamps (253 or 366 nm), and with ceric ammonium molybdate (CAM),
KMnO4, ninhydrin, or vanillin staining. For PTLC silica gel glass plates with a thickness of 2.0
mm from Merck KGaA were used.
5.2.5 High-Performance Liquid Chromatography (HPLC)
Normal-phase analytical HPLC measurements were performed on a Shimadzu LC-20AT instru-
ment using a Reprospher 100 Si, 5 µm column (100 x 10 mm) from Maisch GmbH. Compounds
were detected with a SPD-M20A diode array detector. Preparative normal-phase HPLC separa-
tions were performed on a Dionex P680 HPLC instrument using a Reprosil 100 Si, 5 µm column
(250 x 40 mm) from Maisch GmbH and compounds were detected with a UV-Vis spectrometer.
5.2.6 Ultra Performance Liquid Chromatography (UPLC)
Reverse-phase UPLC measurements were performed on a Acquity H-Class UPLC system
equipped with an ESI-SQD mass spectrometer, using a Acquity UPLC BEH column (2.1 x
50 mm) with a pore size of 1.7 µm.
5.2.7 Column chromatography
Column chromatography were performed using Silica gel 60 (40-63 µm) from Sigma Aldrich or
SilicaFlash P60 (40-63 µm) from Silicycle®.
5.2.8 Ultraviolet/Visible (UV/Vis) absorption spectroscop
UV/Vis spectra were recorded on a Perkin Elmer Lamda 40 UV/Vis spectrometer, or a NanoDrop
2000/2000c spectrophotometer, using a quarz standard absorption cells. All measurements were
performed at room temperature and the wavelength of the absorption band (λ) are reported in
nm.
5.2.9 Photo reactors
Photolysis reactions were performed in a Lumos 43A equipped with a LED lamp or in a Tran-
silluminator reactor equipped with 4 RPR-3500 A˚, which emitted light at 360 nm or 405 nm.
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5.2.10 Microscops
Images were acquired on a Leica Live Imaging Microscope equipped with a HCX Plan Fluotar
63x/1.4 oil objective, a Photometrics CCD Camera CoolSnap HQ2 with Metamorph 7.1 software
(Molecular devices) and a 50 mW FRAP scanning laser (UV-Diode Laser, 355 nm, 30 Hz) or
a Leica EL600 microscope equipped with a mercury metal halide lamp (filter cube: ex: 377±25
nm, em: 447±30 nm, dichrioic mirror: 409 nm; 63x objective: 63xHCX Plan-Fluotar, NA: 1.25
[oil]).
5.3 Experimental procedures
5.3.1 Synthetic procedures
5.3.1.1 Synthesis of C16-carbamy rapalogs
General Procedure 1 (GP1): Lewis acid-mediated substitution of the C16
methoxy group of rapamycin
Rapamycin (0.10 mmol) and the indicated carbamate (0.60 mmol) were dissolved in CH2Cl2
(20 mL). The reaction mixture was cooled to -40○C prior to the addition of BF3-Et2O
(0.40 mmol). This solution was stirred for 5 min prior to the addition of THF (10 mL).
After stirring the mixture for 30 min stirring at -40○C, the reaction was quenched with
a saturated aqueous solution of NaHCO3. The aqueous layer was extracted three times
with EtOAc, the combined organic layer was dried over Na2SO4 and concentrated under
reduced pressure. To determine the amount of remaining rapamycin, an aliquot (1 mg) of
the resulting white solid was dissolved in CH2Cl2 (1 mL) and subjected to HPLC analysis
(injection volume 50 µL). The sample was eluted using a 60-min linear gradient of 100:0 to
96:4 (CH2Cl2/MeOH) and a flow rate of 2 mL⋅min-1. The crude mixture was redissolved in
CH2Cl2 (20 mL) and cooled down to -40
○C. BF3-Et2O (0.40 mmol) were added and the
mixture was stirred for 5 min, prior to THF addition (10 mL). The mixture was stirred for
30 min at -40○C. The reaction was quenched with a saturated aqueous solution of NaHCO3
and the aqueous layer were extracted three times with EtOAc. The combined organic layer
was dried over Na2SO4 and concentrated under reduced pressure. This reaction procedure was
repeated 3-4 times until complete consumption of rapamycin (HPLC monitoring). The product
was purified and the diastereomers were separated by column chromatography (CH2Cl2/MeOH).
Preparation of C16-phenyl carbamyl rapamycin (pcRap)
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According to GP1, starting with rapamycin (100 mg, 0.11 mmol, 1 eq), phenyl carbamate
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(90 mg, 0.66 mmol, 6 eq), BF3-Et2O (57 µL, 0.44 mmol, 4 eq), column chromatography
(CH2Cl2/MeOH 40:1 to 20:1) afforded 92 mg of pcRap as a mixture of two diastereomers (83%
yield; 52:48 ratio). The product obtained after column chromatography was further purified by
preparative HPLC using a 90-min linear gradient of 100:0 to 94:6 (CH2Cl2:methanol) and a flow
rate of 30 mL⋅min-1. Purity of the resulting fractions was determined using analytical HPLC.
Therefore, 50 µL of a 100 µM solution of product in CH2Cl2 were injected and eluted using a
60-min linear gradient of 100:0 to 96:4 (CH2Cl2:methanol) and a flow rate of 2 mL⋅min-1.
Mixture of diastereomers:
ESI-MS m/z: 1041.57, 999.56, 864.53, 685.44, 607.39, 551.33, 412.17, 351.25, 279.02, 256.00,
189.96.
HRMS for C57H82O14N2 [M-Na]
+: calcd:. 1041.5658, found 1041.5664.
(R)-pcRap:
Rt analytical: 40.3 min
Rt preperative: 37.9 min
1H-NMR (600MHz, DMSO − d6) δ: 7.87 (d, J = 7.8 Hz, 1H, H52), 7.37 (dd, J = 6.8 Hz, 8.0
Hz, 2H, H56), 7.19 (t, J = 6.8 Hz, 1H, H57), 7.09 (d, J = 8.0 Hz, 2H, H55), 6.40 (dd, J = 10.8
Hz, 11.4 Hz, 1H, H19), 6.39 (s, 1H, OH10), 6.21 (dd, J = 11.4, 12.4 Hz, 1H, H20), 6.13 (d, J =
10.6 Hz, 12.4 Hz, 1H, H21), 6.08 (d, J = 10.8 Hz, 1H, H18), 5.52 (dd, J = 9.4 Hz, 12.4 Hz, 1H,
H22), 5.24 (d, J = 4.4 Hz, 1H, OH28), 5.22 (d, J = 9.8 Hz, 1H, H30), 5.10 (m, 1H, H34), 4.96
(d, J = 5.3 Hz, 1H, H2), 4.59 (d, J = 4.3 Hz, 1H, OH40), 4.07 (m, 1H, H28), 4.02 (m, 1H, H16),
4.01 (m, 1H, H27), 3.95 (m, 1H, H14), 3.57 (m, 1H, H6), 3.31 (m, 3H, H51), 3.27 (m, 1H, H31),
3.18 (m, 3H, H50), 3.16 (m, 1H, H40), 3.06 (m, 1H, H6), 2.81 (m, 1H, H39), 2.81 (m, 1H, H33),
2.44 (m, 1H, H33), 2.39 (m, 1H, H25), 2.25 (m, 1H, H23), 2.16 (m, 1H, H3), 2.04 (m, 1H, H11),
1.91 (m, 1H, H38), 1.84 (m, 1H, H15), 1.75 (m, 1H, H41), 1.74 (m, 3H, H47), 1.72 (m, 3H, H44),
1.70 (m, 1H, H35), 1.67 (m, 1H, H4), 1.64 (m, 1H, H13), 1.61 (m, 1H, H12), 1.60 (m, 1H, H3),
1.55 (m, 1H, H12), 1.52 (m, 3H, H5, H15, H42), 1.40 (m, 1H, H24), 1.36 (m, 2H, H4, H5), 1.31
(m, 1H, H13), 1.27 (m, 1H, H37), 1.17 (m, 1H, H41), 1.10 (m, 1H, H36), 1.04 (m, 1H, H24), 0.99
(m, 3H, H45), 0.96 (m, 1H, H36), 0.91 (m, 3H, H48), 0.85 (m, 1H, H42), 0.81 (m, 3H, H46), 0.80
(m, 3H, H49), 0.76 (m, 3H, H43), 0.58 (m, 1H, H38).
13C-NMR (126 MHz, DMSO − d6) δ: 210.2 (C26), 208.0 (C32), 199.0 (C9), 169.4 (C1), 167.0
(C8), 153.8 (C53), 151.1 (C54), 140.0 (C17), 138.4 (C22), 136.9 (C29), 131.8 (C20), 130.4 (C21),
129.2 (C56), 127.6 (C19), 124.8 (C57), 124.6 (C30), 123.6 (C18), 121.6 (C55), 99.0 (C10), 85.5
(C27), 83.8 (C39), 75.7 (C28), 73.4 (C34), 73.2 (C40), 66.6 (C14), 56.9 (C50), 56.8 (C51), 53.7
(C16), 51.2 (C2), 44.8 (C31), 43.9 (C6), 40.4 (C33), 39.9 (C25), 39.6 (C24), 39.4 (C15), 38.3
(C36), 35.2 (C38), 34.7 (C11), 34.4 (C23), 33.5 (C35), 32.9 (C41), 32.6 (C37), 31.3 (C13, C42),
26.6 (C3), 26.4 (C12), 24.4 (C5), 21.5 (C45), 20.5 (C4), 16.0 (C48), 15.6 (C43), 15.2 (C44), 15.0
(C49), 13.8 (C47), 12.9 (C46).
(S)-pcRap:
Rt analytical: 37.6 min
Rt preperative: 35.5 min
1H-NMR (600MHz, DMSO − d6) δ: 8.07 (d, J = 8.8 Hz, 1H, H52), 7.37 (dd, J = 7.38 Hz, 7.68
Hz, 2H, H56), 7.19 (t, J = 7.38 Hz, 1H, H57), 7.07 (d, J = 7.68 Hz, 2H, H55), 6.51 (s, 1H, OH10),
6.36 (dd, J = 11.3 Hz, 13.1 Hz, 1H, H19), 6.20 (dd, J = 10.8 Hz, 13.1 Hz, 1H, H20), 6. 12 (dd,
J = 10.8 Hz, 13.1 Hz, 1H, H21), 6.05 (d, J = 10.9 Hz, 1H, H18), 5.48 (dd, J = 9.2 Hz, 13.1 Hz,
1H, H22), 5.27 (d, J = 4.4 Hz, 1H, OH28), 5.10 (d, J = 10.0 Hz, 1H, H30), 4.99 (m, 1H, H34),
4.96 (d, J = 6.3 Hz, 1H, H2), 4.60 (m, 1H, OH40), 4.13 (m, 1H, H16), 4.01 (m, 1H, H28), 3.94
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(m, 1H, H14), 3.87 (d, J = 5.0 Hz, 1H, H27), 3.45 (m, 1H, H6), 3.33 (m, 1H, H31), 3.32 (m, 3H,
H51), 3.25 (m, 1H, H6), 3.17 (m, 1H, H40), 3.16 (m, 3H, H50), 2.83 (m, 1H, H39), 2.76 (m, 1H,
H33), 2.49 (m, 1H, H25), 2.44 (m, 1H, H33), 2.22 (m, 1H, H23), 2.08 (m, 1H, H3), 2.05 (m, 1H,
H11), 1.96 (m, 1H, H15), 1.92 (m, 1H, H38), 1.82 (m, 1H, H13), 1.75 (m, 6H, H41, H42, H44),
1.74 (m, 3H, H47), 1.70 (m, 1H, H35), 1.67 (m, 1H, H4), 1.63 (m, 1H, H3), 1.58 (m, 1H, H5),
1.54 (m, 1H, H12), 1.52 (m, 1H, H12), 1.43 (m, 1H, H15), 1.41 (m, 2H, H4, H24), 1.31 (m, 1H,
H5), 1.28 (m, 1H, H37), 1.25 (m, 1H, H13), 1.18 (m, 1H, H41), 1.07 (m, 1H, H36), 1.06 (m, 1H,
H24), 0.98 (m, 3H, H45), 0.97 (m, 1H, H36), 0.89 (m, 3H, H48), 0.86 (m, 1H, H42), 0.85 (m, 3H,
H46), 0.79 (m, 3H, H49), 0.76 (m, 3H, H43), 0.60 (m, 1H, H38).
13C-NMR (126 MHz, DMSO − d6) δ: 210.9 (C26), 207.7 (C32), 198.9 (C9), 169.2 (C1), 166.8
(C8), 154.2 (C53), 151.1 (C54), 138.9 (C22), 138.2 (C17), 132.0 (C20), 130.4 (C21), 129.3 (C56),
127.3 (C19), 125.5 (C18), 124.9 (C57), 125.3 (C30), 121.7 (C55), 99.0 (C10), 85.9 (C27), 83.8
(C39), 75.8 (C28), 73.7 (C34), 73.2 (C40), 66.8 (C14), 57.1 (C50), 56.7 (C51), 54.9 (C16), 50.6
(C2), 45.3 (C31), 43.4 (C6), 39.7 (C33), 39.6 (C24), 39.2 (C25), 38.4 (C15, C36), 37.4 (C29),
35.4 (C38), 34.9 (C11, C23), 33.3 (C35), 32.9 (C41), 32.6 (C37), 31.2 (C42), 29.6 (C13), 26.4
(C3), 26.2 (C12), 24.4 (C5), 21.6 (C45), 20.4 (C4), 15.6 (C43), 15.5 (C48), 14.7 (C49), 13.7
(C46), 13.2 (C47), 11.9 (C44).
Preparation of C16-benzyl carbamyl rapamycin (bnRap) According to GP1, starting
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with rapamycin (100 mg, 0.11 mmol, 1 eq), benzyl carbamate (100 mg, 0.66 mmol, 6 eq),
BF3-Et2O (57 µL, 0.44 mmol, 4 eq), column chromatography (CH2Cl2/MeOH 40:1 to 20:1)
afforded 99 mg of X as a mixture of two diastereomers (88% yield; 51:49 ratio).
Mixture of diastereomers:
ESI-MS m/z: 1055.58, 1033.60, 1015.59, 882.54, 864.52, 846.51, 814.49, 793.56, 663.45, 607.39,
496.27, 411.17, 351.25, 309.2.
HRMS for C57H82O14N2 [M]: calcd: 1033.5995, found 1033.5992.
(R)-benzyl carbamyl rapamycin:
1H-NMR (600MHz, DMSO − d6) δ: 7.45 (d, J = 7.7 Hz, 1H, H52), 7.38 (m, 2H, H57), 7.35 (m,
1H, H58), 7.08 (m, 2H, H56), 6.37 (dd, J = 10.8 Hz, 12.4 Hz, 1H, H19), 6.34 (s, 1H, OH10), 6.17
(dd, J = 10.8 Hz, 12.4 Hz, 1H, H20), 6.13 (dd, J = 10.8 Hz, 12.0 Hz, 1H, H21), 6.02 (d, J =
10.8 Hz, 1H, H18), 5.50 (dd, J = 8.8 Hz, 12.0 Hz, 1H, H22), 5.23 (m, 1H, OH28), 5.21 (m, 1H,
H30), 5.08 (m, 1H, H34), 5.01 (m, 2H, H54), 4.95 (d, J = 5.3 Hz, 1H, H2), 4.59 (d, J = 4.65 Hz,
1H, OH40), 4.07 (m, 1H, H28), 3.95 (m, 1H, H16), 3.88 (m, 1H, H27), 3.85 (m, 1H, H14), 3.57
(m, 1H, H6), 3.30 (m, 3H, H51), 3.27 (m, 1H, H31), 3.18 (m, 3H, H50), 3.15 (m, 1H, H40), 3.03
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(m, 1H, H6), 2.82 (m, 1H, H39), 2.79 (m, 1H, H33), 2.50 (m, 2H, H33, H25), 2.42 (m, 1H, H23),
2.15 (m, 1H, H3), 2.02 (m, 1H, H11), 1.90 (m, 1H, H38), 1.76 (m, 1H, H41), 1.73 (m, 3H, H47),
1.72 (m, 1H, H15), 1.69 (m, 1H, H35), 1.68 (m, 1H, H4), 1.65 (m, 3H, H44), 1.59 (m, 1H, H3),
1.58 (m, 1H, H12), 1.56 (m, 2H, H13, H42), 1.52 (m, 1H, H12), 1.51 (m, 1H, H5), 1.40 (m, 2H,
H15, H24), 1.39 (m, 1H, H5), 1.38 (m, 1H, H4), 1.29 (m, 1H, H13), 1.27 (m, 1H, H41), 1.26 (m,
1H, H37), 1.09 (m, 1H, H36), 1.03 (m, 1H, H24), 0.99 (m, 3H, H45), 0.95 (m, 1H, H36), 0.90 (m,
3H, H48), 0.86 (m, 3H, H46), 0.85 (m, 1H, H42), 0.79 (m, 3H, H49), 0.73 (m, 3H, H43), 0.57 (m,
1H, H38).
13C-NMR (126 MHz, DMSO − d6) δ: 210.2 (C26), 207.9 (C32), 199.1 (C9), 169.4 (C1), 167.0
(C8), 156.3 (C55), 155.7 (C53), 137.2 (C17), 138.3 (C22), 137.2 (C29), 131.5 (C20), 130.4 (C21),
128.3 (C57), 127.7 (C58), 127.6 (C19), 127.4 (C56), 124.4 (C30), 123.3 (C18), 99.0 (C10), 85.9
(C27), 83.8 (C39), 75.8 (C28), 73.4 (C34), 73.2 (C40), 67.0 (C14), 65.2 (C54), 56.9 (C50), 56.8
(C51), 53.7 (C16), 51.3 (C2), 44.9 (C31), 43.8 (C6), 40.4 (C33), 39.9 (C25), 39.6 (C24), 39.5
(C15), 38.4 (C36), 35.4 (C38), 34.7 (C11), 34.4 (C23), 33.5 (C35), 33.0 (C41), 32.6 (C37), 31.8
(C13), 31.2 (C42), 26.4 (C3, C12), 24.5 (C5), 21.5 (C45), 20.5 (C4), 16.0 (C48), 15.6 (C43), 15.0
(C49), 14.1 (C46), 14.0 (C47), 12.0 (C44).
(S)-benzyl carbamyl rapamycin:
1H-NMR (600MHz, DMSO − d6) δ: 7.58 (d, J = 9.0 Hz, H52, 1H), 7.34 (m, 2H, H57), 7.32 (m,
1H, H58) 7.07 (m, 2H, H56), 6.45 (s, 1H, OH10), 6.33 (dd, J = 10.8 Hz, 12.4 Hz, 1H, H19), 6.19
(dd, J = 10.2 Hz, 12.4 Hz, 1H, H20), 6.12 (dd, J = 10.2 Hz, 12.8 Hz, 1H, H21), 6.01 (d, J =
10.8 Hz, 1H, H18), 5.49 (dd, J = 8.8 Hz, 12.8 Hz, 1H, H22), 5.28 (m, 1H, OH28), 5.10 (m, 1H,
H30), 5.03 (m, 1H, H54), 4.98 (m, 1H, H34), 4.95 (d, J = 4.9 Hz, 1H, H2), 4.59 (d, J = 4.38 Hz,
1H, OH40), 4.11 (m, 1H, H16), 4.01 (m, 1H, H28), 3.87 (m, 1H, H27), 3.86 (m, 1H, H14), 3.42
(m, 1H, H6), 3.32 (m, 4H, H31, H51), 3.21 (m, 1H, H6), 3.18 (m, 1H, H40), 3.16 (m, 3H, H50),
2.83 (m, 1H, H39), 2.76 (m, 1H, H33), 2.50 (m, 2H, H33, H25), 2.23 (m, 1H, H23), 2.08 (m, 1H,
H3), 2.02 (m, 1H, H11), 1.92 (m, 1H, H38), 1.88 (m, 1H, H15), 1.76 (m, 1H, H41), 1.74 (m, 3H,
H47), 1.69 (m, 1H, H35), 1.68 (m, 3H, H44), 1.65 (m, 1H, H4), 1.62 (m, 1H, H3), 1.54 (m, 3H,
H5, H12, H13), 1.53 (m, 1H, H42), 1.45 (m, 1H, H12), 1.39 (m, 1H, H4), 1.37 (m, 1H, H15), 1.36
(m, 1H, H24), 1.31 (m, 1H, H5), 1.30 (m, 1H, H37), 1.26 (m, 2H, H13, H41), 1.12 (m, 1H, H36),
1.08 (m, 1H, H24), 0.99 (m, 3H, H45), 0.96 (m, 1H, H36), 0.89 (m, 3H, H48), 0.86 (m, 1H, H42),
0.85 (m, 3H, H46), 0.79 (m, 3H, H49), 0.75 (m, 3H, H43), 0.60 (m, 1H, H38).
13C-NMR (126 MHz, DMSO − d6) δ: 210.8 (C26), 207.7 (C32), 198.8 (C9), 169.2 (C1), 166.9
(C8), 156.4 (C55), 155.6 (C53), 139.1 (C17), 138.7 (C22), 137.2 (C29), 131.8 (C20), 130.5 (C21),
128.3 (C57), 127.7 (C58), 127.6 (C19), 127.4 (C56), 125.1 (C30), 125.0 (C18), 98.8 (C10), 85.9
(C27), 83.9 (C39), 75.9 (C28), 73.8 (C34), 73.3 (C40), 67.0 (C14), 65.2 (C54), 57.2 (C50), 56.8
(C51), 53.4 (C16), 50.8 (C2), 45.4 (C31), 43.6 (C6), 39.7 (C24), 39.6 (C33), 39.3 (C25), 38.7
(C15), 38.3 (C36) 35.5 (C38), 34.9 (C11, C23), 33.4 (C35), 33.0 (C41), 32.8 (C37), 31.3 (C13,
C42), 26.4 (C3, C12), 24.5 (C5), 21.7 (C45), 20.5 (C4), 15.7 (C43), 15.5 (C48), 14.9 (C49), 13.7
(C46), 13.4 (C47), 12.1 (C44).
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Preparation of C16-butyl carbamyl rapamycin (buRap) According to GP1, starting with
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rapamycin (100 mg, 0.11 mmol, 1 eq), butyl carbamate (77 mg, 0.66 mmol, 6 eq), BF3-Et2O
(57 µL, 0.44 mmol, 4 eq), column chromatography (CH2Cl2/MeOH 40:1 to 20:1) afforded 79
mg of X as a mixture of two diastereomers (73% yield; 51:49 ratio).
Mixture of diastereomers:
ESI-MS m/z: 1141.83, 1097.80, 1021.59, 979.59, 699.38, 619.44, 351.25, 279.02, 208.13.
HRMS for C55H86O14N2 [M-Na]
+: calcd:. 1021.5971, found 1021.5945.
(R)-butyl carbamyl rapamycin:
1H-NMR (600MHz, DMSO − d6) δ: 7.43 (d, J = 7.8 Hz, 1H, H52), 6.36 (dd, J = 10.7 Hz, 12.3
Hz, 1H, H19), 6.34 (s, 1H, OH10), 6.17 (dd, J = 11.0 Hz , 12.3 Hz, 1H, H20), 6.13 (dd, J = 11.0
Hz, 12.3 Hz, 1H, H21), 6.01 (d, J = 10.7 Hz, 1H, H18), 5.50 (dd, J = 9.8 Hz, 12.3 Hz, 1H, H22),
5.23 (d, J = 4.1 Hz, 1H, OH28), 5.22 (d, J = 11.1 Hz, 1H, H30), 5.09 (m, 1H, H34), 4.95 (d,
J = 5.1 Hz, 1H, H2), 4.59 (d, J = 4.53 Hz, 1H, OH40), 4.07 (m, 1H, H28), 4.03 (m, 1H, H27),
3.95 (m, 1H, H16), 3.93 (m, 2H, H54), 3.86 (m, 1H, H14), 3.57 (m, 1H, H6), 3.30 (m, 3H, H51),
3.26 (m, 1H, H31), 3.18 (m, 3H, H50), 3.16 (m, 1H, H40), 3.03 (m, 1H, H6), 2.81 (m, 1H, H39),
2.78 (m, 1H, H33), 2.50 (m, 1H, H33), 2.35 (m, 1H, H25), 2.25 (m, 1H, H23), 2.16 (m, 1H, H3),
2.02 (m, 1H, H11), 1.91 (m, 1H, H38), 1.76 (m, 1H, H41), 1.73 (m, 3H, H47), 1.72 (m, 3H, H15,
H55), 1.69 (m, 1H, H35), 1.68 (m, 1H, H4), 1.67 (m, 3H, H44), 1.61 (m, 1H, H3), 1.57 (m, 1H,
H13), 1.53 (m, 3H, H5, H12), 1.52 (m, 3H, H42, H55), 1.45 (m, 1H, H15), 1.39 (m, 1H, H24),
1.38 (m, 1H, H4), 1.37 (m, 1H, H5), 1.29 (m, 2H, H56), 1.26 (m, 1H, H37), 1.25 (m, 1H, H13),
1.17 (m, 1H, H41), 1.09 (m, 1H, H36), 1.03 (m, 1H, H24), 0.99 (m, 3H, H45), 0.95 (m, 1H, H36),
0.90 (m, 3H, H48), 0.85 (m, 4H, H42, H57), 0.81 (m, 3H, H46), 0.80 (m, 3H, H49), 0.74 (m, 3H,
H43), 0.57 (m, 1H, H38).
13C-NMR (126 MHz, DMSO − d6) δ: 209.9 (C26), 207.8 (C32), 198.8 (C9), 169.3 (C1), 167.0
(C8), 155.6 (C53), 140.4 (C17), 138.0 (C22), 136.7 (C29), 130.2 (C21), 127.4 (C19), 124.1 (C30),
123.0 (C18), 99.0 (C10), 85.2 (C27), 83.6 (C39), 75.5 (C28), 73.2 (C34), 73.0 (C40), 66.8 (C14),
65.4 (C54), 56.6 (C50), 56.5 (C51), 53.5 (C16), 50.8 (C2), 44.6 (C31), 43.6 (C6), 39.8 (C25), 39.6
(C33), 39.3 (C15, C24), 38.1 (C36), 35.0 (C38), 34.4 (C11), 34.2 (C23), 33.2 (C35), 32.8 (C41),
32.7 (C55), 32.4 (C37), 31.0 (C13, C42), 26.2 (C3, C12), 24.2 (C5), 22.3 (C56), 21.3 (C45), 20.3
(C4), 15.8 (C48), 15.4 (C43), 15.0 (C44), 14.8 (C49), 14.7 (C57), 13.7 (C47), 12.6 (C46).
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(S)-butyl carbamyl rapamycin:
1H-NMR (600MHz, DMSO − d6) δ: 7.25 (d, J = 8.8 Hz, 1H, H52), 6.44 (s, 1H, OH10), 6.33
(dd, J = 10.9 Hz, 12.4, 1H, H19), 6.19 (dd, J = 10.4 Hz, 12.4, 1H, H20), 6.12 (dd, J = 10.4 Hz,
11.3 Hz, 1H, H21), 6.02 (d, J = 11.3 Hz, 1H, H18), 5.48 (dd, J = 9.5 Hz, 12.4 Hz, 1H, H22),
5.10 (s, 1H, OH28), 5.09 (m, 1H, H30), 4.99 (m, 1H, H34), 4.96 (m, 1H, H2), 4.59 (d, J = 4.37
Hz, 1H, OH40), 4.10 (m, 1H, H16), 4.01 (d, J = 5.2 Hz, 1H, H28), 3.93 (m, 2H, H54), 3.88 (d, J
= 5.2Hz, 1H, H27), 3.83 (M, 1H, H14), 3.44 (m, 1H, H6), 3.32 (m, 3H, H51), 3.31 (m, 1H, H31),
3.23 (m, 1H, H6), 3.17 (m, 1H, H40), 3.14 (s, 3H, H50), 2.81 (m, 1H, H39), 2.75 (m, 1H, H33),
2.49 (m, 1H, H25), 2.41 (m, 1H, H33), 2.22 (m, 1H, H23), 2.09 (m, 1H, H3), 2.02 (m, 1H, H11),
1.91 (m, 1H, H38), 1.88 (m, 1H, H15), 1.79 (m, 1H, H13), 1.76 (m, 2H, H4, H41), 1.74 (m, 4H,
H35, H47), 1.73 (m, 3H, H44), 1.55 (m, 1H, H5), 1.53 (m, 2H, H42, H3), 1.52 (m, 2H, H55), 1.47
(m, 1H, H12), 1.44 (m, 1H, H12), 1.41 (m, 1H, H24), 1.34 (m, 1H, H15), 1.30 (m, 2H, H4, H5),
1.28 (m, 1H, H37), 1.26 (m, 2H, H56), 1.24 (m, 1H, H13), 1.16 (m, 1H, H41), 1.09 (m, 1H, H36),
1.06 (m, 1H, H24), 0.99 (m, 3H, H45), 0.96 (m, 1H, H36), 0.89 (m, 3H, H48), 0.86 (m, 3H, H57),
0.85 (m, 1H, H42), 0.84 (m, 3H, H46), 0.79 (m, 3H, H49), 0.75 (m, 3H, H43), 0.60 (m, 1H, H38).
13C-NMR (126 MHz, DMSO − d6) δ: 210.8 (C26), 207.9 (C32), 198.8 (C9), 169.1 (C1), 166.4
(C8), 155.5 (C53), 138.5 (C22), 137.5 (C17), 131.7 (C20), 130.2 (C21), 127.1 (C19), 125.0 (C30),
124.9 (C18), 99.0 (C10), 85.5 (C27), 83.6 (C39), 75.5 (C28), 73.5 (C34), 72.9 (C40), 67.0 (C14),
65.4 (C54), 57.3 (C50), 56.8 (C16), 56.5 (C51), 50.4 (C2), 45.0 (C31), 43.2 (C6), 39.5 (C25,
C33), 39.3 (C24), 38.2 (C15, C36), 35.1 (C38), 34.6 (C11, C23), 32.7 (C55), 32.6 (C35, C41),
31.2 (C42), 30.9 (C37), 29.6 (C5), 28.7 (C13), 26.0 (C3, C55), 25.9 (C12), 22.3 (C56), 21.4
(C45), 20.3 (C4), 15.4 (C43), 15.3 (C48), 14.7 (C57), 14.5 (C49), 13.5 (C46), 13.0 (C44), 12.9
(C47).
Preparation of C16-tert.-butyl carbamyl rapamycin (tbuRap) According to GP1,
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starting with rapamycin (100 mg, 0.11 mmol, 1 eq), tert.-butyl carbamate (77 mg, 0.66 mmol,
6 eq), BF3-Et2O (57 µL, 0.44 mmol, 4 eq), column chromatography (CH2Cl2/MeOH 40:1 to
20:1) afforded 85 mg of X as a mixture of two diastereomers (78% yield; 51:49 ratio).
Mixture of diastereomers:
ESI-MS m/z: 1021.60, 999.62, 897.55, 879.54, 846.51, 412.17, 351.25.
HRMS for C55H86O14N2 [M-Na]
+: calcd:. 1021.5971, found 1021.5865.
(R)-C16-tert.-butyl carbamyl rapamycin:
1H-NMR (600MHz, DMSO − d6) δ: 6.98 (d, J = 9.0 Hz, 1H, H52). 6.42 (s, 1H, OH10), 6.33
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(dd, J = 11.1 Hz, 12.4 Hz, 1H, H19), 6.18 (dd, J = 11.9 Hz, 12.4 Hz, 1H, H20), 6.11 (dd, J =
11.9 Hz, 12.4 Hz, 1H, H21), 5.97 (d, J = 11.1 Hz, 1H, H18), 5.49 (dd, J = 9.1 Hz, 12.4 Hz, 1H,
H22), 5.11 (m, 2H, OH28, H30), 5.08 (m, 1H, H34), 4.95 (d, J = 4.9 Hz, 1H, H2), 4.52 (m, 1H,
OH40), 4.08 (m, 1H, H16), 4.07 (m, 1H, H28), 4.05 (m, 1H, H27), 3.83 (m, 1H, H14), 3.55 (m,
1H, H6), 3.31 (m, 3H, H51), 3.26 (m, 1H, H31), 3.18 (m, 3H, H50), 3.17 (m, 1H, H40), 3.00 (m,
1H, H6), 2.81 (m, 1H, H39), 2.77 (m, 1H, H33), 2.50 (m, 1H, H25), 2.43 (m, 1H, H33), 2.23 (m,
1H, H23), 2.11 (m, 1H, H3), 1.92 (m, 1H, H11), 1.91 (m, 1H, H38), 1.75 (m, 1H, H41), 1.74 (m,
3H, H47), 1.70 (m, 1H, H15), 1.69 (m, 1H, H35), 1.67 (m, 1H, H4), 1.66 (m, 3H, H44), 1.60 (m,
1H, H3), 1.57 (m, 1H, H42), 1.52 (m, 1H, H12), 1.50 (m, 2H, H13, H5), 1.42 (m, 1H, H15), 1.40
(m, 2H, H24, H12), 1.37 (m, 5H, H5, H4, H55), 1.26 (m, 2H, H37, H13), 1.25 (m, 1H, H41), 1.09
(m, 1H, H36), 1.03 (m, 1H, H24), 0.98 (m, 3H, H45), 0.95 (m, 1H, H36), 0.90 (m, 3H, H48), 0.86
(m, 4H, H46, H42), 0.79 (m, 3H, H49), 0.73 (m, 3H, H43), 0.59 (m, 1H, H38).
13C-NMR (126 MHz, DMSO − d6) δ: 210.1 (C26), 207.7 (C32), 198.8 (C9), 169.2 (C1), 166.9
(C8), 155.0 (C53), 139.1 (C17), 138.7 (C22), 137.2 (C29), 131.8 (C20), 130.5 (C21), 127.6 (C19),
125.1 (C30), 125.0 (C18), 98.8 (C10), 85.4 (C27), 83.9 (C39), 77.6 (C54), 75.9 (C28), 73.8
(C34), 73.3 (C40), 67.0 (C14), 57.2 (C50), 56.8 (C51), 53.4 (C16), 50.8 (C2), 45.4 (C31), 43.6
(C6), 39.7 (C24), 39.6 (C33), 39.3 (C25), 38.7 (C15), 38.4 (C36), 35.5 (C38), 34.9 (C11, C23),
33.4 (C35), 33.0 (C41), 32.8 (C37), 31.3 (C13, C42), 28.3 (C55), 26.4 (C3, C12), 24.5 (C5), 21.7
(C45), 20.5 (C4), 15.7 (C43), 15.5 (C48), 14.9 (C49), 13.7 (C46), 13.4 (C47), 12.1 (C44).
(S)-C16-tert.-butyl carbamyl rapamycin:
1H-NMR (600MHz, DMSO − d6) δ: 7.07 (d, J = 9.0 Hz, 1H, H52). 6.39 (s, 1H, OH10) 6.36
(m, 1H, H19), 6.15 (m, 1H, H20), 6.12 (m, 12.4 Hz, 1H, H21), 5.99 (m, 1H, H18), 5.51 (dd, J =
9.1 Hz, 12.4 Hz, 1H, H22), 5.22 (s, 1H, OH28), 5.20 (m, 1H, H30), 4.98 (m, 1H, H34), 4.95 (d,
J = 5.60 Hz, 1H, H2), 4.04 (m, 1H, H16), 4.02 (m, 1H, H27), 3.89 (m, 1H, H28), 3.84 (m, 1H,
H14), 3.44 (m, 1H, H6), 3.32 (m, 3H, H51), 3.30 (m, 1H, H31), 3.20 (m, 1H, H6), 3.17 (m, 1H,
H40), 3.15 (m, 3H, H50), 2.83 (m, 1H, H39), 2.75 (m, 1H, H33), 2.50 (m, 1H, H25), 2.43 (m, 1H,
H33), 2.23 (m, 1H, H23), 2.11 (m, 1H, H3), 2.01 (m, 1H, H11), 1.91 (m, 1H, H38), 1.83 (m, 1H,
H15), 1.76 (m, 1H, H35), 1.74 (m, 1H, H41), 1.73 (m, 3H, H47), 1.67 (m, 1H, H4), 1.66 (m, 3H,
H44), 1.55 (m, 2H, H5, H13), 1.54 (m, 1H, H12), 1.53 (m, 1H, H42), 1.52 (m, 2H, H12), 1.51 (m,
1H, H3), 1.40 (m, 1H, H24), 1.39 (m, 1H, H4), 1.37 (m, 9H, H55), 1.32 (m, 2H, H5, H15), 1.31
(m, 1H, H13), 1.28 (m, 1H, H37), 1.18 (m, 1H, H41), 1.17 (m, 1H, H36), 1.06 (m, 1H, H24), 0.97
(m, 3H, H45), 0.89 (m, 3H, H48), 0.86 (m, 1H, H36), 0.85 (m, 1H, H42), 0.83 (m, 3H, H46), 0.78
(m, 3H, H49), 0.74 (m, 3H, H43), 0.60 (m, 1H, H38).
13C-NMR (126 MHz, DMSO − d6) δ: 209.9 (C26), 207.9 (C32), 198.8 (C9), 169.5 (C1), 167.0
(C8), 155.2 (C53), 138.2 (C22), 137.8 (C29), 136.8 (C17), 131.4 (C20), 130.5 (C21), 127.8 (C19),
124.4 (C30), 123.1 (C18), 99.0 (C10), 85.4 (C27), 83.9 (C39), 77.7 (C54), 75.8 (C28), 73.4 (C34),
73.2 (C40), 67.3 (C14), 56.9 (C50), 56.8 (C51), 53.7 (C16), 51.3 (C2), 44.9 (C31), 43.7 (C6), 40.0
(C25), 39.8 (C15), 39.6 (C33), 39.5 (C24), 38.7 (C36), 35.5 (C38), 35.4 (C11), 34.5 (C23), 33.5
(C35), 33.0 (C41), 31.8 (C37), 31.3 (C42), 31.2 (C13), 28.3 (C55), 26.5 (C3, C12), 24.5 (C5),
21.6 (C45), 20.6 (C4), 16.0 (C48), 15.6 (C43), 15.1 (C49), 14.1 (C47), 14.0 (C46), 12.1 (C44).
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5.3.1.2 Synthesis of BG-NH2[48]
Preparation of (4-(aminomethyl)phenyl)methanol (2)
CN
MeO2C
HO
NH2
2
81 %
1
LiAlH4
THF, 70°C, 16 h
LiAlH4 (10.4 g, 273 mmol, 3.0 eq) was added portionwise to a solution of methyl-4-cyanobenzoate
1) (14.7 g, 91 mmol, 1.0 eq) in THF (500 mL) over a period of 2 h. The mixture was stirred at
70○C for 16 h. After allowing the reaction to cool to room temperature, the remaining excess of
LiAlH4 was quenched by carefully adding H2O (25 mL), followed by addition of an aqueouse 1M
NaOH solution (25 mL) and H2O (25 mL). This mixture was vigorously stirred for 1h at room
temperature. The resulting white precipitate was filtrated over a short pat of celite. The filtrate
was dried over Na2SO4 and concentrated under reduce pressure to afford compound 2 (11.1 g,
81%), which was used in the next step without purification.
1H-NMR (400MHz, DMSO − d6) δ: 7.29 (d, J = 8.0 Hz, 2H), 7.22 (d, J = 8.0 Hz, 2H), 4.60 (s,
2H), 3.77 (s, 2H), 2.37 (s, 3H).
The 1H-NMR spectrum is in agreement with the literature[48].
Preparation of 2,2,2-trifluoro-N-(4-(hydroxymethyl)benzyl)acetamide (3)
HO
NH2
2
Ethyl trifluoroacetate, NEt3
MeOH, r.t., 16 h O
CF3
HO H
N
3
93 %
Compound 2 (10.9 g, 79.5 mmol, 1.0 eq) was dissolved in MeOH (100 mL), prior to the addition
of NEt3 (11.1 µL, 79.5 mmol, 1.0 eq) and ethyl trifluoroacetate (12.5 mL, 103.4 mmol, 1.3 eq).
The reaction mixture was stirred at room temperature for 16 h. The reaction was quenched
with H2O and the aqueous solution was extracted three times with EtOAc. The organic layer
was washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The crude
product was purified by column chromatography (cylcohexane/EtOAc 3:1) to afford 3 (16.5 g,
93%).
1H-NMR (400MHz, DMSO − d6) δ: 9.98 (s, 1H), 7.30 (d, J = 8.1 Hz, 2H), 7.23 (d, J = 8.1 Hz,
2H), 5.17 (t, J = 5.7 Hz, 1H), 4.48 (d, J = 5.7 Hz, 2H) 4.37 (d, J = 6.0 Hz, 2H).
The 1H-NMR spectrum is in agreement with the literature[48].
Preparation of 1-(2-amino-9H-purin-6-yl)-1-methylpyrrolidin-1-ium chloride (5)
N
NN
N
H
Cl
NH2 N
NN
N
H
N
NH2
ClN-Methylpyrrolidine
DMR, r.t., 16 h
5
91%
4
Chloroguanine 4 (15 g, 88 mmol, 1.0 eq) was dissolved in DMF (250 mL), N-methylpyrrolidine
(28 mL, 264 mmol, 3.0 eq) was added and the mixture was stirred at room temperature for 16 h.
After the addition of acetone (175 mL), the formed precipitate was filtered, washed with diethyl
ether, and dried under reduced pressure to yield 5 (20.3 g, 91%).
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1H-NMR (400MHz, DMSO − d6) δ: 13.45 (s, 1H), 8.34 (s, 1H), 7.11 (s, 2H), 4.59 (dt, J = 12.3,
6.6 Hz, 2H), 3.97 (dt, J = 13.5 Hz, 7.51 Hz, 2H), 3.65 (s, 3H), 2.26-2.22 (m, 2H), 2.07-2.03 (m,
2H).
The 1H-NMR spectrum is in agreement with the literature[48].
Preparation of N-(4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)-2,2,2-
trifluoroacetamide (6)
N
NN
N
H
N
NH2
Cl NaH, DMAP
DMF, r.t., 16 h
5
+
O
CF3
HO H
N
3
N
NN
N
H
O
NH2
H
N CF3
O
6
81%
Compound 3 (2.704 g, 11.60 mmol, 1.0 eq) was dissolved in DMF (20 mL). NaH (60%, 1.392
g, 34.8 mmol, 3.0 eq) was added portionwise and the mixture was stirred for 30 min, prior to
the addition of 5 (2.955 g, 11.60 mmol, 1.0 eq) and DMAP (0.142 g, 1.16 mmol, 0.1 eq). The
reaction mixture was further stirred at room temperature for 16 h. The reaction was carefully
quenched with a sataturated aqueous solution of NH4Cl. The product was extracted three times
with EtOAc, dried over Na2SO4 and the solvent was evaporated under reduced pressure. The
crude product was purified by column chromatography (CH2Cl2/MeOH 20:1 to 10:1) to afford
6 (3.6 g, 85%).
19F-NMR (400MHz, DMSO − d6) δ: -74.25.
The 19F-NMR spectrum is in agreement with the literature[48].
Preparation of 6-((4-(aminomethyl)benzyl)oxy)-9H-purin-2-amine (BG-NH2)
N
NN
N
H
O
NH2
H
N CF3
O
6
Methylamine
EtOH/MeOH, r.t., 16 h N
NN
N
H
O
NH2
NH2
BG-NH2
90 %
A 33% solution of methylamine in ethanol (80 mL) was added to a mixture of 6 (3.0 g, 8.1
mmol) in dry MeOH (20 mL). The reaction mixture was stirred at room temperature for 16 h.
The resulting precipitate was filtered, washed with cold EtOH and dried under reduced pressure
to yield BG-NH2 (2.0 g, 90%).
1H-NMR (400MHz, DMSO − d6) δ: 7.81 (s, 1H), 7.43 (d, J = 8.1 Hz, 2H), 7.34 (d, J = 8.1 Hz,
2H), 6.26 (s, 2H), 5.44 (s, 2H), 3.71 (s, 2H).
The 1H-NMR spectrum is in agreement with the literature[48].
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5.3.1.3 Synthesis of Halo-PEGn-Br building blocks[128]
General procedure 2 (GP2): Alkylation of 1-chloro-6-iodohexane with polyethylene
glycols
NaH (60% in mineral oil, 1.3 mmol) was added portionwise to a solution of poly-ethyleneglycol
(1 mmol) in a THF/DMF (vol. 3:1) mixture at 0○C. After stirring the reaction mixture for
30 min, 6-chloro-1-iodohexane (1 mmol) was added at 0○C. The mixture was further stirred
at room temperature for 16 h. The excess of NaH was carefully quenched with water and the
crude mixture was poured into water and extracted three times with EtOAc. The combined
organic layer was dried over Na2SO4, concentrated under reduce pressure and the crude oil was
purified by column chromatography (CH2Cl2/MeOH).
Preparation of 18-chloro-3,6,9,12-tetraoxaoctadecan-1-ol (8a)
HO O OH3 HO
O O3
ClNaH, 6-chloro-1-iodohexane
THF/DMF, r.t., 16 h
8a
48%
7a
According to GP2, starting from NaH (60% in mineral oil, 1.23 g, 30 mmol, 1.3 eq),
tetraethyleneglycol (7a)(5 g, 25.7 mmol, 1 eq) and 6-chloro-1-iodohexane (4.3 mL, 28 mmol,
1eq), column chromatography (CH2Cl2/MeOH 30:1) afforded 8a as colorless oil (2.9 g, 48%).
1H-NMR (400 MHz, CDCl3) δ: 3.73-3.70 (m, 2H), 3.67-3.57 (m, 14H) 3.53 (t, J = 6.7 Hz, 2H),
3.38 (t, J = 6.7 Hz, 2H), 1.81-1.74 (m, 2H), 1.63-1.56 (m, 2H), 1.49-1.35 (m, 4H).
The 1H-NMR spectrum is in agreement with the literature[128].
Preparation of 21-chloro-3,6,9,12,15-pentaoxahenicosan-1-ol (8b)
HO O OH4 HO
O O4
ClNaH, 6-chloro-1-iodohexane
THF/DMF, r.t., 16 h
8b
56%
7b
According to GP2, starting from NaH (60% in mineral oil, 1.72 g, 46 mmol, 1.3 eq), pen-
taethyleneglycol (7b)(10 g, 42 mmol, 1 eq) and 6-chloro-1-iodohexane (6.4 mL, 42 mmol, 1 eq),
column chromatography (CH2Cl2/MeOH 30:1) afforded 8b (5.3 g, 56%).
1H-NMR (400 MHz, CD3OD) δ: 3.67-3.61 (m, 16H), 3.58-3.54 (m, 6H), 3.47 (t, J = 6.5 Hz,
2H), 1.80-1.73 (m, 2H), 1.62-1.55 (m, 2H), 1.49-1.37 (m, 4H).
13C-NMR (100.6 MHz, CD3OD) δ: 73.6, 72.1, 71.6, 71.5, 71.5, 71.4, 71.1, 62.2, 45.7, 33.7,
30.5, 27.7, 26.5.
Preperation of 24-chloro-3,6,9,12,15,18-hexaoxatetracosan-1-ol (8c)
HO O OH5 HO
O O5
ClNaH, 6-chloro-1-iodohexane
THF/DMF, r.t., 16 h
8c
54%
7c
According to GP2, starting from NaH (60% in mineral oil, 370 mg, 9.2 mmol, 1.3 eq), hex-
aethyleneglycol (7c)(2.1 mL, 8.4 mmol, 1 eq) and 6-chloro-1-iodohexane (1.3 mL, 8.4 mmol, 1
eq), column chromatography (CH2Cl2/MeOH 20:1) afforded 8c (2.0 g, 54%).
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1H-NMR (400 MHz, CD3OD) δ: 3.67-3.61 (m, 20H), 3.58-3.54 (m, 6H), 3.47 (t, J = 6.51 Hz,
2H), 1.80-1.73 (m, 2H), 1.62-1.55 (m, 2H), 1.50-1.37 (m, 4H).
13C-NMR (100.6 MHz, CD3OD) δ: 73.6, 72.1, 71.6, 71.5, 71.5, 71.5, 71.1, 62.2, 45.7, 33.7,
30.5, 27.7, 26.5.
General procedure 3 (GP3): Apple reaction of the HaloTag substrates 8a,
8b, and 8c with CBr4
Triphenylphosphine (1.15 mmol) and carbon tetrabromide (1.15 mmol) were added portionwise
to a solution of corresponding chloroalkane (1 mmol) in THF (5 mL) at 0○C. The resulting
mixture was stirred at room temperature for 16 h. The solvent was evaporated under reduced
pressure and the crude oil was purified by column chromatography (cylcohexane/EtOAc) to
yield the desired product as a colourless oil.
Preparation of 1-bromo-18-chloro-3,6,9,12-tetraoxaoctadecane (Halo-PEG4-Br)
According to GP3, starting from triphenylphosphine (1.45g, 5.53 mmol, 1.15 eq), carbon tetra-
bromide (1.83g, 5.53 mmol, 1.15 eq) and compound 8a (1.5 g, 4.8 mmol, 1 eq), column chro-
matography (cylcohexane/EtOAc 3:1) yielded Halo-PEG4-Br (1.23 g, 69%).
1H-NMR (400 MHz, CDCl3) δ: 3.81 (t, J = 6.3 Hz, 2H), 3.68-3.63 (m, 10H), 3.59-3.66 (m,
2H), 3.53 (t, J = 6.7 Hz, 2H), 3.49-3.44 (m, 4H), 1.81-1.74 (m, 2H), 1.63-1.56 (m, 2H), 1.49-1.35
(m, 4H).
The 1H-NMR spectrum is in agreement with the literature[128].
Preparation of 1-bromo-21-chloro-3,6,9,12,15-pentaoxahenicosane (Halo-PEG5-
Br)
According to GP3, starting from triphenylphosphine (1.69 g, 6.44 mmol, 1.15 eq), carbon tetra-
bromide (2.13g, 6.44 mmol, 1.15 eq) and compound 8b (2 g, 5.6 mmol, 1 eq), column chromatog-
raphy (cylcohexane/EtOAc 3:1) yielded Halo-PEG5-Br (1.6 g, 68%).
1H-NMR (400 MHz, CD3OD) δ: 3.80 (t, J = 6.0 Hz, 2H), 3.66-3.61 (m, 14H), 3.58-3.54 (m,
4H), 3.51 (t, J = 6.0 Hz, 2H), 3.78 (t, J = 6.5 Hz, 2H), 1.77 (m, 2H), 1.58 (m, 2H), 1.36-1.52
(m, 4H).
13C-NMR (100.6 MHz, CD3OD) δ: 72.3, 72.1, 71.6, 71.5, 71.5, 71.4, 71.1, 45.7, 33.7, 31.4, 30.5,
27.7, 26.4.
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Preparation of 1-bromo-24-chloro-3,6,9,12,15,18-hexaoxatetracosane (Halo-PEG6-
Br)
According to GP3, starting from triphenylphosphine (721 mg, 2.76 mmol, 1.15 eq), carbon
tetrabromide (900 mg, 2.76 mmol, 1.15 eq) and compound 8c (950 mg, 2.37 mmol, 1 eq) column
chromatography (cylcohexane/EtOAc 3:1) yielded Halo-PEG6-Br (800 mg, 73%).
1H-NMR (400 MHz, CD3OD) δ: 3.80 (t, J = 6.0 Hz, 2H), 3.66-3.61 (m, 18H), 3.58-3.54 (m,
4H), 3.51 (t, J = 6.0 Hz, 2H), 3.48 (t, J = 6.6 Hz, 2H), 1.80-1.73 (m, 2H), 1.62-1.55 (m, 2H),
1.49-1.37 (m, 4H).
13C-NMR (100.6 MHz, CD3OD) δ: 72.3, 72.1, 71.6, 71.4, 71.2, 45.7, 33.8, 31.4, 30.6, 27.7,
26.5.
5.3.1.4 Synthesis of Halo-NH2 building block[256]
Preparation of tert.-butyl (2-(2-hydroxyethoxy)ethyl)carbamate (10)
HO O NH2 HO O NHBoc
10
95%
9
Boc2O
EtOH, r.t., 6 h
Boc2O (17 g, 78 mmol, 1.0 eq) was slowly added to a solution of 2-(2-aminoethoxy)ethanol (9)
(8 g, 78 mmol, 1.0 eq) in anhydrous EtOH (150 mL) at 0○C. The mixture was stirred at room
temperature for 6 h. The reaction mixture was diluted with EtOAc and washed with brine. The
organic layer was dried over Na2SO4 and concentrated under reduced pressure to give 10 (15.2
g, 95%) as a colorless oil, which was used without further purification.
1H-NMR (400 MHz, CDCl3) δ: 5.11 (s, 1H), 3.75-3.73 (m, 2H), 3.59-3.54 (m, 4H), 3.35-3.31
(m, 2H), 2.64 (s, 1H), 1.45 (s, 9H).
The 1H-NMR spectrum is in agreement with the literature[256].
Preparation of tert.-butyl (2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)carbamate (11)
HO O NHBoc
10
BocHN O O Cl
11
61%
NaH, 6-chloro-1-iodohexane
DMF, r.t., 16 h
NaH (60% in mineral oil, 2.7 g, 67 mmol, 1.3 eq) was portionwise added to a solution of 10 (10.7
g, 52 mmol, 1.0 eq) in DMF (20 mL) at 0○C. The mixture was stirred for 30 min at 0○C prior
to the addition of 1-chloro-6-iodohexane 18 (12.8 g, 51.8 mmol, 1.0 eq). The resulting mixture
was stirred at room temperature for 16 h. The reaction was quenched with a saturated aqueous
solution of NH4Cl and the product was extracted three times with EtOAc. The combined organic
layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The
crude product was purified by column chromatography (cylcohexane/EtOAc 3:1 to 1:1) to afford
11 (7.5 g, 46%).
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1H-NMR (400 MHz, DMSO − d6) δ: 6.7 (s, 1H), 3.61 (t, J = 6.60 Hz, 2H), 3.49-3.44 (m, 4H),
3.38-3.35 (m, 4H), 3.06 (q, J = 6.0 Hz, 2H), 1.74-1.67 (m, 2H), 1.52-1.45 (m, 2H), 1.41-1.28 (m,
13H).
The 1H-NMR spectrum is in agreement with the literature[256].
Preparation of 2-(2-((6-chlorohexyl)oxy)ethoxy)ethan-1-amine (Halo-NH2)
Compound 11 (5 g, 16 mmol) was dissolved in CH2Cl2 (10 mL). 10 mL of a 4M HCl solution in
dioxane were added and the reaction mixture was stirred at 80○C for 2 h. After cooling to room
temperature the solvent was evaporated under reduced pressure to afford Halo-NH2 as its HCl
salt (3.5 g, 85%).
1H-NMR (400MHz, DMSO − d6) δ: 8.13 (s, 3H), 3.64-3.60 (m, 4H), 3.57-3.48 (m, 4H), 3.38 (t,
J = 6.6 Hz, 4H), 2.93 (t, J = 5.2 Hz, 2H), 1.74-1.67 (m, 2H), 1.53-1.46 (m, 2H), 1.42-1.28 (s,
13H).
The 1H-NMR spectrum is in agreement with the literature[256].
5.3.1.5 Synthesis of Nb-HaXS molecules
General procedure 4 (GP4): Alkylation of 3-(hydroxymethyl)-4-nitrophenol
with Halo-PEGn-Br
Halo-PEGn-Br (1 mmol) and 5-hydroxynitrobenzyl alcohol (1 mmol) were dissolved in DMF
(5 mL). K2CO3 (1 mmol) was added and the mixture was stirred at 60
○C for 16 h. The reaction
was quenched with H2O (75 mL) and extracted three times with EtOAc. The combined organic
layer was dried over Na2SO4 and concentrated under reduce pressure. The crude oil was pu-
rified by column chromatography (CH2Cl2/MeOH) to yield the desired product as a yellowish oil.
Preparation of (5-((18-chloro-3,6,9,12-tetraoxaoctadecyl)oxy)-2-
nitrophenyl)methanol (13a)
HO
O2N
O O Cl4
HO
O2N
OH
13a 
42%
12
K2CO3
DMF, 60°C, 16 h
Br O O Cl3
Halo-PEG4-Br
+
According to GP4, starting from K2CO3 (106.7 mg, 0.77 mmol, 1 eq), 5-hydroxynitrobenzyl
alcohol (12) (130.6 mg, 0.77 mmol, 1 eq) and compound Halo-PEG4-Br (290 mg, 0.77 mmol,
1 eq), column chromatography (CH2Cl2/MeOH 30:1) afforded 13a (150 mg, 42%).
1H-NMR (400 MHz, CD3OD) δ: 8.10 (d, J = 9.1 Hz, 1H), 7.38 (d, J = 2.8 Hz, 1H), 6.95 (dd,
J = 9.1, 2.8 Hz, 1H), 4.95 (s, 2H), 4.79 (s, 1H), 4.25-4.23 (m, 2H), 3.88-3.85 (m, 2H), 3.69-3.51
(m, 14H), 3.43 (t, J = 6.5 Hz, 2H), 1.76-1.69 (m, 2H), 1.57-1.50 (m, 2H), 1.44-1.32 (m, 4H).
13C-NMR (100.6 MHz, CD3OD) δ: 164.7, 143.00, 141.00, 128.5, 114.3, 113.9, 72.1, 71.7, 71.5,
71.5, 71.4, 71.1, 70.4, 69.3, 62.2, 45.7, 33.7, 30.5, 27.7, 26.4.
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Preparation of (5-((21-chloro-3,6,9,12,15-pentaoxahenicosyl)oxy)-2-
nitrophenyl)methanol (13b)
HO
O2N
O O Cl5
HO
O2N
OH
13b 
41%
12
K2CO3
DMF, 60°C, 16 h
Br O O Cl4
Halo-PEG5-Br
+
According to GP4, starting from K2CO3 (235 mg, 2.14 mmol, 1 eq), 5-hydroxynitrobenzyl alcohol
(12) (362 mg, 2.14 mmol, 1 eq) and compound Halo-PEG5-Br (900 mg, 2.14 mmol, 1 eq),
column chromatography (CH2Cl2/MeOH 30:1) afforded 13b (450 mg, 41%).
1H-NMR (400 MHz, CD3OD) δ: 8.12 (d, J = 9.1 Hz, 1H), 7.39 (d, J = 2.8 Hz, 1H), 6.97 (dd,
J = 9.1, 2.8 Hz, 1H), 4.95 (s, 2H), 4.79 (s, 1H), 4.26-4.24 (m, 2H), 3.88-3.86 (m, 2H), 3.69-3.51
(m, 18H), 3.43 (t, J = 6.6 Hz, 2H), 1.77-1.70 (m, 2H), 1.58-1.51 (m, 2H), 1.46-1.33 (m, 4H).
13C-NMR (100.6 MHz, CD3OD) δ: 164.8, 143.0, 141.1, 128.5, 114.4, 114.0, 72.1, 71.8, 71.6,
71.5, 71.1, 70.5, 69.3, 62.2, 45.7, 33.7, 30.5, 27.7, 26.4.
Preparation of (5-((24-chloro-3,6,9,12,15,18-hexaoxatetracosyl)oxy)-2-
nitrophenyl)methanol (13c)
HO
O2N
O O Cl6
HO
O2N
OH
13c 
46%
12
K2CO3
DMF, 60°C, 16 h
Br O O Cl5
Halo-PEG6-Br
+
According to GP4, starting from K2CO3 (295 mg, 02.14 mmol), 5-hydroxynitrobenzyl alcohol
(12) (362 mg, 2.14 mmol) and compound Halo-PEG6-Br (1.09 g, 2.14 mmol), column chro-
matography (CH2Cl2/MeOH 30:1) afforded 13c (550 mg, 46%).
1H-NMR (400 MHz, CDCl3) δ: 8.03 (d, J = 9.1 Hz, 1H), 7.30 (d, J = 2.8 Hz, 1H), 6.78 (dd, J
= 9.1, 2.8 Hz, 1H), 4.92 (s, 2H), 4.17-4.15 (m, 2H), 3.81-3.78 (m, 2H), 3.63-3.42 (m, 22H), 3.36
(t, J = 6.6 Hz, 2H), 1.71-1.64 (m, 2H), 1.53-1.46 (m, 2H), 1.39-1.26 (m, 4H).
13C-NMR (100.6 MHz, CDCl3) δ: 163.5, 141.4, 140.0, 132.1, 132.0, 128.6, 128.5, 127.7, 113.8,
113.5, 71.2, 70.9, 70.6, 70.6, 70.6, 70.5, 70.1, 69.5, 68.2, 62.3, 45.1, 32.5, 29.4, 26.7, 25.4.
General procedure 5 (GP5): Carbamate formation between BG-NH2 and com-
pounds 13a, 13b and 13c
Compounds 13a, 13b or 13c (1 mmol) were slowly added to a solution of bis(4-nitrophenyl)
carbonate (1 mmol) in DMF (5 mL) at 0○C. NEt3 (1.4 mmol) was added and the reaction
mixture was stirred at room temperature for 16 h. BG-NH2 (1 mmol) and NEt3 (1.4 mmol)
were added to the solution and the mixture was stirred at 50○C for 5 h. The mixture was poured
onto H2O and the product was extraxted with EtOAc. The combined organic layer was dried
over Na2SO4 and concentrated under reduce pressure. The crude oil was purified by column
chromatography (CH2Cl2/MeOH) to yield the desired product.
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Preparation of 5-((18-chloro-3,6,9,12-tetraoxaoctadecyl)oxy)-2-nitrobenzyl (4-(((2-
amino-9H-purin-6-yl)oxy)methyl)benzyl)carbamate (Nb-HaXS1)
According to GP5, starting from bis(4-nitrophenyl) carbonate (35 mg, 0.22 mmol, 1 eq), com-
pound 13a (100 mg, 0.22 mmol), NEt3 (43 µL, 0.38 mmol, 1.4 eq), BG-NH2 (58 mg, 0.22
mmol, 1 eq) and NEt3 (43 µL, 0.38 mmol, 1.4 eq), column chromatography (CH2Cl2/MeOH
30:1) yielded Nb-HaXS1 (90 mg, 55%).
1H-NMR (400 MHz, DMSO − d6) δ: 12.4 (s, 1H), 8.18 (d, J = 9.1 Hz, 1H), 8.08 (s, 1H), 7.79
(s, 1H), 7.46 (d ;J = 7.9 Hz, 2H), 7.30 (d, J = 7.9 Hz, 2H), 7.17 (d, J = 2.8 Hz, 1H), 7.12 (dd, J
= 9.1, 2.8 Hz, 1H), 6.27 (s, 2H), 5.45 (s, 2H), 5.40 (s, 2H), 4.24-4.21 (m, 2H), 3.77-3.75 (m, 2H),
3.61-3.32 (m, 18H), 1.70-1.63 (m, 2H), 1.47-1.41 (m, 2H), 1.36-1.23 (m, 4H).
13C-NMR (100.6 MHz, CD3OD) δ: 164.7, 161.6, 158.3, 131.2, 140.5, 138.1, 136.9, 129.7, 128.8,
128.5, 114.5, 72.1, 71.8, 71.5, 71.5, 77.1, 70.5, 69.4, 68.7, 64.5, 45.7, 45.3, 33.7, 30.5, 27.7, 26.5.
Photophysical properties: λmax: 329 nm, 360: 1690 M
-1cm-1, 405: 682 M
-1cm-1.
Preparation of 5-((21-chloro-3,6,9,12,15-pentaoxahenicosyl)oxy)-2-nitrobenzyl
(4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)carbamate (Nb-HaXS2)
According to GP5, starting from bis(4-nitrophenyl) carbonate (259 mg, 0.85 mmol, 1 eq), com-
pound 13b (430 mg, 0.85 mmol, 1.4 eq), NEt3 (134 µL, 1.19 mmol, 1 eq), BG-NH2 (229 mg,
0.85 mmol, 1 eq) and NEt3 (134 µL, 1.19 mmol, 1 eq) column chromatography (CH2Cl2/MeOH
30:1) afforded Nb-HaXS2 (353 mg, 53%).
1H-NMR (400 MHz, CDCl3) δ: 8.02 (d, J = 9.1 Hz, 1H), 7.27 (d, J = 8.0 Hz, 2H), 7.2 (d, J =
8.0 Hz, 2H), 7.03 (s, 1H), 6.8 (d, J 9.1 Hz, 1H), 5.46-5.29 (m, 6H), 4.33-4.31 (m, 2H), 4.06-4.05
(m, 2H), 3.74-3.73 (m, 2H), 3.47-3.50 (m, 14H), 3.46 (t, J = 6.7 Hz, 2H), 3.38 (t, J = 6.7 Hz,
2H),172-1.65 (m, 2H), 1.55-1.48 (m, 2H), 1.40-1.26 (m, 4H).
13C-NMR (100.6 MHz, CDCl3) δ: 163.2, 159.4, 156.4, 139.7, 138.9, 136.8, 135.1, 129.0, 127.6,
113.6, 113.1, 71.2, 70.7, 70.5, 70.4, 69.3, 68.0, 63.6, 45.1, 32.5, 29.4, 26.6, 25.4.
Photophysical properties: λmax: 329 nm, 360: 1730 M
-1cm-1, 405: 674 M
-1cm-1.
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Preparation of 5-((24-chloro-3,6,9,12,15,18-hexaoxatetracosyl)oxy)-2-nitrobenzyl (4-
(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)carbamate (Nb-HaXS3)
According to GP5, starting from bis(4-nitrophenyl) carbonate (180 mg, 0.59 mmol, 1 eq), com-
pound 13c (324 mg, 0.59 mmol, 1 eq), NEt3 (92 µL, 0.82 mmol, 1.4 eq), BG-NH2 (158 mg,
0.59 mmol, 1 eq) and NEt3 (92 µL, 0.82 mmol, 1.4 eq), column chromatography (CH2Cl2/MeOH
30:1) afforded Nb-HaXS3 (285 mg, 57%).
1H-NMR (400 MHz, DMSO − d6) δ: 12.43 (s, 1H), 8.18 (d, J = 9.1 Hz, 1H), 8.10 (s, 1H), 7.83
(s, 1H), 7.47 (d, J = 8.0 Hz, 2H), 7.31(d, J = 8.0 Hz, 2H), 7.18 (d, J = 2.7 Hz, 1H), 7.12 (dd, J
= 9.1, 2.7 Hz, 1H), 6.26 (s, 2H), 5.46 (s, 2H), 5.41 (s, 2H), 4.26-4.21 (m, 2H), 3.77-3.75 (m, 2H),
3.61-3.43 (m, 20H), 3.34 (t, J = 6.5 Hz, 2H), 1.71-1.64 (m, 2H), 1.50-1.43 (m, 2H), 1.39-1.26 (m,
4H).
13C-NMR (100.6 MHz, CDCl3) δ: 163.2, 159.5, 156.4, 139.9, 139.0, 136.9, 135.3, 129.1, 127.8,
113.6, 113.2, 71.2, 70.8, 70.6, 70.5, 70.1, 69.3, 68.1, 63.7, 45.1, 32.6, 29.5, 26.7, 25.4.
Photophysical properties: λmax: 329 nm, 360: 1796 M
-1cm-1, 405: 677 M
-1cm-1.
5.3.1.6 Synthesis of MeNV-HaXS
Preparation of 1-(4-(benzyloxy)-3-methoxyphenyl)ethan-1-one (15)
O
OH
O O
O
O
Bn
15
84%
14
Benzyl bromide, K2CO3
DMF, 80°C, 16 h
Acetovanillone (14) (5 g, 30.1 mmol, 1 eq) and benzyl bromide (5.15 g, 30.1 mmol, 1 eq) were
dissolved in DMF (5 mL). K2CO3 (4.15 g, 30.1 mmol, 1 eq) was added and the mixture was
stirred at 80○C for 16 h. The reaction was quenched with a saturated aqueous solution of NH4Cl
and extracted three times with EtOAc. The combined organic layer was dried over Na2SO4 and
concentrated under reduced pressure to give 15 (6.5 g, 84%), which was used in the next step
without further purification.
1H-NMR (400 MHz, CDCl3) δ: 7.48 (d, J = 2.01 Hz, 1H), 7.43 (dd, J = 8.26 Hz, 2.01 Hz, 1H),
7.36 (d, J = 7.23 Hz, 2H), 7.31 (td, J = 7.23 Hz, 1.54 Hz, 2H), 7.25 (tt, J = 7.12 Hz, 1.54 Hz,
2H), 6.82 (d, J = 8.26 Hz, 1H), 5.16 (s, 2H), 3.88 (s, 3H), 2.47 (s, 3H).
13C-NMR (100.6 MHz, CDCl3) δ: 196.9, 152.5, 149.6, 136.4, 130.8, 128.7, 128.1, 127.2, 123.1,
112.2, 110.5, 70.8, 56.1, 26.2.
HRMS C16H17O3 [M-H]
+ calcd: 257.1172, found: 257.1166
83 ∣ p a g e
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Preparation of 1-(4-(benzyloxy)-5-methoxy-2-nitrophenyl)ethan-1-one (16)
O
O
O O
O
O
Bn
16
53%
15
Nitric acid
Acetic acid, r.t., 16 h
Bn O2N
Nitric acid (1.4 mL, 69%) was added dropwise to a solution of 15 (1.5 g, 5.8 mmol) in acetic acid
(4.9 mL) and acetic anhydride (1.4 mL) at 0○C. The mixture was stirred at room temperature
for 16 h. The reaction was poured into ice water and extracted three times with EtOAc. The
combined organic layer was washed with a saturated aqueous solution of NaHCO3 and brine and
dried over Na2SO4. The solvent was evaporated under reduced pressure and the crude product
was purified by column chromatography (cylcohexane/EtOAc 4:1) to give 16 (718 mg, 53%).
1H-NMR (400 MHz, CDCl3) δ: 7.67 (s, 1H), 7.46-7.29 (m, 5H), 6.77 (s, 1H), 5.22 (s, 2H), 3.98
(s, 3H), 2.49 (s, 3H).
13C-NMR (100.6 MHz, CDCl3) δ: 200.1, 154.6, 148.6, 138.3, 135.3, 133.1, 128.9, 128.6, 127.6,
108.8, 71.4, 56.7, 30.4.
HRMS C16H16O5N [M-H]
+ calcd: 302.1023, found: 302.1017.
Preparation of 1-(4-hydroxy-5-methoxy-2-nitrophenyl)ethan-1-one (17)
O
O
O O
OH
O
17
88%
16
HBr
acetic acid, 80°C, 2 h
Bn O2NO2N
6-Nitro-O-benzylacetovanillone (16) (4.3 g, 14.3 mmol, 1 eq) was dissolved in acetic acid (30 mL,
99%), and heated to 85○C. HBr (15 mL, 48%) was added to the mixture and stirred for 1.5 h.
The Mixture was poured onto ice water and extracted three times with EtOAc. The combined
organic layer was washed with a saturated aqueous solution of NaHCO3, brine and dried over
Na2SO4. The solvent was evaporated under reduced pressure. The crude product was purified
by column chromatography (cylcohexane/EtOAc, 2:1) to yield 17 (1.1 g, 88%).
1H-NMR (400 MHz, CDCl3) δ: 9.76 (s, 1H), 7.60 (s, 1H), 6.81 (s, 1H), 3.98 (s, 3H), 2.48 (s,
3H).
13C-NMR (100.6 MHz, CDCl3) δ: 199.7, 152.3, 147.8, 138.8, 130.4, 110.8, 108.8, 56.2, 29.9.
HRMS C9H10O5N [M-H]
+ calcd: 212.0553, found: 212.0553.
Preparation of 1-(4-((24-chloro-3,6,9,12,15,18-hexaoxatetracosyl)oxy)-5-methoxy-2-
nitrophenyl)ethanone (18)
O
OH
O
17
K2CO3
DMF, 60°C, 16 h
O2N
+ Halo-PEG6-Br O
O2N O
O
O Cl6
18
69%
Compound 17 (455 mg, 2.2 mmol, 1 eq) and K2CO3 (297 mg, 2.2 mmol, 1 eq) were added to a
solution of Halo-PEG6-Br (1.0 g, 2.2 mmol, 1 eq) in DMF (6 mL). The mixture was stirred
at 60○C for 16 h. The reaction mixture was poured onto a saturated aqueous solution of NH4Cl
and extracted three times with EtOAc. The combined organic layer was dried over Na2SO4, the
solvent was evaporated under reduced pressure and the crude product was purified by column
chromatography (cylcohexane/EtOAc, 1:3) to afford 18 (830 mg, 69%).
84 ∣ p a g e
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1H-NMR (400 MHz, DMSO − d6) δ: 7.69 (s, 1H), 6.76 (s, 1H), 4.28 (m, 2H), 3.96 (s, 3H), 3.92
(m, 2H), 3.74 (m, 2H), 3.69-3.62 (m, 18H), 3.56 (m, 2H), 3.53 (t, J = 6.8 Hz, 2H), 3.45 (t, J =
6.8 Hz, 2H), 2.50 (s, 3H), 1.77 (m, 2H), 1.59 (m, 2H), 1.49-1.34 (m, 4H).
13C-NMR (100.6 MHz, DMSO − d6) δ: 200.1, 154.4, 149.0, 138.3, 133.0, 108.9, 108.7, 71.2,
71.0, 70.7, 70.6, 70.1, 69.4, 69.3, 56.7, 53.6, 45.1, 32.6, 30.4, 29.5, 26.7, 25.5.
HRMS C27H45O11ClN [M-H]
+ calcd: 594.2676, found: 594.2664.
Preparation of 1-(4-((24-chloro-3,6,9,12,15,18-hexaoxatetracosyl)oxy)-5-methoxy-2-
nitrophenyl)ethanol (19)
NaBH4
MeOH/Dioxane, r.t., 2 h
O
O2N O
O
O Cl6
18
HO
O2N O
O
O Cl6
19
84%
Compound 18 (675 mg, 1.1 mmol, 1 eq) was dissolved in MeOH/dioxane mixture (7 mL each).
NaBH4 (51 mg, 2.0 mmol, 1.8 eq) was added portionwise at 0
○C. The mixture was stirred at room
temperature for 2 h. The mixture was poured onto water, neutralised with a 1 M solution of HCl
and extracted three times with CH2Cl2. The combined organic layer was dried over Na2SO4 and
the solvent was evaporated under reduced pressure. The crude product was purified by column
chromatography (CH2Cl2/MeOH, 20:1) to yield 19 (568 mg, 84%) as yellow oil.
1H-NMR (400 MHz, DMSO − d6) δ: 7.61 (s, 1H), 7.29 (s, 1H), 5.53 (q, J = 6.3 Hz, 1H), 4.21
(m, 2H), 3.95 (s, 3H), 3.88 (m, 2H), 3.70 (m, 2H), 3.59-3.66 (m, 18H), 3.55 (m, 2H), 3.51 (m,
2H), 3.43 (m, 2H), 2.50 (s, 3H), 1.75 (m, 2H), 1.57 (m, 2H), 1.52 (d, J = 6.3 Hz, 3H), 1.32-1.46
(m, 4H).
13C-NMR (100.6 MHz, DMSO − d6) δ: 153.4, 146.3, 138.9, 138.1, 109.1, 108.6, 70.2, 70.0, 69.8,
69.5, 68.8, 68.4, 66.4, 56.0, 54.9, 45.3, 32.0, 29.1, 26.1, 25.2, 25.0.
HRMS C27H47O11ClNNa [M-Na]
+ calcd: 619.2730, found: 619.2724.
Preparation of 1-(4-((24-chloro-3,6,9,12,15,18-hexaoxatetracosyl)oxy)-5-methoxy-
2-nitrophenyl)ethyl (4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)carbamate
(MeNV-HaXS)
Compound 19 (829 mg, 1.4 mmol, 1 eq) was slowly added to a solution of bis(4-nitrophenyl)
carbonate (423 mg, 1.4 mmol, 1 eq) in DMF (10 mL) at 0○C. NEt3 (320µL, 2.0 mmol, 1.4 eq) was
added and the mixture was stirred at room temperature for 16 h. BG-NH2 (379 mg, 1.4 mmol,
1 eq) and NEt3 (320µL, 2.0 mmol, 1.4 eq) were added and the reaction was further stirred at
70○C for 6 h. The reaction was quenched with H2O and extracted three times with EtOAc. The
combined organic layer was dried over Na2SO4 and the solvent was evaporated under reduced
pressure. The crude product was purified by column chromatography (CH2Cl2/MeOH, 20:1) to
yield MeNV-HaXS (687 mg, 55%).
1H-NMR (400 MHz, MeOD) δ: 7.66 (s, 1H), 7.43 (d, J = 7.9, 2H), 7.21 (d, J = 7.9, 2H), 7.14
(s, 1H), 6.28 (q, J = 6.5 Hz, 1H), 5.51 (m, 2H), 4.14-4.31 (m, 5H), 3.80-3.86 (m, 6H), 3.68-3.70
(m, 2H), 3.50-3.64 (m, 24H), 3.43 (t, J = 6.6 Hz, 2H), 1.69-1.74 (m, 2H), 1.59 (d, J = 6.5 Hz,
3H), 1.52-1.59 (m, 2H), 1.30-1.46 (m, 4H).
85 ∣ p a g e
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13C-NMR (100.6 MHz, MeOD) δ: 148.7, 141.0, 140.4, 129.7, 128.4, 110.8, 109.5, 72.2, 71.8,
71.6, 71.5, 71.2, 70.7, 70.3, 70.1, 68.8, 56.9, 45.8, 45.1, 33.8, 30.6, 27.7, 26.5, 22.4.
HRMS C41H59O13ClN7 [M-H]
+ calcd: 892.3854, found: 892.3842.
Photophysical properties: λmax: 355 nm, 360: 4058 M
-1cm-1, 405: 1248 M
-1cm-1, φ360: 0.075,
φ405: 0.072.
5.3.1.7 Synthesis of HCM-HaXS
Preparation of 4-(chloromethyl)-7-hydroxy-2H-chromen-2-one (21)
Cl
O
O
OH
OH
OH
Ethyl 4-chloroacetoacetate
MeHSO3, 60°C, 16 h
21
67%
20
Resorcinol 20 (5.0 g, 45.5 mmol, 1 eq) was dissolved in MeHSO3 (10 mL). Ethyl 4-
chloroacetoacetate (7.5 g, 45.5 mmol, 1 eq) was added and the mixture was stirred at 60○C
for 16 h. The reaction mixture was poured onto ice water and stirred for 30 min. The precip-
itate was filtered, washed with water and cold EtOAc and dried in vacuum to give the desired
compound 21 (6.4 g, 67% yield), which was used in the next step without further purification.
1H-NMR (400 MHz, DMSO − d6) δ: 7.66 (d, J = 8.8 Hz, 1H), 6.82 (dd, J = 8.8, 2.4 Hz, 1H),
6.74 (d, J = 2.4 Hz, 1H), 6.39 (s, 2H), 4.92 (s, 2H).
13C-NMR (100.6 MHz, DMSO − d6) δ: 161.5, 160.2, 155.3, 150.9, 126.5, 113.1, 111.1, 109.4,
102.6, 41.40.
Preparation of 7-hydroxy-4-(hydroxymethyl)-2H-chromen-2-one (22)
Cl
O
O
OH
H2O/Dioxane
110°C, 16 h
21
HO
O
O
OH
22
53%
Compound 21 (4 g,19.1 mmol) was dissolved in a mixture of water and dioxane (10 mL each).
The reaction mixture was stirred at 110○C for 16 h and diluted with water. The product was
extracted with three times EtOAc, the combined organic layer was dried over Na2SO4 and the
solvent evaporated under reduced pressure. The product was purified by column chromatography
(CH2Cl2/MeOH 20:1) to give the desired compound 22 (1.94 g, 53%).
1H-NMR (400 MHz, DMSO − d6) δ: 7.48 (d, J = 8.7 Hz, 1H), 6.75 (dd, J = 8.7, 2.3 Hz, 1H),
6.71 (d, J = 2.3 Hz, 1H), 6.23 (s, 2H), 4.69 (s, 2H).
13C-NMR (100.6 MHz, DMSO − d6) δ: 161.1, 160.8, 156.8, 155.0, 125.5, 112.9, 109.7, 106.7,
102.4, 59.2.
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Preparation of 7-((18-chloro-3,6,9,12-tetraoxaoctadecyl)oxy)-4-(hydroxymethyl)-
2H-chromen-2-one (23)
HO
O
O
O
Halo-PEG4-Br, K2CO3
DMF, 60°C, 16 h
23
61%
HO
O
O
OH
22
O Cl
4
Halo-PEG4-Br (460 mg, 1 mmol, 1 eq) was added to a solution of 22 (192 mg, 1 mmol,
1 eq) and K2CO3 (135 mg, 1 mmol, 1 eq) DMF (2 mL). The mixture was stirred at 60
○C
for 16 h. The reaction mixture was poured onto a saturated aqueous solution of NH4Cl and
extracted three times with EtOAc. The combined organic layer was dried over Na2SO4, the
solvent was evaporated under reduced pressure and the crude product was purified by column
chromatography (CH2Cl2/MeOH 40:1) to afford 23 (300 mg, 61%).
1H-NMR (400 MHz, CD3OD) δ: 7.51 (d, J = 8.5 Hz, 1H), 6.89 (dd, J = 8.8, 2.5 Hz, 1H), 6.86
(d, J = 2.5 Hz, 1H), 6.37 (s, 2H), 4.79 (d, J = 6.8 Hz, 2H), 4.20-4.17 (m, 2H), 3.87-3.84 (m, 2H),
3.70-3.50 (m, 14H), 3.42 (t, J = 6.5 Hz, 2H), 1.75-1.68 (m, 2H), 1.57-1.50 (m, 2H), 1.45-1.31 (m,
4H).
13C-NMR (100.6 MHz, CD3OD) δ: 163.6, 163.4, 158.0, 156.4, 126.0, 113.9, 112.3, 108.7, 102.5,
72.1, 71.8, 71.6, 71.5, 71.1, 70.5, 69.3, 60.8, 45.7, 33.7, 30.5, 27.7, 26.5.
Preparation of (7-((18-chloro-3,6,9,12-tetraoxaoctadecyl)oxy)-2-oxo-2H-chromen-
4-yl)methyl (4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)carbamate (HCM-
HaXS)
Compound 23 (200 mg, 0.41 mmol) and CDI (67 mg,0.41 mmol) were dissolved in DMF (2 mL).
The mixture was stirred at room temperature for 16 h. BG-NH2 (107 mg, 0.41 mmol) and
DIPEA (70 µL, 0.41 mmol) were added to the solution. The mixture was stirred at 50○C for 5
h. The mixture was poured onto H2O and extracted three times with EtOAc. The combined
organic layer was dried over Na2SO4 and concentrated under reduce pressure. The crude product
was purified by flash column chromatography (CH2Cl2/MeOH 10:1) to yield HCM-HaXS (154
mg, 48%).
1H-NMR (400 MHz, CDCl3) δ: 7.26-7.08 (m, 6H), 6.71 (d, J = 8.3 Hz, 1H), 6.66 (s, 1H), 6.32
(s, 1H), 5.58 (s, 2H), 5.17 (s, 4H), 4.35 (s, 2H), 3.79 (s, 2H), 3.66-3.53 (m, 12H), 3.47 (t, J = 6.7
Hz, 2H), 3.40 (t, J = 6.6 Hz, 2H), 1.74-1.67 (m, 2H), 1.57-1.50 (m, 2H), 1.40-1.24 (m, 2H).
13C-NMR (100.6 MHz, CDCl3) δ: 161.9, 161.5, 159.8, 159.6, 156.4, 156.1, 155.1, 150.7, 138.6,
136.9, 135.2, 129.0, 128.9, 127.7, 124.4, 112.9, 110.6, 109.0, 101.7, 71.3, 70.8, 70.6, 70.5, 70.1,
69.4, 68.0, 61.6, 45.1, 32.6, 29.5, 26.7, 25.4. Photophysical properties: λmax: 320 nm, 360: 990
M-1cm-1, 405: 678 M
-1cm-1.
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5.3.1.8 Synthesis of CACM-HaXS
Preparation of ethyl (3-hydroxyphenyl)carbamate (33a)
Ethyl chloroformate, K2CO3
DMF, r.t., 16 h
OH
NH2
OH
N
H
O
O
33a
92%
30a
3-Aminophenol (30a) (20.0 g, 183.2 mmol, 1 eq) and K2CO3 (37.8 g, 273.2 mmol, 1.5 eq), were
dissolved in DMF (100 mL). Ethyl chloroformate (23.9 g, 219.8 mmol, 1.2 eq) was added and the
mixture was stirred at room temperature for 16 h. The reaction was quenched with a saturated
aqueous solution of NH4Cl. The product was extracted three times with EtOAc, the combined
organic layer was dried over Na2SO4 and the solvent was evaporated under reduced pressure.
The crude product was purified by column chromatography (cylcohexane/EtOAc, 3:1) to give
the desired compound 33a (30.5 g, 92%).
1H-NMR (400 MHz, CDCl3) δ: 7.38 (s, 1H), 7.13 (t, J = 8.1 Hz, 1H), 6.73 (s, 1H), 6.63 (dd, J
= 18.1 Hz, 2.2 Hz, 1H), 6.58 (dd, J = 8.1 Hz, 2.2 Hz, 1H), 4.23 (q, J = 7.1 Hz, 2H), 1.31 (t, J
= 7.1 Hz, 3H).
13C-NMR (100.6 MHz, CDCl3) δ: 157.1, 154.2, 139.0, 130.1, 110.8, 110.5, 106.0, 61.8, 14.6.
Preparation of ethyl (4-methyl-2-oxo-2H-chromen-7-yl)carbamate (34a)
Ethyl acetoacetate
MeHSO3, 60°C, 16 h
OH
N
H
O
O
33a
O
O
N
H
O
O
34a
77%
Compound 33a (20.0 g, 110.4 mmol, 1 eq) was dissolved in MeHSO3 (30 mL). Ethyl acetoacetate
(17.2 g, 132.4 mmol, 1.2 eq) was added and the mixture was stirred at 60○C for 16 h. The reaction
mixture was poured onto ice water and stirred for 30 min. The precipitate was filtered, washed
with EtOAc and dried in vacuum to give the desired compound 34a (21.0 g, 77% yield), which
was used in the next step without further purification.
1H-NMR (400 MHz, DMSO − d6) δ: 10.1 (s, 1H), 7.65 (d, J = 8.7 Hz, 1H), 7.53 (d, J = 2.1
Hz, 1H), 7.38 (dd, J = 8.7 Hz, 2.1 Hz, 1H), 6.20 (d, J = 1.3 Hz, 1H), 4.15 (q, J = 7.1 Hz, 2H),
2.36 (d, J = 1.3 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H).
13C-NMR (100.6 MHz, DMSO − d6) δ: 160.2, 153.9, 153.3, 143.0, 126.0, 114.3, 111.9, 104.4,
60.8, 18.1, 14.5.
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Preparation of 4-methyl-7-(methylamino)-2H-chromen-2-one (35a)
H2SO4
Acetic acid, 100°C, 16 h
O
O
NH2
35a
73%
O
O
N
H
O
O
34a
Compound 34a (10.0 g, 38.3 mmol, 1 eq) was dissolved in a mixture of conc. sulfuric acid (5
mL) and acetic acid (5 mL). The reaction mixture was stirred at 100○C for 16 h. The reaction
was allowed to cool to room temperature. The resulting precipitated was filtered, washed with
water and dried under reduced pressure to give compound 25a (5.3 g, 73%), which was used in
the next step without further purification.
1H-NMR (400 MHz, DMSO − d6) δ: 7.39 (d, J = 8.6 Hz, 1H), 6.65 (dd, J = 8.6 Hz, 2.0 Hz,
1H), 6.41 (d, J = 2.0 Hz, 1H), 6.09 (s, 2H), 5.89 (s, 1H), 2.29 (s, 3H).
13C-NMR (100.6 MHz, DMSO − d6) δ: 160.7, 155.4, 153.7, 153.1, 126.2, 111.2, 108.8, 107.5,
98.5, 18.0.
Preparation of tert.-butyl 2-(methyl(4-methyl-2-oxo-2H-chromen-7-
yl)amino)acetate (36a)
tert-Butyl bromoacetate, K2CO3
DMF, 100°C, 16 h
O
O
N
H
36a
67%
O
O
NH2
35a
O
O
Compound 35a (10 g, 57.1 mmol, 1 eq) and K2CO3 (39.2 g, 284.8 mmol, 5 eq) were dissolved in
DMF (100 mL). tert.-butyl bromoacetate (33.2 g, 170.9 mmol, 3 eq) were added and the mixture
was stirred at 100○C for 16 h. The reaction mixture was allowed to cool to room temperature
and quenched with a saturated aqueous solution of NH4Cl. The mixture was extracted three
times with EtOAc. The combined organic layer was dried over Na2SO4 and the solvent was
evaporated under reduced pressure. The crude product was purified by column chromatography
(cylcohexane/EtOAc, 3:1) to yield compound 36a (11.2 g, 67%).
1H-NMR (400 MHz, CDCl3) δ: 7.37 (d, J = 8.7 Hz, 1H), 6.64 (dd, J = 8.7 Hz, 2.4 Hz, 1H),
6.39 (d, J = 2.4 Hz, 1H), 6.00 (d, J = 1.3 Hz, 1H), 4.86 (q, J = 5.14 Hz, 1H), 3.84 (d, J = 4.75
Hz, 2H), 2.34 (d, J = 5.1 Hz, 3H), 1.51 (s, 9H).
13C-NMR (100.6 MHz, CDCl3) δ: 169.4, 161.9, 156.0, 153.0, 150.4, 125.7, 111.2, 110.7, 110.0,
98.5, 82.8, 45.8, 28.2, 18.7.
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Preparation of tert.-butyl 2-((4-(hydroxymethyl)-2-oxo-2H-chromen-7-
yl)amino)acetate (37a)
1) SeO2
    p-Xylene, 140°C, 16 h
2) NaBH4
    THF/MeOH, r.t., 4 h
O
O
N
H
37a
13%
O
O
O
O
N
H
36a
O
O
HO
Compound 36a (11.0 g, 38.0 mmol, 1 eq) was dissolved in p-xylene (50 mL). Freshly sublimated
SeO2 (5.1 g 45.6 mmol, 1.2 eq) was added and the mixture was vigorous stirring at 140
○C for
16 h. The reaction was allowed to cool to room temperature, the mixture was filtered and
concentrated under reduced pressure. The resulting oil was dissolved in a mixture of THF (20
mL) and methanol (5 mL). NaBH4 (1.4 g, 38.0 mmol, 1 eq) was added and the solution was
stirred for 4 h at room temperature. The suspension was neutralised with 1 M aqueous HCl,
diluted with water, and partially concentrated under reduced pressure to remove methanol. The
mixture was extracted three times with CH2Cl2, the combined organic layer was dried over
Na2SO4, and the solvent was removed under reduced pressure. The crude product was purified
by column chromatography (cylcohexane/EtOAc, 3:1) to give compound 37a (1.5 g, 13%).
1H-NMR (400 MHz, CDCl3) δ: 7.29 (d, J = 8.7 Hz, 1H), 6.51 (dd, J = 8.7 Hz, 2.3 Hz, 1H),
6.38 (d, J = 2.3 Hz, 1H), 6.32 (s, 1H), 4.82 (m, 3H), 3.83 (d, J = 3.6 Hz, 2H), 1.51 (s, 9H).
13C-NMR (100.6 MHz, CDCl3) δ: 169.5, 162.5, 156.0, 155.2, 150.4, 124.6, 110.9, 108.4, 106.6,
98.6, 82.9, 60.9, 45.7, 28.2.
Preparation of 2-((4-(hydroxymethyl)-2-oxo-2H-chromen-7-yl)amino)acetic acid
(32a)
TFA
CH2Cl2, r.t., 3 h
O
O
N
32a
87%
OH
O
O
O
N
H
37a
O
O
HOHO
Compound 37a (1 g, 3.3 mmol, 1 eq) was dissolved in a mixture of CH2Cl2 (5 mL) and TFA (5
mL). The mixture was stirred at room temperature for 3 h. The solvent was evaporated under re-
duced pressure and the crude product was purified by column chromatography (CH2Cl2/MeOH,
10:1, 0.1% acetic acid) to give compound 32a (715 mg, 87%).
1H-NMR (400 MHz, DMSO − d6) δ: 7.36 (d, J = 8.80 Hz, 1H); 6.72 (s, 1H), 6.62 (dd, J = 8.8
Hz, 1.9 Hz, 1H), 6.40 (d, J = 1.9 Hz, 1H), 4.65 (s, 2H), 3.80 (s, 2H).
13C-NMR (100.6 MHz, DMSO − d6) δ: 171.8, 160.6, 155.9, 152.3, 151.2, 125.8, 110.5, 108.4,
106.6, 97.2, 44.2, 41.5.
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Preparation of N-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)-2-((4-(hydroxymethyl)-2-
oxo-2H-chromen-7-yl)amino)acetamide (31a)
1) NHS, DCC
    DMF, r.t. 2 h
2) Halo-NH2, NEt3
    DMF, r.t., 16 h
O
O
N
H
31a
55%
H
N
O
O
O
N
H
32a
OH
O
HOHO
O O Cl
Compound 32a (500 mg, 2.0 mmol, 1 eq) was dissolved in DMF. DCC (414 mg, 2.0 mmol,
1 eq) and NHS (230 mg, 2. mmol, 1 eq) were added and the mixture was stirred at room
temperature for 2 h. Halo-NH2 (5.18 mg, 2.0 mmol, 1 eq) and NEt3 (560 µL, 4.0 mmol, 2 eq)
were added and the solution was further stirred at room temperature for 16 h. The reaction was
quenched with a saturated aqueous solution of NH4Cl, extracted three times with EtOAc and
the combined organic layer was dried over Na2SO4. The solvent was evaporated under reduced
pressure and the crude product was purified by column chromatography (CH2Cl2/MeOH, 20:1)
to give compound 31a (500 mg, 55%).
1H-NMR (400 MHz, CDCl3) δ: 7.31 (d, J = 8.7 Hz, 1H), 6.81 (t, J = 5.3 Hz, 1H), 6.52 (dd, J
= 8,7 Hz, 2.4 Hz, 1H), 6.41 (d, J = 2.4 Hz, 1H), 6.33 (t, J = 1.2 Hz, 1H), 5.08 (t, J = 5.3 Hz,
1H), 4.81 (t, J = 2.4 Hz, 2H), 3.83 (d, J = 5.2 Hz, 2H), 3.61 - 3.41 (m, 12 H), 1.79 - 1.74 (m,
2H), 1.62-1.54 (m, 2H), 1.47 - 1.32 (m, 4H).
13C-NMR (100.6 MHz, DMSO − d6) δ: 169.3, 161.1, 157.0, 155.4, 151.9, 124.8, 110.7, 106.8,
104.2, 97.0, 70.2, 69.6, 69.4, 69.1, 69.0, 59.1, 46.0, 45.4, 32.0, 29.1, 26.1, 24.9.
Preparation of (7-((2-((2-(2-((5-chloropentyl)oxy)ethoxy)ethyl)amino)-2-
oxoethyl)amino)-2-oxo-2H-chromen-4-yl)methyl 4-(((2-amino-9H-purin-6-
yl)oxy)methyl)benzylcarbamate (CACM-HaXS)
O
O
N
H
31a
H
N
O
HO
O O Cl
1) bis(4-Nitrophenyl) carbonate, NEt3
    DMF, r.t., 16 h
2) BG-NH2, NEt3
    DMF, 50°C, 5 h
O
O
N
H
CACM-HAXS
32%
H
N
O
O
O O Cl
H
N
O
O
N
NN
N
H NH2
Compound 31a (300 mg, 0.66 mmol, 1 eq) was added slowly to a solution of bis(4-nitrophenyl)
carbonate (201 mg, 0.66 mmol, 1 eq) in CH2Cl2 (10 mL) at 0
○C. NEt3 (138 µL, 0.99 mmol,
1.5 eq) was added and the mixture was stirred at room temperature for 3 h. The reaction was
quenched with a saturated aqueous solution of NH4Cl. The product was extracted three times
with EtOAc. The combined organic layer was dried over Na2SO4 and the solvent was evaporated
under reduced pressure. Filtration over a short pad of silica gave the carbonate of 31a, which was
directly used for the carbamate formation. Therefore, the carbonate was dissolved in DMF (3
mL), BG-NH2 (178 mg, 0.66 mmol, 1 eq) and NEt3 (138 µL, 0.99 mmol, 1.5 eq) were added and
the solution was stirred for 3 h at 60○C. The reaction was quenched with water and the product
was extracted three times with EtOAc. The combined organic layer was dried over Na2SO4 and
the solvent was evaporated under reduced pressure. The crude product was purified by column
chromatography (CH2Cl2/MeOH, 10:1) to give compound CACM-HaXS (158 mg, 32%).
1H-NMR (400 MHz, DMSO − d6) δ: 12.42, (s, 1H), 8.0.8 (t, J = 6.0 Hz, 1H), 8.05 (t, J = 6.0
Hz, 1H), 7.78 (s, 1H), 7.44 (d, J = 7.9 Hz, 2H), 7.40 (d, J = 8.8 Hz, 1H), 7.28 (d, J = 7.9 Hz,
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2H), 7.00 (t, J = 6.0 Hz, 1H), 6.61 (dd, J = 8.8 Hz, 2.3 Hz, 1H), 6.38 (d, J = 2.3 Hz, 1H), 5.98
(s, 1H), 5.44 (s, 2H), 5.21 (s, 2H), 4.23 ( d, J = 6.1 Hz, 2H), 3.74 (d, J = 5.9 Hz, 2H), 3.57 (t, J
= 6.6 Hz, 2H), 3.45-3.23 (m, 12H), 1.71-1.64 (m, 2H), 1.49-1.42 (m, 2H), 1.39-1.25 (m, 4H).
13C-NMR (100.6 MHz, DMSO − d6) δ: 169.2, 160.6, 159.9, 159.7, 155.7, 155.5, 155.2, 152.2,
152.1, 139.3, 137.8, 135.5, 128.6, 127.1, 125.0, 113.5, 110.6, 106.3, 104.8, 97.0, 70.2, 69.6, 69.4,
69.0, 66.5, 61.1, 55.8, 45.9, 45.3, 43.7, 32.0, 29.0, 26.1, 24.9.
Photophysical properties: λmax: 365 nm, 360: 23120 M
-1cm-1, 405: 2622 M
-1cm-1, φ360: 0.006,
φ405: 0.016.
5.3.1.9 Alternative synthesis of 32a
Preparation of ethyl 2-((3-hydroxyphenyl)amino)acetate (39)
OH
NH2
OH
NH
O
O
Ethyl-iodoacetate, K2CO3
DMF, r.t., 16 h
39
78%
30a
3-Aminophenol (30a) (10 g, 91.7 mmol, 1.2 eq) and K2CO3 (12.67 g, 91.7 mmol, 1.2 eq) were
dissolved in DMF (150 mL). Ethyl-2-iodoacetate (9.0 mL, 76.4 mmol, 1 eq) was added and the
mixture was stirred at room temperature for 16 h. The reaction was quenched with a saturated
aqueous solution of NH4Cl. The product was extracted three times with EtOAc, the combined
organic layer was dried over Na2SO4 and the solvent was evaporated under reduced pressure.
The resulting oil was purified by column chromatography (cylcohexane/EtOAc, 3:1) to give the
desired compound 39 (11.6 g, 78%).
1H-NMR (400 MHz, CDCl3) δ: 6.98 (t, J = 8.1 Hz, 1H), 6.64 (dd J = 8.10, 1.94 Hz, 1H), 6.14
(dd, J = 8.1, 1.94 Hz, 1H) 6.06 (t, J = 1.94, 1H), 4.20 (q, J = 7.12 Hz, 2H), 3.81 (s, 2H), 1.25
(t, J = 7.12 Hz, 3H).
13C-NMR (100.6 MHz, CDCl3) δ: 171.9, 157.0, 148.5, 130.3, 105.7, 105.6, 100.5, 61.6, 45.8, 14.1.
Preparation of ethyl 2-((ethoxycarbonyl)(3-hydroxyphenyl)amino)acetate (40)
OH
NH
O
O
Chloroformate, K2CO3
DMF, r.t., 16 h
39
OH
N
O
O
O
O
40
73%
Compound 39 (10 g, 51.2 mmol, 1.2 eq) and K2CO3 (7.0 g, 51.2 mmol, 1.2 eq) were dissolved
in DMF (100 mL). Chloroformate was added and the mixture was stirred at room temperature
for 16 h. The reaction was quenched with a saturated aqueous solution of NH4Cl. The product
was extracted three times with EtOAc, the combined organic layer was dried over Na2SO4 and
the solvent was evaporated under reduced pressure. The crude product was purified by column
chromatography (cylcohexane/EtOAc, 3:1) to give the desired compound 40 (9.9 g, 73%).
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1H-NMR (400 MHz, DMSO − d6) δ: 9.52 (s, 1H), 7.13 (t, J = 8.1 Hz, 1H), 6.71-6.69 (m, 2H),
6.14 (dd, J = 8.11, 1.94 Hz, 1H) 4.29 (s, 2H), 4.14 (q, J = 7.01 Hz, 2H), 4.06 (q, J = 7.01 Hz,
2H), 1.20 (t, J = 7.01 Hz, 3H), 1.13 (t, J = 7.01 Hz, 3H).
13C-NMR (100.6 MHz, DMSO − d6) δ: 169.5, 157.5, 154.5, 143.2, 129.6, 116.7, 115.9, 113.5,
61.4, 60.7, 51.9, 14.4, 14.04.
Preparation of ethyl 2-((4-(chloromethyl)-2-oxo-2H-chromen-7-
yl)(ethoxycarbonyl)amino)acetate (41)
OH
N
O
O
O
O
40
N
O
O
O
O
O
O
Cl
41
63%
Ethyl-4-chloroacetoacetate
MeHSO3, 60°C, 16 h
Compound 40 (5 g, 18.7 mmol, 1 eq) was dissolved in MeHSO3 (8 mL). Ethyl 4-
chloroacetoacetate (3.7 g, 22.4 mmol, 1.2 eq) was added and the mixture was stirred at 60○C for
16 h. The reaction was quenched with water. The product was extracted three times with EtOAc,
the combined organic layer was dried over Na2SO4 and the solvent was evaporated under reduced
pressure. The crude product was purified by column chromatography (cylcohexane/EtOAc, 3:1)
to give the desired compound 41 (4.3 g, 63%).
1H-NMR (400 MHz, CDCl3) δ: 7.65 (d, J = 8.59 Hz, 1H), 7.33 (m, 2H), 6.54 (t, J = 0.66 Hz,
1H), 5.30 (s, 1H), 4.65 (d, J = 0.66 Hz, 2H), 4.40 (s, 2H), 4.27-4.22 (m, 4H), 1.32-1.25 (m, 6H).
13C-NMR (100.6 MHz, CDCl3) δ: 169.8, 169.3, 160.3, 154.9, 154.2, 149.2, 145.9, 129.9, 124.6,
122.4, 115.5, 63.0, 61.8, 51.9, 41.3, 14.5, 14.3.
Preparation of ethyl 2-((4-(chloromethyl)-2-oxo-2H-chromen-7-
yl)(ethoxycarbonyl)amino)acetate (42)
N
O
O
O
O
O
O
Cl
41
NH
OH
O
O
O
Cl
42
63%
H2SO4
Acetic acid, 100°C, 16 h
Compound 41 (2 g, 2.7 mmol) was dissolved in a mixture of conc. sulfuric acid (2 mL) and acetic
acid (2 mL). The reaction mixture was stirred at 100○C for 16 h. The reaction was allowed to
cool to room temperature and set to pH 5.3. The resulting precipitated was filtered, washed with
ice cold EtOH and dried under reduced pressure to give compound 42 (499 mg, 69%), which was
used in the next step without further purification.
1H-NMR (400 MHz, DMSO − d6) δ: 7.53 (d, J = 8.8 Hz, 1H), 6.68 (dd, J = 8.8, 2.2 Hz, 1H),
6.45 (d, J = 2.2 Hz, 1H), 6.22 (s, 1H), 4.89 (s, 2H), 3.95 (s, 2H).
13C-NMR (100.6 MHz, CDCl3) δ: 171.8, 160.6, 155.9, 152.3, 151.3, 138.0, 125.8, 110.5, 108.4,
106.6, 97.2, 44.1, 41.5.
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Preparation of ethyl 2-((4-(chloromethyl)-2-oxo-2H-chromen-7-
yl)(ethoxycarbonyl)amino)acetate (43)
N
O
O
O
O
O
O
Cl
41
N
O
O
O
O
HO
43
52%
H2O/Dioxane
110°C, 16 h
O
O
Compound 41 (2 g, 2.7 mmol) was dissolved in a mixture of water and dioxane (10 mL each).
The reaction mixture was stirred at 110○C for 16 h and diluted with water. The product was
extracted with three times EtOAc, the combined organic layer was dried over Na2SO4 and the
solvent evaporated under reduced pressure. The product was purified by column chromatography
(CH2Cl2/MeOH 40:1) to give the desired compound 22 (490 mg, 52%).
1H-NMR (400 MHz, DMSO − d6) δ: 7.68 (d, J = 8.6 Hz, 1H), 7.36 (dd, J = 2.2 Hz, 1H), 7.31
(dd, J = 8.6, 2.2 Hz, 1H), 6.43 (s, 1H), 5.67 (t, J = 5.5 Hz, 1H), 4.75 (d, J = 5.5 Hz, 2H), 4.47
(s, 2H), 4.18-4.10 (m, 4H), 1.22-1.14 (m, 6H).
13C-NMR (100.6 MHz, CDCl3) δ: 169.2, 160.1, 154.8, 154.2, 149.2, 145.9, 124.5, 122.3, 115.5,
115.3, 114.4, 67.2, 62.9, 61.7, 51.9, 14.5, 14.3.
Preparation of ethyl 2-((4-(chloromethyl)-2-oxo-2H-chromen-7-
yl)(ethoxycarbonyl)amino)acetate (32a)
N
O
O
O
O
O
O
HO
43
NH
OH
O
O
O
HO
32a
71%
H2SO4
Acetic acid, 100°C, 16 h
Compound 43 (200 mg, 0.6 mmol) was dissolved in a mixture of conc. sulfuric acid (1 mL) and
acetic acid (1 mL). The reaction mixture was stirred at 100○C for 16 h. The reaction was allowed
to cool to room temperature and set to pH 5.3. The resulting precipitated was filtered, washed
with ice cold EtOH and dried under reduced pressure to give compound 32a (101 mg, 71%),
which was used in the next step without further purification.
1H-NMR (400 MHz, DMSO − d6) δ: 7.36 (d, J = 8.80 Hz, 1H); 6.72 (s, 1H), 6.62 (dd, J = 8.8
Hz, 1.9 Hz, 1H), 6.40 (d, J = 1.9 Hz, 1H), 4.65 (s, 2H), 3.80 (s, 2H).
13C-NMR (100.6 MHz, DMSO − d6) δ: 171.8, 160.6, 155.9, 152.3, 151.2, 125.8, 110.5, 108.4,
106.6, 97.2, 44.2, 41.5.
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5.3.1.10 Synthesis of CMACM-HaXS1 and CMACM-HaXS2
Preparation of 3-methyl aminophenol (30b)
OH
NH2
OH
N
H
30b
73%
30a
K2CO3, Iodomethan
DMF, r.t., 16 h
3-Aminophenol (30a) (20 g, 183.2 mmol, 1.2 eq) and K2CO3 (25.2 g, 183.2 mmol, 1.2 eq), were
dissolved in DMF (100 mL). Iodomethan (21.6 g, 152.8 mmol, 1 eq) was added dropwise and the
mixture was stirred at room temperature for 16 h. The reaction was quenched with a saturated
aqueous solution of NH4Cl. The product was extracted three times with EtOAc, the combined
organic layer was dried over Na2SO4 and the solvent was evaporated under reduced pressure.
The crude product was purified by column chromatography (cylcohexane/EtOAc, 3:1) to give
the desired compound 30b (18.0 g, 73%).
1H-NMR (400 MHz, CDCl3) δ: 7.02 (t, J = 8.0, 1H), 6.20 (m, 2H), 6.08 (t, J = 2.3 Hz, 1H),
4.37 (m, 2H), 2.76 (s, 3H).
13C-NMR (100.6 MHz, CDCl3) δ: 156.9, 150.9, 130.3, 105.9, 104.9, 99.9, 31.0.
Preparation of ethyl (3-hydroxyphenyl)(methyl)carbamate (33b)
Ethyl chloroformate, K2CO3
DMF, r.t., 16 h
OH
N
H
OH
N O
O
33b
76%
30b
Compound 30b (13.0 g, 105.5 mmol, 1 eq) and K2CO3 (21.9 g, 158.3 mmol, 1.5 eq), were dissolved
in DMF (100 mL). Ethyl chloroformate (17.2 g, 158.3 mmol, 1.5 eq) was added and the mixture
was stirred for 16 h at room temperature. The reaction was quenched with a saturated aqueous
solution of NH4Cl. The product was extracted three times with EtOAc, the combined organic
layer was dried over Na2SO4 and the crude product was purified by column chromatography
(cylcohexane/EtOAc, 3:1) to give the desired compound 33b (15.6 g, 76%).
1H-NMR (400 MHz, CDCl3) δ: 7.15 (t, J = 8.0 Hz, 1H), 6.71 (m, 3H), 4.18 (q, J = 7.1 Hz,
2H), 3.25 (s, 3H), 1.25 (t, J = 7.1 Hz, 3H).
13C-NMR (100.6 MHz, CDCl3) δ: 156.8, 156.3, 144.0, 129.6, 117.3, 113.7, 113.3, 62.2, 37.8,
14.6.7.
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Preparation of ethyl methyl(4-methyl-2-oxo-2H-chromen-7-yl)carbamate (34b)
Ethyl acetoacetate
MeHSO3, 60°C, 16 h
OH
N O
O
33b
O
O
N
O
O
34b
76%
Compound 33b (10.0 g, 51.2 mmol, 1 eq) was dissolved in MeHSO3 (20 mL). Ethyl acetoacetate
(8.0 g, 61.5 mmol, 1.2 eq) was added and the mixture was stirred for 16 h at 60○C. The reaction
mixture was poured onto ice water and stirred for 30 min. The precipitate was filtered and
washed with EtOAc. The precipitate was dried in vacuum to give the desired compound 34b
(10.4 g, 78% yield), which was used in the next step without further purification.
1H-NMR (400 MHz, CDCl3) δ: 7.71 (d, J = 8.5 Hz, 1H), 7.37 (m, 2H), 6.33 (s, 1H), 4.12 (q, J
= 7.1 Hz, 2H), 3.29 (s, 3H), 2.41 (s, 3H), 1.20 (t, J = 7.1 Hz, 3H).
13C-NMR (100.6 MHz, CDCl3) δ: 159.8, 154.3, 153.0, 152.9, 146.1, 125.3, 120.8, 116.5, 113.4,
112.0, 61.6, 36.7, 18.0, 14.3.
Preparation of 4-methyl-7-(methylamino)-2H-chromen-2-one (35b)
H2SO4
Acetic acid, 100°C, 16 h
O
O
NH
35b
71%
O
O
N
O
O
34b
Compound 34b (10.0 g, 38.3 mmol, 1 eq) was dissolved in a mixture of conc. sulfuric acid (5
mL) and acetic acid (5 mL). The reaction mixture was stirred at 100○C for 16 h. The reaction
was allowed to cool to room temperature. The resulting precipitated was filtered, washed with
water and dried under reduced pressure to give compound 35b (5.3 g, 73%).
1H-NMR (400 MHz, CDCl3) δ: 7.35 (d, J = 8.6 Hz, 1H), 6.52 (dd, J = 8.6 Hz, 2.3 Hz, 1H),
6.44 (d, J = 2.3 Hz, 1H), 5.97 (d, J = 1.0 Hz, 1H), 4.39 (s, 1H), 2.90 (s, 3H), 2.34 (d, J = 1.0
Hz, 3H).
13C-NMR (100.6 MHz, CDCl3) δ: 162.1, 156.0, 153.1, 152.5, 125.4, 110.4, 110.1, 109.3, 97.7,
30.2, 18.6.
Preparation of tert.-butyl 2-(methyl(4-methyl-2-oxo-2H-chromen-7-
yl)amino)acetate (36b)
tert-Butyl bromoacetate, K2CO3
DMF, 100°C, 16 h
O
O
N
36b
55%
O
O
N
H
35b
O
O
Compound 35b (5 g, 26.5 mmol, 1 eq) and K2CO3 (18.2 g, 132.2 mmol, 5 eq) were dissolved in
DMF (50 mL). tert.-butyl bromoacetate (15.4 g, 79.3 mmol, 3 eq) were added and the mixture
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was stirred at 100○C for 16 h. The reaction mixture was allowed to cool to room temperature
and quenched with a saturated aqueous solution of NH4Cl. The mixture was extracted three
times with EtOAc. The combined organic layer was dried over Na2SO4 and the solvent was
evaporated under reduced pressure. The crude product was purified by column chromatography
(cylcohexane/EtOAc, 3:1) to give compound 36b (4.4 g, 55%).
1H-NMR (400 MHz, CDCl3) δ: 7.41 (d, J = 8.9 Hz, 1H), 6.59 (dd, J = 8.9 Hz, 2.6 Hz, 1H),
6.50 (d, J = 2.6 Hz, 1H), 5.99 (d, J = 1.1 Hz, 1H), 4.01 (s, 2H), 3.13 (s, 3H), 2.35 (d, J = 1.1
Hz, 3H), 1.44 (s, 9H).
13C-NMR (100.6 MHz, CDCl3) δ: 169.1, 162.1, 155.7, 152.9, 152.1, 125.6, 110.6, 110.0, 108.9,
98.8, 82.4, 55.0, 39.9, 28.2, 18.6.
Preparation of tert.-butyl 2-((4-(hydroxymethyl)-2-oxo-2H-chromen-7-
yl)amino)acetate (37b)
1) SeO2
    p-Xylene, 140°C, 16 h
2) NaBH4
    THF/MeOH, r.t., 4 h
O
O
N
37b
51%
OH
O
O
O
N
36b
O
O
HO
Compound 36b (4.1 g, 13.5 mmol, 1 eq) was dissolved in p-xylene (50 mL). Freshly sublimated
SeO2 (1.8 g 16.2 mmol, 1.2 eq) was added and the mixture was vigorous stirring at 120
○C
for 16 h. After the reaction cooled down to room temperature the mixture was filtered and
concentrated under reduced pressure. The resulting oil was dissolved in a mixture of THF (20
mL) and methanol (5 mL). Sodium borohydride (500 mg, 13.5 mmol, 1 eq) was added and the
solution was stirred for 4 h at room temperature. The suspension was neutralised with 1 M
aqueous HCl, diluted with water, and partially concentrated under reduced pressure to remove
methanol. The mixture was extracted three times with CH2Cl2, the combined organic layer was
dried over Na2SO4, and the solvent was removed under reduced pressure. The crude product
was purified by column chromatography (cylcohexane/EtOAc, 3:1) to yield compound 37b (2.2
g, 51%).
1H-NMR (400 MHz, CDCl3) δ: 7.28 (d, J = 8.9 Hz, 1H), 6.53 (dd, J = 8.9 Hz, 2.6 Hz, 1H),
6.46 (d, J = 2.6 Hz, 1H), 6.30 (t, J = 1.37 Hz, 1H), 4.76 (s, 2 H), 4.00 (s, 2H), 3.21 (s, 1H), 3.10
(s, 3H), 1.45 (s, 9H).
13C-NMR (100.6 MHz, CDCl3) δ: 169.3, 162.7, 155.6, 155.3, 151.9, 124.3, 109.1, 107.8, 106.4,
98.8, 82.6, 60.7, 54.9, 39.8, 28.2.
Preparation of 2-((4-(hydroxymethyl)-2-oxo-2H-chromen-7-yl)(methyl)amino)acetic
acid (32b)
TFA
CH2Cl2, r.t., 3 h
O
O
N
32b
81%
OH
O
O
O
N
37b
O
O
HOHO
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Compound 37b (2 g, 6.3 mmol, 1 eq) was dissolved in a mixture of CH2Cl2 (5 mL) and TFA (5
mL). The mixture was stirred at room temperature for 3 h. The solvent was evaporated under re-
duced pressure and the crude product was purified by column chromatography (CH2Cl2/MeOH,
10:1, 0.1% acetic acid) to give compound 32b (1.3 g, 81%).
1H-NMR (400 MHz, DMSO − d6) δ: 7.36 (d, J = 8.9 Hz, 1H), 6.60 (d, J = 8.9 Hz, 1H), 6.44
(s, 1H), 6.06 (s, 1H), 4.64 (s, 2H), 3.87 (s, 2H), 3.02 (s, 3H).
13C-NMR (100.6 MHz, DMSO − d6) δ: 161.2, 157.0, 155.2, 152.6, 124.4, 109.0, 105.9, 104.0,
97.4, 59.0, 55.8, 39.7.
Preparation of N-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)-2-((4-(hydroxymethyl)-2-
oxo-2H-chromen-7-yl)(methyl)amino)acetamideacid (31b)
1) NHS, DCC
    DMF, r.t. 2 h
2) Halo-NH2, NEt3
    DMF, r.t., 16 h
O
O
N
31b
63%
H
N
O
O
O
N
32b
OH
O
HOHO
O O Cl
Compound 32b (500 mg, 1.9 mmol, 1 eq) was dissolved in DMF (3 mL). DCC (392 mg, 1.9
mmol, 1 eq) and NHS (219 mg, 1.9 mmol, 1 eq) were added and the mixture was stirred at room
temperature for 2 h. Halo-NH2 (492 mg, 1.9 mmol, 1 eq) and NEt3 (530 µL, 3.8 mmol, 2 eq)
were added and the mixture was further stirred at room temperature for 16 h. The reaction was
quenched with a saturated aqueous solution of NH4Cl, extracted three times with EtOAc and
the combined organic layer was dried over Na2SO4. The solvent was evaporated under reduced
pressure and the crude product was purified by column chromatography (CH2Cl2/MeOH, 20:1)
to give compound 31b (553 mg, 63%).
1H-NMR (400 MHz, CDCl3) δ: 7.23 (d, J = 8.8 Hz, 1H), 6.94 (t, J = 5.4 Hz, 1H), 6.53 (dd,
J = 8.8 Hz, 2.6 Hz, 1H), 6.49 (d, J = 2.6 Hz, 1H), 6.24 (t, J = 1.4 Hz, 1H); 4.69 (d, J = 1.4
Hz, 2H), 3.97 (s, 2H), 3.55-3.36 (m, 12 H), 3.10 (s, 3H), 1.76-1.69 (m, 2H), 156-149 (m, 2H),
1.44-1.28 (m, 4H).
13C-NMR (100.6 MHz, CDCl3) δ: 169.3, 162.1, 155.5, 154.9, 151.9, 124.4, 109.5, 108.3, 107.0,
99.4, 71.4, 70.3, 70.00, 69.9, 60.6, 57.3, 45.2, 39.8, 39.3, 32.6, 29.5, 26.8, 25.5.
Preparation of (7-((2-((2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)amino)-2-
oxoethyl)(methyl)amino)-2-oxo-2H-chromen-4-yl)methyl (4-(((2-amino-9H-purin-6-
yl)oxy)methyl)benzyl)carbamate (CMACM-HaXS1)
O
O
N
31b
H
N
O
HO
O O Cl
1) bis(4-Nitrophenyl) carbonate, NEt3
    DMF, r.t., 16 h
2) BG-NH2, NEt3
    DMF, 50°C, 5 h
O
O
N
CMACM-HAXS1
31%
H
N
O
O
O O Cl
H
N
O
O
N
NN
N
H NH2
Compound 31b (400 mg, 0.85 mmol, 1 eq) was added slowly to a solution of bis(4-nitrophenyl)
carbonate (260 mg, 0.85 mmol, 1 eq) in CH2Cl2 (10 mL) at 0
○C. NEt3 (178 µL, 1.28 mmol,
1.5 eq) was added and the mixture was stirred for 3 h at rt. The reaction was quenched with a
saturated aqueous solution of NH4Cl. The product was extracted three times with EtOAc the
combined organic layer was dried over Na2SO4 and the solvent was evaporated under reduced
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pressure. Filtration over a short pad of silica gave the carbonate of 31b, which was directly used
for the carbamate formation. Therefore, the carbonate was dissolved in DMF (5 mL), BG-NH2
(300 mg, 0.66 mmol, 1 eq) and NEt3 (178 µL, 1.28 mmol, 1.5 eq) were added and the solution was
stirred for 3 h at 60○C. The reaction was quenched with water and the product was extracted
three times with EtOAc. The combined organic layer was dried over Na2SO4 and the solvent was
evaporated under reduced pressure. The crude product was purified by column chromatography
(CH2Cl2/MeOH, 10:1) to give compound CMACM-HaXS1 (350 mg, 46%).
1H-NMR (400 MHz, DMSO − d6) δ: 12.4 (s, 1H), 8.13-8.09 (m, 2H), 7.80 (s, 1H), 7.49-7.45 (m,
3H), 7.30 (d, J = 8.0 Hz, 2H), 6.65 (dd, J = 9.0, 2.4 Hz, 1H), 6.53 (d, J = 2.4 Hz, 1H), 6.29 (s,
2H), 6.04 (s, 1H), 5.46 (s, 2H), 5.25 (s, 2H), 4.24 (d, J = 6.0 Hz, 2H), 4.06 (s, 2H), 3.60 (t, J
= 6.6 Hz, 2H), 3.54-3.20 (m, 10H), 3.07 (s, 3H), 1.71-1.65 (m, 2H), 1.48-1.43 (m, 2H), 1.37-1.25
(m, 4H).
13C-NMR (100.6 MHz, DMSO − d6) δ: 168.7, 160.6, 159.8, 159.6, 155.7, 155.2, 152.3, 151.9,
139.3, 137.8, 135.4, 129.6, 128.5, 127.1, 125.0, 113.5, 109.2, 106.2, 105.3, 97.8, 70.2, 69.6, 69.4,
69.0, 66.5, 61.1, 55.8, 44.4, 43.8, 40.0, 38.5, 32.0, 29.0, 26.1, 24.9.
λmax: 370 nm, 360: 11230 M
-1cm-1, 405: 2411 M
-1cm-1.
Preparation of N-(4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)-2-((4-
(hydroxymethyl)-2-oxo-2H-chromen-7-yl)(methyl)amino)acetamide (38)
1) NHS, DCC
    DMF, r.t. 2 h
2) BG-NH2, NEt3
    DMF, r.t., 16 h
O
O
N
38
58%
H
N
O
O
O
N
32b
OH
O
HOHO O
N
N NH
N
H2N
Compound 32b (300 mg, 1.1 mmol, 1 eq) was dissolved in DMF (5 mL). DCC (227 mg, 1.1
mmol, 1 eq) and NHS (127 mg, 1.1 mmol, 1 eq) were added and the mixture was stirred at
room temperature for 2 h. BG-NH2 (286 mg, 1.1 mmol, 1 eq) and NEt3 (153 µL, 1.1 mmol,
1 eq) were added and the mixture was stirred at room temperature for 16 h. The reaction was
quenched with a saturated aqueous solution of NH4Cl, extracted three times with EtOAc and
the combined organic layer was dried over Na2SO4. The solvent was evaporated under reduced
pressure and the crude product was purified by column chromatography (CH2Cl2/MeOH, 10:1)
to give compound 38 (329 mg, 58%).
1H-NMR (400 MHz, DMSO − d6) δ:12.44 (s, 1H), 8.56 (t, J = 6.1 Hz, 1H), 7.81 (s, 1H), 7.46
(d, J = 9.0 Hz, 1H), 7.43 (d, J = 8.2 Hz, 2H), 7.26 (d, J = 8.2 Hz, 2H), 6.65 (dd, J = 9.0 Hz,
2.5 Hz, 1H), 6.55 (d, J = 2.5 Hz, 1H), 6.29 (s, 2H), 6.12 (t, J = 1.4 Hz, 1H), 5.57 (s, 2H), 4.69
(dd, J = 5.7 Hz, 1.5 Hz, 2H), 4.29 (d, J = 5.9 Hz, 2H), 4.12 (s, 2H), 3.09 (s, 3H).
13C-NMR (100.6 MHz, DMSO − d6) δ: 168.8, 161.0, 159.6, 156.9, 155.2, 155.1, 152.1, 139.2,
137.8, 135.3, 134.5, 128.5, 127.2, 124.8, 118.4, 109.0, 106.7, 104.7, 97.8, 66.5, 59.0, 55.0, 41.9.
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Preparation of (7-((2-((4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-
2-oxoethyl)(methyl)amino)-2-oxo-2H-chromen-4-yl)methyl (2-(2-((6-
chlorohexyl)oxy)ethoxy)ethyl)carbamate (CMACM-HaXS2)
1) bis(4-Nitrophenyl) carbonate, NEt3
    DMF, r.t., 16 h
2) BG-NH2, NEt3
    DMF, 50°C, 5 h
H
N
O
H2N NH
NN
N
N
O
O
O
HO
H
N
O
H2N NH
NN
N
N
O
O
O
O
H
N
O
OOCl
CMACM-HAXS2
37%
38
58%
Compound 38 (200 mg, 0.39 mmol, 1 eq) was added slowly to a solution of bis(4-nitrophenyl)
carbonate (120 mg, 0.39 mmol, 1 eq) in CH2Cl2 (5 mL) at 0
○C. NEt3 (83 µL, 0.59 mmol, 1.5 eq)
was added and the mixture was stirred for 3 h at rt. The reaction was quenched with a saturated
aqueous solution of NH4Cl. The product was extracted three times with EtOAc the combined
organic layer was dried over Na2SO4 and the solvent was evaporated under reduced pressure.
Filtration over a short pad of silica gave the carbonate of 38, which was directly used for the
carbonate formation. Therefore, the carbonate was dissolved in DMF (3 mL), Halo-NH2 (101
mg, 0.39 mmol, 1 eq) and NEt3 (108 µL, 0.78 mmol, 2 eq) were added. The solution was stirred
for 3 h at 60○C. The reaction was quenched with water and the product was extracted three
times with EtOAc. The combined organic layer was dried over Na2SO4 and the solvent was
evaporated under reduced pressure. The crude product was purified by column chromatography
(CH2Cl2/MeOH, 10:1) to give compound CMACM-HaXS2 (120 mg, 41%).
1H-NMR (400 MHz, DMSO − d6) δ: 12.44 (s, 1H), 8.58 (s, 1H), 7.80 (s, 1H), 7.57 (s, 1H), 7.48
(d, J = 9.0 Hz, 1H), 7.44 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 8.0 Hz, 2H), 6.69 (dd, J = 9.0, 2.5
Hz, 1H), 6.57 (d, J = 2.5 Hz, 1H), 6.29 (s, 1H), 6.02 (s, 1H), 5.44 (s, 2H), 5.24 (s, 1H), 4.29 (d, J
= 5.9 Hz, 1H), 4.14 (s, 1H), 3.60 (t, J = 6.6 Hz, 2H), 3.51-3.23 (m, 10H), 3.10 (s, 3H), 1.70-1.65
(m, 2H), 1.50-1.44 (m, 2H), 1.32-1.26 (m, 4H).
13C-NMR (100.6 MHz, DMSO − d6) δ: 168.7, 160.6, 159.6, 159.8, 155.5, 155.2, 152.4, 152.0,
147.9, 137.8, 135.3, 129.6, 128.5, 127.2, 125.0, 113.5, 109.3, 106.2, 105.2, 97.9, 70.2, 69.6, 69.4,
69.0, 66.5, 60.9, 55.0, 45.4, 41.9, 32.0, 29.0, 26.1, 24.9. Photophysical data: λmax: 370 nm, 360:
11598 M-1cm-1, 405: 2390 M
-1cm-1.
5.3.1.11 Synthesis of GUCM-HaXS
Preparation of ethyl 2-((3-hydroxyphenyl)amino)acetate (44)
N
O
O
O
O
O
O
Cl
43
N
OH
O
O
O
HO
44
53%
H2O/Dioxane
110°C, 48 h
O
O
Compound 41 (4.0 g, 10.8 mmol) was dissolved in a mixture of water and dioxane. The reac-
tion mixture was stirred at 110○C for 48 h. The reaction mixture was diluted with water and
acidified with an aqueous 1M HCl solution. The product was extracted three times with EtOAc,
the combined organic layer was dried over Na2SO4 and the solvent evaporated under reduced
pressure. The product was purified by column chromatography (CH2Cl2/MeOH 20:1 with 0.1%
acetic acid) to give the desired compound 44 (1.85 g, 53%).
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1H NMR (400 MHz, DMSO − d6) δ: 7.67 (d, J = 8.63 Hz, 1H), 7.35 (d, J = 2.26 Hz, 1H), 7.31
(dd, J = 8.63, 2.26 Hz, 1H), 6.43 (t, J = 1.53 Hz, 1H), 4.76 (d, J = 1.53 Hz, 2H), 4.38 (s, 2H),
4.12 (q, J = 7.02 Hz, 2H), 1.17 (t, J = 7.02 Hz, 3H).
13C-NMR (100.6 MHz, DMSO − d6) δ: 170.8, 160.1, 156.1, 154.2, 153.0, 145.1, 124.3, 121.7,
114.8, 113.0, 110.0, 61.9, 59.0, 51.3, 14.3.
Preparation of ethyl (2-((2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)amino)-2-
oxoethyl)(4-(hydroxymethyl)-2-oxo-2H-chromen-7-yl)carbamate (45)
N
OH
O
O
O
HO
44
O
O
1) NHS, DCC
DMF, r.t. 2 h
2) Halo-NH2, NEt3
DMF, r.t., 16 h
O
O
N
45
46%
H
N
O
HO
O O Cl
O O
Compound 44 (1 g, 3.1 mmol, 1 eq) was dissolved in DMF (5 mL). DCC (642 mg, 3.1 mmol, 1 eq)
and NHS (357 mg, 3.1 mmol, 1 eq) were added and the mixture was stirred for 3 h. Halo-NH2
(803 mg, 3.1 mmol, 1 eq) and NEt3 (860 µL, 6.2 mmol, 2 eq) were added and the mixture was
stirred for 16 h at rt. The reaction was quenched with a saturated aqueous solution of NH4Cl.
The product was extracted three times with EtOAc, the combined organic layer was dried over
Na2SO4 and the solvent was evaporated under reduced pressure. The product was purified with
column chromatography (CH2Cl2/MeoH 20:1) to give compound 45 (670 mg, %)
1H-NMR (400 MHz, CDCl3) δ: 7.34 (d, J = 8.50 Hz, 1H), 7.28-7.27 (m, 2H), 6.67 (t, J = 5.07
Hz, 1H), 6.51 (t, J = 1.27 Hz, 1H), 4.77 (d, J = 1.27 Hz, 2H), 4.31 (s, 2H), 4.25 (q, J = 6.73
Hz, 2H), 3.74 (t, J = 5.42 Hz, 1H), 3.64-3.44 (m, 12H), 1.79-1.72 (m, 2H), 1.63-1.56 (m, 2H),
1.46-1.33 (m, 4H), 1.28 (t, J = 6.73 Hz, 3H).
13C-NMR (100.6 MHz, CDCl3) δ: 168.6, 161.0, 155.1, 154.3, 153.7, 145.4, 123.6, 121.7, 115.3,
113.7, 111.3, 71.4, 70.4, 70.1, 69.7, 63.0, 60.4, 53.6, 45.2, 39.6, 32.6, 31.1, 29.5, 26.8, 25.5, 14.6.
Preparation of N-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)-2-((4-(hydroxymethyl)-2-
oxo-2H-chromen-7-yl)amino)acetamide (46)
2 M NaOH
H2O, r.t., 2 h
O
O
N
45
H
N
O
HO
O O Cl
O O
O
O
46
72%
HO
N N
O
O
O
O
Cl
Compound 45 (400 mg, 0.76 mmol, 1 eq) was dissolved in a 2 M aqueous NaOH solution (5 mL)
and stirred at room temperature for 16 h. The reaction was acidified to pH 4, with 1 M aqueous
HCl solution. The product was extracted three times with EtOAc, the combined organic layer
was dried over Na2SO4 and the solvent evaporated under reduced pressure. The crude product
was purified by column chromatography (CH2Cl2/MeoH 10:1) to afford 46 (263 mg, 72%)
1H-NMR (400 MHz, CDCl3) δ: 7.55 (m, 2H), 7.49 (d, J = 9.38 Hz, 1H), 6.53 (t, J = 1.58 Hz,
1H), 4.87 (d, J = 1.58 Hz, 2H), 4.33 (s, 2H), 3.86-3.83 (m, 2H), 3.80-3.77 (m, 2H), 3.68-3.64 (m,
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2H), 3.58-3.55 (m, 2H), 3.51 (t, J = 6.68 Hz, 2H), 3.43 (t, J = 6.68 Hz, 2H), 1.77-1.70 (m, 2H),
1.59-1.52 (m, 2H), 1.44-1.29 (m, 4H).
13C-NMR (100.6 MHz, CDCl3) δ: 167.6, 160.8, 154.4, 153.6, 140.6, 124.5, 113.6, 113.4, 110.8,
105.6, 71.3, 70.1, 69.9, 67.2, 60.6, 49.5, 45.1, 38.4, 32.5, 29.5, 26.7, 25.4.
Preparation of (7-((2-((2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)amino)-2-
oxoethyl)amino)-2-oxo-2H-chromen-4-yl)methyl 4-(((2-amino-9H-purin-6-
yl)oxy)methyl)benzylcarbamate (GUCM-HaXS)
O
O
46
HO
N N
O
O
O
O
Cl
1) bis(4-Nitrophenyl) carbonate, NEt3
    DMF, r.t., 16 h
2) BG-NH2, NEt3
    DMF, 50°C, 5 h
O
O
O
N N
O
O
O
O
Cl
O
H
N
O
N
NN
N
H NH2
GUCM-HaXS
49%
Compound 46 (200 mg, 0.42 mmol, 1 eq) was added slowly to a solution of bis(4-nitrophenyl)
carbonate (128 mg, 0.42 mmol, 1 eq)in CH2Cl2 (10 mL) at 0
○C. NEt3 (58 µL, 0.42 mmol, 1
eq) was added and the mixture was stirred for 3 h at rt. The reaction was quenched with a
saturated aqueous solution of NH4Cl. The product was extracted three times with EtOAc the
combined organic layer was dried over Na2SO4 and the solvent was evaporated under reduced
pressure. Filtration over a short pad of silica gave the carbonate of 11, which was directly used
for the carbamate formation. Therefore, the carbonate was dissolved in DMF (2 mL), BG-NH2
(110 mg, 0.42, 1 eq) and NEt3 (58 µL, 0.42 mmol, 1 eq) were added and the solution was stirred
for 3 h at 60○C. The reaction was quenched with water and the product was extracted with
three times EtOAc. The combined organic layer was dried over Na2SO4 and the solvent was
evaporated under reduced pressure. The crude product was purified by column chromatography
(CH2Cl2/MeOH, 10:1) to give compound GUCM-HaXS (160 mg, 49%).
1H-NMR (400 MHz, DMSO − d6) δ: 12.40 (s, 1H), 8.13 (t, J = 5.85 Hz, 1H), 7.80 (s, 1H), 7.75
(d, J = 8.38 Hz, 1H), 7.70-7.67 (m, 2H), 7.46 (d, J = 8.38 Hz, 2H), 7.32 (d, J = 8.38 Hz, 2H),
6.34 (t, J = 1.55 Hz, 1H), 6.28 (s, 2H), 5.46 (s, 2H), 5.34 (s, 2H), 4.58 (s, 2H), 4.27 (d, J = 6.07
Hz, 2H), 3.64-3.33 (m, 12H), 1.68-1.61 (m, 2H), 1.47-1.40 (m, 2H), 1.36-1.22 (m, 4H).
13C-NMR (100.6 MHz, DMSO − d6) δ: 168.6, 159.8, 159.8, 159.6, 155.6, 155.2, 154.2, 153.8,
151.4, 141.2, 139.2, 137.8, 135.5, 128.6, 127.1, 125.4, 114.0, 113.5, 112.2, 105.0, 70.2, 69.5, 69.4,
66.5, 66.4, 61.0, 49.8, 45.3, 43.8, 38.0, 32.0, 29.1, 26.1, 24.9.
Photophysical properties: λmax: 330 nm, 360: 2364 M
-1cm-1, 405: 1313 M
-1cm-1, φ360: 0.007,
φ405: 0.009.
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5.3.2 NMR experiments to determine the mechanism
5.3.2.1 Reference NMR spectra
Under a nitrogen atmosphere and in a standard NMR tube, rapamycin (2.2 mg, 2.4 µmol),
phenyl carbamate (1.97 mg, 14.4 µmol), or BF3-Et2O (1.1 µL, 7.2 µmol) were dissolved in 0.4
mL CD2Cl2 . The tubes were transfered to the NMR spectrometer. For solutions containing
rapamycin, or phenyl carbamate the 1H-, 13C-, 1H-1H COSY-, 1H-1H NOESY-, 1H-1H
ROESY-, 1H-1H TOSCY-, 1H-13C HMQC-, and 1H-13C HMBC-NMR spectra were recorded
at -30○C. For the BF3-Et2O containing solution the 1H-, 11B-, and 19F-NMR spectra were
recorded. After these measurements, THF (0.2 mL) was added to each tube and the same NMR
experiments as described above were repeated.
5.3.2.1 NMR spectra of rapamycin and BF3-Et2O in CD2Cl2
Under a nitrogen atmosphere and in a standard NMR tube, rapamycin (2.2 mg, 2.4 µmol, 1
eq) was dissolved in 0.4 mL CD2Cl2. The solution was cooled to -30
○C and BF3-Et2O (1.1 µL,
7.2 µmol, 4 eq) was added. The NMR tube was briefly shaken, quickly transfered to the NMR
spectrometer, and the 1H-, 13C-, 11B-, 19F-, 1H-1H COSY-, 1H-1H NOESY-, 1H-1H ROESY-,
1H-1H TOSCY-, 1H-13C HMQC-, and 1H-13C HMBC-NMR spectra were recorded at -30○C.
5.3.2.1 NMR spectra of rapamycin and BF3-Et2O in a mixture of CD2Cl2
and THF
Under a nitrogen atmosphere and in a standard NMR tube, rapamycin (2.2 mg, 2.4 µmol, 1
eq) was dissolved in 0.4 mL CD2Cl2. The solution was cooled to -30
○C and BF3-Et2O (1.1 µL,
7.2 µmol, 4 eq) was added. The NMR tube was shaken for 3 minutes prior to the addition of
THF (0.2 mL). The mixture was quickly transfered to the NMR spectrometer and the 1H-, 13C-,
11B-, 19F-, 1H-1H COSY-, 1H-1H NOESY-, 1H-1H ROESY-, 1H-1H TOSCY-, 1H-13C HMQC-,
and 1H-13C HMBC-NMR spectra were recorded at -30○C.
5.3.2.3 NMR spectra of phenyl carbamate and BF3-Et2O in CD2Cl2
Under a nitrogen atmosphere and in a standard NMR tube, phenyl carbamate (1.97 mg, 14.4
µmol, 1.5 eq) was dissolved in 0.4 mL CD2Cl2. The solution was cooled to -30○C and BF3-Et2O
(1.1 µL, 7.2 µmol, 1 eq) was added. The NMR tube was briefly shaken, quickly transfered to
the NMR spectrometer, and the 1H-, 13C-, 11B-, 19F-, 1H-1H COSY-, 1H-1H NOESY-, 1H-1H
ROESY-, 1H-1H TOSCY-, 1H-13C HMQC-, and 1H-13C HMBC-NMR spectra were recorded at
-30○C.
5.3.2.4 NMR spectra of phenyl carbamate and BF3-Et2O in a mixture of CD2Cl2
and THF
Under a nitrogen atmosphere and in a standard NMR tube, phenyl carbamate (1.97 mg, 14.4
µmol, 1.5 eq) was dissolved in 0.4 mL CD2Cl2. The solution was cooled to -30○C and BF3-Et2O
(1.1 µL, 7.2 µmol, 1 eq) was added. The NMR tube was shaken for 3 minutes prior to the
addition of THF (0.2 mL). The mixture was quickly transfered to the NMR spectrometer and
the 1H-, 13C-, 11B-, 19F-, 1H-1H COSY-, 1H-1H NOESY-, 1H-1H ROESY-, 1H-1H TOSCY-,
1H-13C HMQC-, and 1H-13C HMBC-NMR spectra were recorded at -30○C.
5.3.2.5 NMR spectra of rapamycin, phenyl carbamate and BF3-Et2O in CD2Cl2
Under a nitrogen atmosphere and in a standard NMR tube, rapamycin (2.2 mg, 2.4 µmol, 1
eq), and phenyl carbamate (1.97 mg, 14.4 µmol, 6 eq) were dissolved in 0.4 mL CD2Cl2. The
solution was cooled to -30○C and BF3-Et2O (1.1 µL, 7.2 µmol, 4 eq) was added. The NMR tube
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was briefly shaken, quickly transfered to the NMR spectrometer, and the 1H-, 13C-, 11B-, and
19F-NMR spectra were recorded at -30○C.
5.3.2.6 NMR spectra of rapamycin, phenyl carbamate and BF3-Et2O in a
mixture of CD2Cl2 and THF
Under a nitrogen atmosphere and in a standard NMR tube, rapamycin (2.2 mg, 2.4 µmol, 1
eq), and phenyl carbamate (1.97 mg, 14.4 µmol, 6 eq)were dissolved in either 0.4 mL CD2Cl2.
The solution was cooled to -30○C and BF3-Et2O (1.1 µL, 7.2 µmol, 4 eq) were added. The
NMR tube was shaken for 3 minutes prior to the addition of THF (0.2 mL). The mixture was
quickly transfered to the NMR spectrometer and the 1H-, 13C-, 11B-, and19F-NMR spectra were
recorded at -30○C.
5.3.3 Determination of photophysical properties
5.3.3.1 Ferrioxalate actinometry to determine the quantum flow of the Lumos 43A
photo reactor
2 [Fe(C2O4)3]3+ 2 Fe3+  +  C2O42-  +  2 CO2
hυ, 360 nm
Ferrioxalate actinometry was used to determine the quantum flow of the Lumos 43A photoreactor
(LED 320 nm, 360 nm or 405 nm lamp). To this end, potassium ferrioxalate (147.5 mg, 0.34
mmol) was dissolved in 40 mL water. 40 mL of 1 N sulfuric acid were added and the solution
was further diluted to 50 mL with water. 3 mL of this solution was pipetted into the absorption
cell and irradiated for a given time. 2 mL of the irradiated solution was mixed with 2 mL of a
5.6 mM aqueous ophenanthroline solution and 1 mL of a sodium acetate buffer. As reference
2 mL of non-irradiated ferrioxalate solution was treated with 2 mL of a 5.6 mM aqueous o-
phenanthroline solution and 1 mL of a sodium acetate buffer. The 2 solutions were stored for
1 hour in absolute darkness prior to measure the absorbance of the solutions at 510 nm. The
quantum flow was calculated using equation (1) and with a quantum yield of 1.26 at 360 nm and
the molar extinction coefficient of the complex at 510 nm (1.11⋅104M-1cm-1).
Quantum Flow [Einstein/s] = A ⋅ V 1 ⋅ V 2
t ⋅ φ ⋅ I ⋅ V 2 (1)
A = absorbance of the irradiated solution at 510 nm V 1 = irradiated volume (3 mL)
t = irradiation time in secondsV 2 = used volume of V1 (2 mL)
φ = quantum yield (1.26 at 360 nm)V 3 = end volume (20 mL)
 = extinction coefficient of the complex at 510 nml = thickness of the cell (1 cm)
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5.3.3.2 Phenylglyoxylic acid actinometry to determine the quantum flow of the Lu-
mos 43A photo reactor
O hυ (360 nm)
H
O
H2O/MeCN 3:1
OH
O
CO2
3 mL of a 0.05 M solution of phenylglyoxylic acid in a mixture of water and acetonitrile (3:1)
were put in a standard absorbance quartz cell (1 cm path length) and irradiated in a LUMOS
43A photoreactor equipped with LED lamps at 360 nm for a given time. A UV/Vis absorbance
spectrum was recorded every 5 minutes of irradiation. The decrease of the optical density at
390 nm (OD < 1) was monitored and used to determine the number of moles photolyzed after
each irradiation. As the absorbance of the product, benzaldehyde, is negligible at 390 nm, the
conversion can be determined by dividing the measured optical density by the optical density
of the starting solution, and multiplying with the starting amount (in mol). The number of
converted mol was plotted as a function of the time. The slope of the regression line was divided
by the published quantum yield of photolysis (φ365 = 0.728) to give a value of 5.445.44⋅10-7
E/min for the photon flux of the 360 nm LED lamp of the LUMOS 43A.
5.3.3.3 General procedure to determine the photolytic quantum yield
3 mL of a 0.5 mM of phtocleavable HaXS molecules in a DMSO/water (1:10) solution were
transferred into a standard absorbance cell and irradiated in the Lumos 43A photoreactor with
light at specific wavelength (360 nm or 405 nm) for different time. The conversion was determined
by UPLC-MS by integration of the absorption peak of the molecule. Disappearance of the
molecule was plotted as a function of the time. The slope of the regression line corresponds to
the rate constant (k). The reaction rate was calculated using equation (2).
r = k[A] (2)
With the measured reaction rates and the quantum flow of Lumos 43A photoreactor at specific
wavelength, the photolysis quantum yield of photocleavable HaXS molecules was calculated with
equation (3).
Quantum Yield = (reaction rate)/(quantum flow) (3)
5.3.3.4 UV/Vis spectra and determination of the molar absorption coefficient
The absorption spectra of different concentrated solutions of the photocleavable HaXS molecules
in DMSO were recorded on a Perkin Elmer Lambda 40 UV/Vis spectrometer or a NanoDrop
2000/2000c spectrophotometer. The molar extinction coefficient at specific wavelength (εnm)
were calculated according to the Beer-Lambert law (equation (4)) or determined graphically,
plotting the absorption of the molecules at specific wavelength against the concentration. The
slope of the resulting straight line corresponds to the molar extinction coefficient at the specific
wavelength.
A =  ⋅ l ⋅ c (4)
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5.3.4 Biological procedures
5.3.4.1 Cloning of expression constructs
The T2098LFRB coding sequence (kind gift from T. Inoue, Baltimore), FKBP12 coding sequence
(kind gift from K. Johnsson, Lausanne), L273YHaloTag7 coding sequence (Promega) SNAPf
coding sequence (kind gift from K. Johnsson, Lausanne) mTFP1 (kind gift of O. Pertz, Basel),
Golgi targeting sequence Giantin (kind gift from T. Inoue, Baltimore), LAMP1 (kind gift from
T. Inoue, Baltimore), plasma membrane targeting sequence CAAX (kind gift of J, Downward,
London) and mTq (kind gift of J. Goedhart Amsterdam) were amplified by PCR (Phusion
polymerase, Finnzymes).
For T2098LFRB-RFP, FKBP12-GFP, L273YHaloTag7-GFP, L273YHaloTag7-RFP, and SNAPf-
GFP expression constructs, T2098LFRB, FKBP12, L273YHaloTag7 and SNAPf were transferred
to pEGFP (Clonetech), or pTag-RFP-N1 (Evrogen) expression vectors.
FKBP12-GFP-CAAX: the membran targeting sequence was introduced into the FKBPGFP
expression vector.
SNAPf-mTFP1: GFP was exchanged in a SNAPf-GFP plasmid by the mTFP1 sequence.
L273YHaloTag7-RFP-Giantin: the Giantin targeting sequence was introduced into the
L273YHaloTag7-RFP expression vector.
NLS-CFP-SNAP: FKBP1x from the NLS-CFP-FKBP1x expression vector (kind gift from S.
Hbner, Wrzburg) was exchanged by the SNAPf sequence.
L273YHaloTag7-RFP-Rheb15: L273YHaloTag7-RFP was amplified by PCR and fused to a Rheb15
sequence to be inserted into the pTag-RFP-N1 backbone with RFP was excised.
Halo-RFP-Rheb15: HA-Raptor was replaced by L273YHaloTag7-RFP in a HA-Raptor-Rheb15
expression vector kindly obtained from Anna Melone.
LAMP-RFP-L273YHaloTag7: the LAMP1 targeting sequence was inserted into the RFP-
L273YHaloTag7 expression vector.
Mito-SYFP-SNAPf: FRB was exchanged into a Mito-SYFP-FRB expression construct (kind
gift of P. Scheiffele, Basel) by the SNAPf sequence.
LifeAct-mTFP1-SNAPf: mTFP1 was fused to LifeAct by PCR, and inserted into the GFP-
SNAPf expression construct (were GFP was excised).
L273YHaloTag7-mTq: GFP was exchanged by the mTq sequence. Maps and expression vector
sequences can be obtained from the authors upon request.
5.3.4.2 Cell Cultuture and Transfection
HeLa, HEK293, and A2058 cells were cultured in complete Dulbeccos’s modified Eagle medium
(DMEM) supplemented with 10% heat-inactivated fetal calf serum (HIFCS), 2 mM L-glutamine
(Gln), 100 units/ml penicillin, 100 µg/ml streptomycin (PEST), at 37○C, 5% CO2. Transfections
were carried out with JetPEITM (Polyplus-transfection), according to manufacturer’s guidelines.
5.3.4.3 Protein denaturation, cell lysis, and immune-blotting
Cells were washed with ice cold PBS and lysed in a NP-40 lysis buffer [1% NP-40, 20 mM Tris-
HCl pH 8.0, 138 mM NaCl, 2.7 mM KCl, 5% glycerol, 40 mM NaF, 2 mM Na3VO4, 20 µM
Leupeptin, 18 µM Pepstatin, 5 µM Aprotinin, 1 mM PMSF, 1 mM MgCl2, 1 mM CaCl2, 5 mM
EDTA]. Cell lysates were cleared by centrifugation at 13000 rpm for 15 min and proteins were
denatured by the addition of 5x sample buffer [312.5 mM Tris-HCl (pH 6.8), 10% SDS, 25% β-
mercaptoethanol, 50% glycerol, bromphenol blue] and cooking for 6 min. Proteins were separated
by SDS-PAGE and transferred to Immobilon PVDF membranes (Millipore). Proteins labeled
with primary and secondary antibodies were visualised enhanced chemiluminescence (Millipore)
and a CCD camera (Fusion Fx7, Vilber).
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For rapalogs: the phosphorylation of p70S6K was analysed using mouse monoclonal antibody
(mAb) to pThr389-S6K, rabbit mAb to S6K1, mouse mAb to pSer473-PKB/Akt and to pThr308-
PKB/Akt (all from Cell Signaling Technology, Danvers) and horseradish peroxidase (HRP)-
coupled secondary goat anti-mouse or anti-rabbit antibodies.
For HaXS molecules: GFP-fusion proteins were analysed, using mAb to GFP (Roche Diagnos-
tics) and horseradish peroxidase (HRP-conjugated goat anti-mouse IgG) as secondary antibody.
5.3.4.4 Statistic analysis Statistical Analysis Statistical analysis was performed with
GraphPad Prism v6. For Student’s test (two sided, non-paired with Welch correction, p < 0.05)≥3 independent experiments were compared.
5.3.4.5 Determination of the effect of pcRap on mTORC1 pathway
HEK293 cells were exposed to DMSO, rapamycin, (S)-pcRap and ((R)-pcRap for 15 min
at 37○C, before cells were lysed, and proteins were separated by SDS-PAGE and analysed by
immune-blotting.
5.3.4.6 In cell Western to determine the IC50 value of (R)-pcRap
A2058 cells were exposed to rapamycin and (R)-pcRap for 1 h at 37○C, before cells were
lysed, and proteins were separated by SDS-Page. The phosphorylation of p70S6K was analysed
by in-cell Western using goat anti-rabbit IRDye800 and goat anti-mouse IRDye680 secundary
antibodies.
5.3.4.7 (R)-pcRap-induced membrane translocation
For microscopy, HeLa cells grown on 12 mm cover slips (Menzel) were transfected with
expression constructs for FKBP12-GFP-CAAX and mutated T2098LFRB-RFP fusion proteins.
Cells were exposed to DMSO or (R)-pcRap for 15 min at 37○C in fully supplemented, complete
DMEM medium 24 h after transfection, were then washed twice with PBS, fixed with 4%
p-formaldehyde (PFA) in PBS, and mounted in Mowiol (Plss-Stauffer) containing 1% Propyl
gallate.
5.3.4.8 In vivo heterodimerization of SNAP-GFP and Halo-GFP with HaXS
molecules
HeLa cells were grown in 6-well cell culture plates (Falcon), and were transfected with expression
constructs for SNAP-GFP and Halo-GFP. After 24 h, cells were exposed to HaXS dimerisers
for 5, 15, 30, 60 or 300 minutes at 37○C. Cells were washed twice in 1 x PBS after treatment
with HaXS molecules. Cells were lysed, proteins were separated by SDS-PAGE, and analysed
by immune-blotting as described above.
5.3.4.9 In vivo photocleavage of SNAP-GFP-Halo-GFP dimers
HeLa cells were grown in 6-well cell culture plates (Falcon), and were transfected with expression
constructs for SNAP-GFP and Halo-GFP. After 24 h, cells were exposed to HaXS dimerisers for
15 minutes at 37○C. Cells were washed twice in 1 x PBS after treatment with HaXS molecules.
Then 600 µl 1x PBS was added to each well. Culture plates were put on ice and irradiated
for 2 or 10 minutes with a high-intensity UV lamp (BlakRay B-100A high intensity UV lamp;
100 Watt, 365 nm, UVP) at a distance of 5 cm. Cells were lysed, proteins were separated by
SDS-PAGE, and analysed by immune-blotting as described above.
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5.3.4.10 SNAP-mTFP1 fusion protein translocation to the the Golgi and subsequent
release
HeLa cells grown on 12 mm cover slips (Menzel) were transfected with SNAP-mTFP1 and
L273YHaloTag7-RFP-Giantin. After 24 h, cells were treated with HaXS dimerisers for 15 min-
utes. Cells were mounted in Ludin chambers (Live Imaging Services) in the closed confirmation
with complete cell culture medium without phenol red. Pictures were taken every second before
illumination of the cells and every 1 or 3 second after illiumination. Single spots within the
indicated region of interest were illuminated for 40 ms with a FRAP scanning laser or for 20
seconds with a mercury halide lamp using a standard DAPI filter. Movies were assembled and
analysed with Fiji (ImageJA, 1.44b). mTFP1 fluorescence at vesicles was calculated according
to the formula mTFP1 = F(mTFP1, vesicle) / F(RFP, whole cell) - F(mTFP1, cytoplasm)
/ F(RFP, whole cell) for every frame. mTPF1 fluorescence in the cytoplasm was calculated
according to the formula mTFP1 = F(mTFP1, vesicle) / F(RFP, whole cell). To illustrate
the fluorescence decrease from vesicles and to measure fluorescence increase in the cytoplasm,
mTFP1 fluorescence intensity was plotted over time.
5.3.4.11 NLS-CFP-SNAP fusion protein translocation to the Golgi, subsequent
release and relocalitation to the nucleus
HeLa cells grown on 12 mm cover slips (Menzel) were transfected with NLS-CFP-SNAP and
L273YHaloTag7-RFP-Giantin. After 24 h, cells were treated with HaXS dimerisers for 15 minutes.
Cells were mounted in Ludin chambers (Live Imaging Services) in the closed confirmation with
complete cell culture medium without phenol red. Pictures were taken every second before
illumination of the cells and every 1 or 3 second after illiumination. Single spots within the
indicated region of interest were illuminated for 40 ms with a FRAP scanning laser. Movies were
assembled and analysed with Fiji (ImageJA, 1.44b). CFP fluorescence at vesicles was calculated
according to the formula CFP = F(CFP, vesicle) / F(RFP, whole cell) - F(CFP, cytoplasm) /
F(RFP, whole cell) for every frame. Nuclear CFP fluorescence intensity was calculated according
to the formula CFP F(CFP, nucleus) / F(RFP, whole cell) for every image. To illustrate the
fluorescence decrease from vesicle and to measure fluorescence increase in the nucleus, CFP
fluorescence intensity was plotted over time.
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6 Appendix
6.1 Contributions
All molecules in this thesis except of 7-((18-chloro-3,6,9,12-tetraoxaoctadecyl)oxy)-4-
(hydroxymethyl)-2H-chromen-2-one (23) and HCM-HaXS, which were synthesised by Dr. Flo-
rent Beaufils, were synthesised and characterised by Ruben Cal. The synthesis of MeNV-HaXS
was developed by Viktor Hoffmann, in the course of his Master thesis and optimised by Ruben
Cal.
NMR spectra to determine the mechanism of the Lewis acid-mediated C16 substitution of ra-
pamycin and NMR spectra to determine the absolute configuration of rapalogs were recorded
by Kaspar Zimmermann in the group of PD. Dr. Daniel Hussinger at the University of Basel.
The spectra were subsequently analysed by Kaspar Zimmermann, PD Dr. Daniel Hussinger and
Ruben Cal.
All in vitro photolysis experiments were performed and analysed by Elia Janett in the group
of Prof. Dr. Christian Bochet at the University of Fribourg. HRMS and ESI-Ms spectra were
recorded by the mass spectroscopy service at the University of Bern.
All biological experiments except for the determination of the IC50 value of rapamycin, which
were performed by Anna Melone, were performed by Mirjam Zimmermann.
6.2 Supplementary figures
Figure S 1: The UV/Vis spectra of the crude mixture of pcRap separated by preparative HPLC.
10 mg of the crude pcRap were dissolved in 2 mL CH2Cl2 and injected into a Dionex P680 HPLC
instrument with a Reprosil 100 Si, 5 µm column (250 x 40 mm). Sample was eluted using a linear
gradient of 100:0 to 94:6 (CH2Cl2:methanol) and a flow rate of 30 mL⋅min-1 over 90 minutes
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Figure S 2: The UV/Vis spectra of pure (R)pcRap separated by analytical HPLC. 50 µL of a 100 µM
solution of product in CH2Cl2 were injected into Shimadzu LC-20AT instrument with a Reprospher 100
Si, 5 µm column (100 x 10 mm)and eluted using a linear gradient of 100:0 to 96:4 (CH2Cl2:methanol)
and a flow rate of 2 mL⋅min-1 over 60 minutes
SNAP-GFPHalo-RFP-Giantin merge
G
o
lg
i 
v
e
s
ic
le
s
M
e
N
V
-H
a
X
S
D
M
S
O
SNAP-GFPHalo-RFP-Rheb15 merge
e
n
d
o
s
o
m
e
s
M
e
N
V
-H
a
X
S
D
M
S
O
Halo-RFPSNAP-GFP-CAAX merge
p
la
s
m
a
 m
e
m
b
ra
n
e
M
e
N
V
-H
a
X
S
D
M
S
O
Halo-mTQMito-SYFP-SNAP merge
m
it
o
c
h
o
n
d
ri
u
m
M
e
N
V
-H
a
X
S
D
M
S
O
SNAP-GFPLAMP1-RFP-Halo merge
ly
s
o
s
o
m
e
M
e
N
V
-H
a
X
S
D
M
S
O
Halo-RFPLifeAct-TFP-SNAP merge
a
c
ti
n
 s
k
e
le
to
n
M
e
N
V
-H
a
X
S
D
M
S
O
a)
b)
c)
d)
e)
f)
Figure S 3: Cytosolic protein translocation to different cellular compartments: a) Giantin was used
to target the Halo-RFP-Giantin to the Golgi, b) the CAAX box of K-Ras targeted SNAP-GFP-CAAX
to the plasma membrane, c) Mito-SYFP-SNAP localized on mitochondria, d) the Rheb15-tagged Halo-
RFP-Rheb15 was localized on early and late endosomes, e) LAMP1 was on lysosomes, and f) LifeAct
served as an anchor on the F-actin cytoskeleton. HeLa cells expressing the indicated organelle anchors
and the indicated cytosolic cargo proteins were grown on 12 mm coverslips (Menzel), before they were in-
cubated with MeNV-HAXS (37○C, 15 min), washed twice with PBS, and fixed with 4% p-formaldehyde
(PFA, in PBS), and mounted in Mowiol (Plss-Stauffer) containing 1% propyl gallate (Sigma-Aldrich).
Translocation of cytosolic Halo-RFP, Halo-mTq or Halo-RFP fusion proteins (cargo) to the respective
anchors is documented.
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Figure S 4: Release of Golgi-trapped SNAP-mTFP1 protein after UV illumination. a) At t = >15
min, HeLa cells expressing SNAP-mTFP1 and Halo-RFP-Giantin were exposed to 5 µM HaXS8 (5 µM
MeNV-HaXS see figure 22, main part), which caused the translocation of cytosolic SNAP-mTFP1 to
the Golgi (labeled as ”before 377 nm”). SNAP-mTFP1 intensity was monitored within the indicated
circular regions of interest by live cell microscopy. At t = 0 illumination with UV light using a standard
DAPI filter set on a conventional fluorescence microscope (t = 20 sec, 377 ± 25 nm) was initiated for
20 s, and cells are shown after illumination (after 377 nm). b) Quantification of mTFP1 fluorescence
intensity of selected regions of interest (circles) at Golgi-derived vesicles (v) and in cytoplasm (c) before
and after illumination as described in a) are shown (values represent means ± SEM, n = 10, error bars
removed where smaller than symbols used). Curves obtained with MeNV-HaXS (see figure 22) are
shown in green.
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